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Abstract 
 
Intestinal macrophages, derived in part from monocytic precursors, are critical targets of IL-10, which 
prevents the development of colitis in mice. In humans, loss-of-function IL-10R mutations cause early-
onset inflammatory bowel disease (IBD). We aimed to test the hypothesis that IL-10 responsiveness 
in monocyte/macrophages is suboptimal in adult IBD patients even in the presence of functional IL-10 
signalling. A novel assay was developed to measure the ability of IL-10 to inhibit LPS-induced TNF 
production by monocyte from blood or extracted from colonic biopsies. In healthy donors, monocyte 
subsets differed in their sensitivity to IL-10: classical monocytes were most sensitive and non-classical 
monocytes least, most likely due to lower levels of STAT3 availability and phosphorylation in response 
to IL-10. In IBD, circulating numbers of classical and intermediate monocytes were comparable to 
controls but non-classical monocytes were reduced. IL-10 was significantly less effective at inhibiting 
TNFα production by classical monocytes from IBD patients than controls (p=0.026), despite increased 
expression of IL-10Rα and IL-10-induced STAT3 phosphorylation. To determine the significance of this 
suboptimal response to IL-10 for monocyte-derived cells in the intestine, colonic CD14+ cells were 
analysed. Two populations were identified: CD14hi (P1) and CD14lo (P2) the latter of which were 
significantly increased in active Crohn’s disease but not ulcerative colitis. Both populations produced 
TNFα in unstimulated cultures, and this response was significantly enhanced following LPS stimulation. 
The increase in TNFα production upon LPS stimulation was greater in P1 cells. Intestinal CD14+ cells 
were more sensitive to IL-10, in contrast to classical blood monocytes, TNF production by P1 and P2 
cells, from non-IBD and inflamed IBD mucosa, was completely inhibited by 2ng/ml IL-10. Since 
inhibition was complete under these conditions it was not possible to draw conclusions about 
differences between health and disease; further studies with less IL-10 may be informative. 
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Chapter 1: Introduction  
1.1 Overview  
 
The gastrointestinal tract (GIT) is made up of the small and large intestine, which are distinct in their 
function and morphology. The small intestine is the site of food digestion and absorption, while the 
large intestine is involved in absorption of water and electrolytes. The overarching function of the 
intestine is the digestion and absorption of nutrients from ingested food. To help achieve this function, 
the intestine is colonised by a diverse community of microorganisms, including bacteria, fungi, and 
viruses, forming the microbiota, which aids in the breakdown and release of nutrients from food 
molecules that are indigestible by the enzymes present in the intestine as well as restricting access to 
invasive pathogens (reviewed by Backhed et al., 2005; Abraham & Medzhitov, 2011). Therefore, the 
intestinal immune system must distinguish between beneficial microbiota and pathogens to maintain 
a balance between regulatory and pro-inflammatory responses. This balance is disturbed in IBD, 
leading to immune reactivity against commensal bacteria in genetically susceptible individuals, which 
results in chronic inflammation and damage to surrounding tissue (reviewed by Baumgart & Carding 
2007). The pathogenesis of IBD is not fully understood.  
This thesis will investigate the contribution of monocytes and intestinal macrophages (Mφs) to the 
pathogenesis of IBD in humans. More specifically, the involvement of IL-10 in the role of monocytes 
and monocyte-derived Mφs (Mo/moMφ) during intestinal inflammation.  
The introduction will begin with a broad overview of the mechanisms that maintain steady-state in 
the intestinal immune system, and how dysregulation of immune responses may give rise to IBD. 
There will then be a focus on understanding the roles of resident Mφs in the intestine and how these 
functions are influenced by IL-10 during steady-state and in the context of intestinal inflammation, 
with supporting evidence from experimental mouse models. Finally, this chapter will introduce the 
aim of the project and a summary of the principal aims. 
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1.2 The immunological challenges of the intestine   
 
The intestine and colonising microbiota have co-evolved to establish a symbiotic relationship; the host 
provides a favourable environment for the bacteria with access to nutrients, and in return, the 
bacteria aid in the digestion and release of nutrients from food that would  be otherwise indigestible 
to the host (reviewed by Backhed et al. 2005). These bacteria also occupy a niche in the intestine, 
providing strong competition for the available nutrients and restricting access to invasive pathogens 
(reviewed by Hooper & MacPherson 2010). The dominant bacteria can be classified into the phyla 
gram-positive Firmicutes and gram-negative Bacteroidetes (reviewed by Hooper & MacPherson 2010). 
However, there is large diversity in the microbiota between individuals, making it difficult to 
distinguish between a healthy microbiome and microbial imbalance (dysbiosis).  
Despite the symbiotic relationship between the intestine and microbiota, their close proximity poses 
an immunological challenge. The intestinal immune system must protect against invasive pathogens 
without responding to beneficial bacteria. Therefore, intestinal immune cells are required to 
distinguish between helpful and harmful bacteria to maintain a balance between regulatory and pro-
inflammatory responses. There are multiple layers of protection against pathogens, which will be 
detailed in this section.  
1.2.1 Barrier function  
 
The first line of defence against invading pathogens in the GIT is the physical barrier formed from 
intestinal epithelial cells (IECs) connected by tight junctions (reviewed by Peterson & Artis 2014), and 
the layers of mucus that protect this barrier. The mucus is made up of two distinct layers: an inner 
stratified layer that that excludes bacteria and is adherent to the epithelium, and a looser outer layer 
that is not attached to the epithelium and is inhabited by bacteria (reviewed by Johansson et al. 2011). 
Goblet cells produce highly glycosylated MUC2 mucin, which are organised into large net-like 
polymers that form the mucus layers (reviewed by Johansson et al. 2011). MUC2 deficient mice display 
19 
 
enhanced susceptibility to invasive pathogens, and reduced MUC2 is associated with the onset of 
intestinal inflammation (Heazlewood et al. 2008; Johansson et al. 2008; Van der Sluis et al. 2006; 
Wenzel et al. 2014). This highlights the important role of mucus in maintaining immune regulation in 
the intestine. Also present in the mucus layers are antimicrobial proteins (AMPs), including defensins, 
lysozymes, and IgA, which further restricting access to bacteria (reviewed by Johansson et al. 2011).  
The intestinal epithelium is made up of a single layer of IECs linked tightly together by tight junction 
proteins (Peterson & Artis 2014). This acts as a physical barrier to the microbiota colonising the 
intestine. There are distinct types of IECs present along the epithelium: enterocytes that assist in the 
absorption of nutrients, goblet cells that produce mucins, Paneth cells that produce AMPs, and tuft 
cells that defend against parasites (reviewed by Hooper & MacPherson 2010). IECs can sense and 
respond to pathogens via pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and 
NOD-like receptors (NLRs); upon activation of these pathways, IECs participate in the coordination of 
an appropriate immune response (reviewed by Abreu 2010). Therefore, IECs have an important role 
in regulating immune responses in the GIT.    
As described above, Paneth cells produce AMPs, including defensins, cathelicidins, and C-type lectins, 
which provide additional protection against invading pathogens. Alpha-defensins are produced 
constitutively, whereas the production of C-type lectins is induced upon exposure to environmental 
microbes (reviewed by Hooper & MacPherson 2010). Germ-free mice (GF) mice maintain their 
capacity to produce defensins (Pütsep et al. 2000). In contrast, mice deficient in MyD88 (an adaptor 
molecule involved in TLR signalling) showed undetectable levels of RegIIIγ (C-type lectin), which was 
associated with impaired clearance of Listeria monocytogenes infection, and reconstitution with 
recombinant RegIIIγ restored bacterial clearance (Brandl et al. 2007). This highlights the role of AMPs 
in protecting intestinal mucosa against invasive pathogens. 
As mentioned earlier, IgA is present in the mucus layers and aids in controlling bacterial access. IgA is 
the dominant antibody in the intestinal barrier and is secreted by terminally differentiated B cells 
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(plasma cells) upon exposure to environmental microbes, as demonstrated in GF mice and neonates, 
which display significantly fewer plasma cells (reviewed MacPherson et al. 2008). Secretory IgA (sIgA) 
is transported across the epithelial barrier by polymeric Ig receptor (pIgR)-mediated transcytosis 
(reviewed by MacPherson et al. 2008). The functions of sIgA include neutralising toxins, limiting 
bacterial attachment to the epithelium, and promoting agglutination (clumping) of bacteria to 
increase the efficiency of microbial elimination by phagocytosis (reviewed MacPherson et al. 2008). 
sIgA deficient mice display an expansion of segmented filamentous bacteria, which induce 
inflammatory responses, and reconstitution with sIgA recovered the normal composition of the 
microbiota and prevented further activation of immune responses (Suzuki et al. 2004). This 
demonstrates an important role of sIgA in regulating the composition of microbiota.  
1.2.2 Innate immunity 
 
If the epithelial barrier is breached, innate immune cells resident in the intestinal mucosa are the next 
line of immune defence against invading bacteria. The innate immune system is made up of a network 
of cells that can elicit a rapid immune response against pathogens recognised using TLRs and other 
PRRs. Innate immune cells include granulocytes, Mφ and dendritic cells (DCs). Granulocytes include 
neutrophils, eosinophils, basophils, and mast cells, which contain granules in their cytoplasm 
composed of different active agents, for example neutrophils contain potent antimicrobial agents that 
aid in bacterial killing by phagocytosis (reviewed by Fournier & Parkos 2012). Granulocytes do not 
reside in the intestine during steady-state, instead they are recruited during inflammatory responses. 
They have an important role in eliminating invasive pathogens that gain access to the intestinal 
mucosa. However, in the context of IBD, these cells can perpetuate the intestinal inflammation, 
consistent with the observation that neutrophils are enriched in the mucosa of IBD patients (reviewed 
by Fournier & Parkos 2012).  
Mφs and DCs are antigen presenting cells (APCs) that interact with and influence the adaptive immune 
response, and therefore bridge the gap between the innate and adaptive immune system. These APCs 
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sample the luminal microbes using several methods. M cells translocate antigens from the lumen into 
the Peyer’s patch (PP), where DC reside (Verrier et al. 2006). However, invasive pathogens can exploit 
M cells as a means of accessing the intestinal mucosa. It was believed that DCs could protrude their 
dendrites between epithelial cells to sample directly from the lumen but more recent studies have 
revealed that the cells that do this are Mφ, which take up soluble antigens and transfer them to DCs 
(Mazzini et al. 2014; Rescigno et al. 2001). However, Mφ and DCs also have distinct roles within the 
intestine. Resident Mφs can phagocytose and clear bacteria detected in the lamina propria (LP), and 
also display the degraded regions of the bacteria on major histocompatibility complex (MHC) 
receptors to present to local effector cells (discussed in section 1.5). Mice deficient in the two major 
mechanisms of bacterial killing by phagocytes formed abscesses containing commensal organisms, 
demonstrating the important role of intestinal Mφ in bacterial clearance (Shiloh et al. 1999). DCs 
sample the luminal microbiota and have the unique ability to migrate to the mesenteric lymph nodes 
(MLNs) (Schulz et al. 2009), where they present the antigens to naïve T cells (Th0) (reviewed by Mowat 
& Bain 2011). These interactions are critical in training the adaptive immune cells to elicit the 
appropriate response when presented with beneficial bacteria or invasive pathogens.   
Innate lymphoid cells (ILCs) are enriched in the intestinal mucosa, where they play a protective role 
against pathogens (reviewed by Geremia & Arancibia-Cárcamo 2017). This population respond to 
environmental stress signals as they lack an antigen-specific receptor typical to lymphocytes but 
reflect functional characteristics of T helper subsets (reviewed by Geremia & Arancibia-Cárcamo 
2017). ILCs have been implicated in the pathogenesis of colitis in murine models, and accumulate in 
the inflamed mucosa of patients with IBD (reviewed by Geremia & Arancibia-Cárcamo 2017).  
1.2.3 Adaptive immunity  
 
In many cases, components of the innate immune stem are sufficient to control intestinal pathogens. 
If this does not occur, innate immune cells can alert the adaptive immune system to generate a highly 
targeted response.  
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As mentioned earlier, DCs in PPs, or those that migrate to draining MLNs or iliac nodes (Schulz et al. 
2009) present antigens sampled from the lumen to Th0 CD4+ T cells, leading to the activation and 
proliferation of the responding T cell (reviewed by Mowat & Bain 2011). The activity of the responding 
T cell is determined at least in part by cytokines produced by the DC (Figure 1.1). Type 1 T helper (Th1) 
cells are important in eliminating intracellular pathogens, and display characteristic cytokine 
production, including IFNγ, TNFα and IL-2 (reviewed by Szabo et al., 2003). IFNγ activates Mφs, 
resulting in increased phagocytosis by induction of nitric oxide (NO) and superoxide for the elimination 
of intracellular pathogens (reviewed by Boehm et al., 1997). Th2 cells are involved in the defence 
against parasites (e.g. helminth infection), and display characteristic cytokine production, including IL-
4, IL-5, and IL-9 (reviewed by Paul and Zhu, 2010). Th2 cells recruit mast cells and eosinophils to the 
intestine through the production of IL-9 and IL-5 respectively (reviewed by Paul and Zhu, 2010). IL-4 is 
critical in the defence against parasites through induction of B cell production of IgE (explained below), 
which activates eosinophils and mast cells, causing degranulation and release of pro-inflammatory 
mediators involved in parasite clearance (reviewed by Paul and Zhu, 2010). Th17 cells produce IL-17A, 
IL-17F, IL-22 and GM-CSF (Annunziato et al. 2007; Wilson et al. 2007). IL-17A and IL-17F are critical in 
the defence against extracellular bacterial and fungal pathogens through the induction of stromal cell 
production of IL-8 and GM-CSF, which recruits neutrophils and induces neutrophil development in the 
BM respectively (reviewed by Witowski, Ksia̧zek and Jörres, 2004). IL-22 production promotes the 
production of antimicrobial peptides by epithelial cells, and therefore enhances epithelial barrier 
function during intestinal infection (Zheng et al. 2008). The evidence that intestinal inflammation in 
CD patients is Th1/Th17-mediated but Th2-mediated in UC patients will be discussed in section 1.3.3.3, 
as well as the critical role of regulatory T cells (Tregs) regulating immune responses in the intestine.  
23 
 
 
Figure 1.1: Th0 cell differentiation. DCs present antigens on MHC-II receptors Th0 cells. 
Differentiation of Th0 cells into effector CD4+ T cells is determined in part by their interactions with 
DC Figure adapted from Bailey et al., 2014. 
 
Naïve CD8+ T cells can only be primed by DCs displaying its respective antigen on MHC class I receptors 
and costimulatory molecules in the presence of IL-12 (Joffre et al. 2012). CD8+ T cells contain pre-
formed granules comprised of perforin, granzyme B, and granulysin. The granules are released in a 
focused manner into virally infected or malignant cells expressing the corresponding antigen, which 
then undergo apoptosis. 
Naïve B cells bear B cell receptors, which in essence are antibodies anchored to their surface. These 
antibodies have two variable regions, which can recognise antigens without the need for APCs, and 
also enable B cells to present antigens. Upon activation, B cells mature into plasma cells, which 
produce their corresponding soluble antibodies. Soluble antibodies have five functions: agglutination, 
neutralisation, opsonisation, and antibody-dependent cellular cytotoxicity (ADCC). Antibodies come 
in 5 different forms: IgA, IgG, IgE, IgM, and IgD. These antibodies stimulate different effects on immune 
cells, which is determined by their Fc region. The Fc region is recognised by Fc receptors (FcR) present 
on the surface of specific immune cells, which elicit distinct immune responses, as described earlier, 
IgA is the dominant antibody in the intestinal barrier.  
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1.3 Inflammatory Bowel Disease  
 
IBD is a chronic, relapsing inflammatory disorder affecting the GIT caused by a breakdown in immune 
regulation, which leads to reactivity against commensal bacteria that reside in the intestine. As a gross 
simplification, the breakdown in immune tolerance against commensal bacteria is the result of 
overactive pro-inflammatory activity or insufficient regulatory signals. IBD is mainly comprised of 
Crohn’s disease (CD) and Ulcerative Colitis (UC), which manifest with distinct patterns of inflammation. 
Although CD and UC are accepted as clinically distinct conditions, 10-15% of cases cannot be diagnosed 
definitively, and are referred to as indeterminate colitis (IC) (reviewed by Guindi & Riddell 2004); this 
indicates a spectrum of disease instead of distinct conditions.  
Despite extensive research into genetic and environmental predisposing factors, it is still unclear what 
triggers IBD in patients. The number of individuals with IBD is increasing with the highest incidence 
rates in industrialised countries; importantly, people who migrate from low to high prevalence areas 
acquire the new incidence rates of the background population with a generation, which is too rapid 
to be accounted for by genetic change (Molodecky et al. 2012). This indicates that there are lifestyle 
and environmental impacts on IBD. However, it has long been known that there are also genetic 
factors. This has been revealed through observing familial aggregation and results from concordance 
studies in twins and Ashkenazi Jewish descendants (Halfvarson et al., 2003; Kenny et al., 2012), and 
more recently through genome-wide association studies (GWAS) that have identified over 163 genetic 
variants influencing susceptibility to IBD (Anderson et al. 2011; Franke et al. 2010a; Jostins et al. 2012; 
McGovern et al. 2010). Thus, a complex picture is emerging, where genetic susceptibility to 
environmental factors, and immune interaction with gut microbiota are all interrelated. 
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1.3.1 Characteristics of IBD   
 
CD is a transmural inflammatory disorder that can affect any region of the GIT. The inflammation 
occurs in segments and can be associated with granulomas (collections of Mφs which are able to form 
a barrier between potential pathogens and host tissues), strictures where the intestine narrows 
causing bowel obstruction, and fistulae where inflammation forms abnormal connections between 
the bowel and the vagina, bladder or skin (reviewed by Baumgart & Sandborn 2012). In UC, 
inflammation occurs continuously, extending proximally from the rectum, and can spread through the 
entire colon; the inflammation is restricted to the mucosal surface, causing extensive superficial 
ulceration (reviewed by Ordás et al. 2012). A serious complication of UC is toxic megacolon, which can 
lead to mortality if not recognised early, and may require a colectomy (removal of the whole colon) if 
drug treatment is unsuccessful (reviewed by Bouma & Strober 2003). Patients with CD or UC present 
with similar symptoms such as recurring diarrhoea, rectal bleeding, abdominal pain, and fatigue. 
Approximately 25% of IBD patients will also develop extraintestinal manifestations (EIM) that can 
affect particularly the skin, eyes, or joints. EIMs may be a result of an overreactive immune system 
associated with intestinal inflammation or a genetic link causing multiple pathologies (reviewed by 
Baumgart & Sandborn 2012; Vavricka et al. 2015).. Endoscopy is used to examine the interior of the 
GIT, which enables imaging of the intestinal inflammation and diagnosis of CD or UC based on the 
characteristics of the inflammation. As well as aiding diagnosis, the extent of inflammation is 
monitored using biomarkers, including C-reactive protein, erythrocyte sedimentation rate (ESR), and 
faecal calprotectin (reviewed by Vermeire et al. 2004). In addition to this, full blood counts (FBC), liver 
function test (LFT), and a host of other measures of blood composition are measured. Collectively, the 
information is used to determine treatment response and inform therapy regimens.  
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Figure 1.2: Summary of characteristics of CD vs UC. Although CD and UC patients present with similar 
symptoms, the inflammation differ in location, depth of inflammation, and complications (Mirza 
Muhammad Adnan 2011). 
 
1.3.2 Epidemiology 
 
The number of IBD cases is growing in industrialised countries, which implicates environmental 
factors. In addition, people who migrate from low to high prevalence areas acquire the new incidence 
rates with a generation, which is too rapid to be accounted for by genetic change (Molodecky et al. 
2012). There are 322 cases of CD per 100,000 people and up to 12.7 new cases per 100,00 people per 
year in Europe alone (Molodecky et al. 2012). UC is more common than CD, with prevalence rates of 
up to 505 cases per 100,000 people and up to 24.3 new cases per 100,00 people per year in Europe 
(Molodecky et al. 2012). The majority of UC patients are diagnosed between 20-30 years, with a 
smaller population of patients being diagnosed between 50-70 years (reviewed by Ordás et al. 2012); 
disease onset later in life indicates a greater environmental cause (Polito et al. 1996). CD and UC both 
display a bimodal pattern of incidence. However, the main onset peak of CD is on average ten years 
earlier then UC (reviewed by Duricova et al. 2014), which may reflect a greater influence of genetic 
factors in CD than UC. This interpretation is supported by concordance studies in twins, where 
monozygotic twins had 50% concordance rates for CD but only 19% for UC, while dizygotic twins had 
concordance rates of 4% for CD and 0% for UC (Halfvarson et al. 2003).   
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1.3.3 Aetiology  
1.3.3.1 Genetic predisposition  
 
Early observations of familial aggregation in IBD patients initiated research into genetic 
predispositions. Nucleotide oligomerisation domain 2 (NOD2) was an early susceptibility gene 
identified in CD patients (Hugot et al. 2001; Ogura et al. 2001). NOD2 is an intracellular PRR expressed 
in monocytes, epithelial cells, and Paneth cells that detects muramyl dipeptide (MDP), which enables 
recognition of intracellular bacteria, leading to activation of nuclear factor kappa B (NFκB) and 
production of pro-inflammatory cytokines (Girardin et al. 2003; Inohara et al. 2003). NOD2 deficient 
mice presented with enhanced TLR2 activation and greater interleukin-12 (IL-12) production, leading 
to Th1-mediated intestinal inflammation, characteristic to CD (Watanabe et al. 2004; Yang et al. 2008). 
Human monocyte-derived DCs (moDCs) derived from CD patients with NOD2 mutations display a 
reduced capacity to process and present antigens (Cooney et al. 2010). This demonstrates the 
importance of the ability of the intestinal immune system to recognise and respond to invasive 
pathogens.   
GWAS is a method of identifying associations between common genetic variants (loci that are usually 
single nucleotide polymorphisms (SNPs)) and traits (usually diseases); 215 susceptibility loci have been 
associated with IBD (Franke et al. 2010; McGovern et al. 2010; Anderson et al. 2011; Jostins et al. 2012; 
De Lange et al. 2017). This has provided insights into the potential pathways that are involved in the 
pathogenesis of IBD, which will be detailed below. The increased risk associated with each 
susceptibility loci is very small, and there is no association with prognosis (Lee et al. 2017). There are 
limitations of GWAS: it covers common genetic variants within the population and may fail to capture 
rare variants, the identity and function of many of the genes bearing the genetic variants remain 
unknown, and the majority of the genetic variants reside in noncoding regions of the genome (Graham 
& Xavier 2013).   
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Out of the 163 susceptibility loci, 30 are exclusively associated with CD and 23 are specific to UC 
(Jostins et al. 2012). This indicates that there are distinct pathways that lead to intestinal inflammation 
characterised as CD or UC, although the majority of genes are common to both diseases. The genes 
that are associated with CD susceptibility include autophagy related 16 like 1 (ATG16L1), which is 
associated with the NOD2 pathway. Upon NOD2 activation, the bacteria undergo autophagy with the 
help of recruited ATG16L1 machinery (Cadwell et al. 2008; Travassos et al. 2009). When there is a 
breakdown in this system, bacterial replication becomes uncontrollable inducing an overwhelming 
inflammatory response (Caprilli et al. 2010). This indicates that defects in recognition and response to 
bacterial encroachment is important in CD pathogenesis.  
The genes that are associated with susceptibility to UC include hepatocyte nuclear factor-4α (HNF4α) 
which regulates expression of tight junction proteins, cadherin-1 (CDH1) which form adherens 
junctions, and laminin-β1 (LAMB1) which is a component of the basement membrane (McGovern et 
al. 2010). All three genes are involved in maintaining the integrity of the epithelial barrier, highlighting 
the importance of the mucosal barrier function in UC pathogenesis. However, it cannot be certain 
whether epithelial barrier integrity is impaired due to inflammatory damage caused by a pathogenic 
infection that is exacerbated by the genetic variants, or whether the genetic variants give pathogenic 
bacteria the opportunity to establish an infection that will cause inflammation and further damage to 
the epithelial barrier. 
The susceptibility genes that are associated with both CD and UC impact on regulatory pathways such 
as IL-10R signalling, including IL-10, signal transducer and activator of transcription 3 (STAT3), and 
tyrosine kinase 2 (TYK2) (Franke et al., 2010). In addition, a comparison of genes responsible for 
monogenic disease with IBD-like pathology and risk loci associated with IBD revealed that genes 
related to IL-10 (IL-10, IL-10RA, and IL-10RB) were the only common variants (Uhlig 2013). 
Susceptibility genes involved in Th17-mediated immunity, including IL-23 and IL-12, are also 
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associated with both CD and UC (Anderson et al. 2011; Granlund et al. 2013). This supports the concept 
that inflammation in IBD arises from excessive effector function and/or failure in regulation. 
Individuals with IBD are genetically predisposed to have dysregulated immune responses. However, 
known genetic variants account for only ~20% of all IBD cases (13.6 % CD and 7.5 % UC) demonstrating 
the role of environmental or non-genetic factors in the pathogenesis of IBD (Jostins et al. 2012). This 
is highlighted in the twin studies mentioned earlier, where monozygotic twins had only 50% 
concordance rates for CD (Halfvarson et al. 2003). It has been proposed that one possibility for the 
unaccounted heritability could be an epigenetic modification that results from the interaction 
between genes and the environment (reviewed by Ventham et al. 2013).  
1.3.3.2 Environmental factors  
 
epidemiological studies of IBD implicate environmental factors in determining the progression of IBD 
in genetically predisposed individuals. Increased incidence in developing countries suggests that the 
environmental factors are related to the ‘western lifestyle’ and industrialisation (reviewed by Ng et al. 
2013). The ‘western lifestyle’ is associated with changes in diet, antibiotic use, hygiene status, and 
pollution. These environmental factors might all converge on their impact on the microbiota.  
A breakdown in immune regulation, which leads to reactivity against commensal bacteria is 
considered to be the basis of IBD (reviewed by Baumgart & Sandborn 2007). The intestinal microbiota 
has a critical role in training the intestinal immune system to recognise commensal bacteria and 
establish regulatory systems that help maintain immune tolerance (reviewed by Belkaid & Harrison 
2017). Therefore, the nature of the microbiota itself an important environmental factor. The 
composition and diversity of commensal bacteria is determined by diet and environmental exposure, 
which may explain the greater incidence in industrialised regions, where there is greater consumption 
of processed food and exposure to pollution. The overuse of antibiotics and hygiene products is a risk 
factor for developing IBD because they have a negative effect on the diversity of the microbiota (Hviid 
et al. 2011), and are also a common feature in westernised societies.  
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Metagenomic studies have revealed a reduced diversity in the commensal bacteria of IBD patients 
(reviewed by Manichanh et al. 2012). The  Firmicute Faecalibacterium prausnitzii has shown anti-
inflammatory effects in mouse models of colitis (refer to section 1.3.3.5)(Sokol et al. 2008). Reduced 
diversity in the Firmicutes is a signature of the dysbiosis in patients with CD (Manichanh et al. 2006). 
In contrast, an increased F. prausnitzii was observed in paediatric CD patients, challenging the concept 
of a beneficial role of Firmicutes in CD (Hansen et al. 2012). An increased prevalence of Escherichia 
coli has been observed in CD and UC patients, which may contribute to disease pathogenesis through 
the invasion of the intestinal epithelium (Boudeau et al. 1999; Darfeuille-Michaud et al. 2004; Knoll et 
al. 2016; Martin et al. 2004). UC patients display a reduced abundance of bacteria that are considered 
to promote gut homeostasis, including Eubacterium rectale and F. prausnitzii (Knoll et al. 2016). UC 
patients display lower levels of major anaerobic bacteria (Bacteroides and Clostridium subcluster 
XIVab) (Nemoto et al. 2012). This dysbiosis is considered to enhance the ability of opportunistic 
pathogens to establish an infection. Whether dysbiosis of the microbiota is a cause or a consequence 
of intestinal inflammation remains to be elucidated. 
The pathogenesis of IBD varies between patients, and the trigger of inflammation is usually 
unidentifiable.  In some cases, infection by pathogens can be the initiator of inflammation, supported 
by seasonal variations in onset of disease (reviewed by Hanauer 2006). This is consistent with an 
infection triggering a breakdown in immune regulation that results in an uncontrolled immune 
response against the commensal bacteria. CD and UC have common environmental risk factors. 
However, smoking has been observed to have a protective effect in UC patients, whereas it is a risk 
factor for developing CD (Benjamin et al. 2012; Mahid et al. 2006). It has been shown that there is an 
increase in the number of sulfate-reducing bacteria in UC patients and that a build-up of sulfide 
becomes toxic. The cyanide from smoke neutralises the sulfide produced by these bacteria into non-
toxic thiocyanate, which could account for the reported beneficial effect (Levitt et al. 1999). This is 
consistent with the concept that CD and UC patients display distinct dysbiosis in their commensal 
bacteria. 
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1.3.3.3  Immune-mediated intestinal inflammation  
 
As previously mentioned, IBD is considered to result from a loss of tolerance against commensal 
bacteria leading to overwhelming inflammation and collateral damage to the surrounding tissue. This 
immune dysregulation is caused by an imbalance between pro-inflammatory and regulatory 
pathways. There is evidence that IBD patients display excessive effector T cell function, which form 
part of the pro-inflammatory system, these include CD8+ T cells, Th1, Th2, and Th17 cells. An early 
observation was that LPMCs showed enhanced capacity to produce pro-inflammatory cytokines, 
including tumour necrosis factor α (TNFα), IL-6, and IL-1β, from the inflamed mucosa of IBD patients 
compared to healthy controls (Reinecker et al. 1993). Anti-TNFα therapy is effective in treating ~50% 
of IBD cases, suggesting a significant role of TNFα in the pathogenesis of IBD (Molander et al. 2013). 
In support of this, over-expression of TNFα in mice leads to mucosal inflammation resembling IBD 
patients (Kontoyiannis et al. 1999). IL-6 and IL-1β are likely to propagate inflammation in the intestine 
by inducing T cell proliferation and promoting the production of interferon γ (IFNγ) and IL-17A (Huff 
et al. 2011). Elevated IFNγ production in CD4+ T cells has also been observed in CD patients, which 
promotes recruitment of innate immune cells, including neutrophils and monocytes, found to be 
enriched at inflammatory sites, leading to further production of pro-inflammatory cytokines (reviewed 
by Boehm et al. 1997). Overall, a higher abundance of pro-inflammatory cytokines is implicated in the 
pathogenesis of IBD.  
Mφs isolated from the inflamed mucosa of CD showed enhanced production of IL-12, which promotes 
IFNγ production by Th1 cells (Liu et al. 1999; Monteleone et al. 1997; Parronchi et al. 1997). Consistent 
with this, T cells isolated from the inflamed mucosa of CD display enhanced STAT4 (indicative of IL-12 
signalling) and IL-12R expression, likely to contribute to their increased capacity to produce IFNγ 
(Parrello et al. 2000), suggesting that intestinal inflammation in CD patients is Th1-mediated. In 
addition, anti-IL-12p40 therapy was shown to be effective in treating CD, suggesting a role of IL-12 or 
IL-23 in the pathogenesis of CD (Mannon et al. 2004; Sandborn et al. 2008). IL-12 and IL-23 are 
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heterodimers, meaning anti-IL-12p40 can neutralise both IL-12 and IL-23 (Oppmann et al. 2000). More 
recent studies have shown that the development of intestinal inflammation was more dependent on 
IL-23 than IL-12. RAG-deficient mice (lack mature lymphocytes) also deficient in IL-23 did not develop 
colitis upon H. Hepaticus infection, whereas the same mice deficient in IL-12 developed colitis (Hue et 
al. 2006; Holm H. Uhlig et al. 2006). Therefore, it has been proposed that CD is mediated by a 
combination of Th1/Th17 responses (reviewed by Bouma & Strober 2003; Strober & Fuss 2011). 
However, the role of IL-17A in the pathogenesis of CD remains unclear because anti-IL-17A therapy 
lead to worsening of symptoms (Hueber et al. 2012), suggesting a protective role in the intestine.  
Th2-mediated inflammation has been suggested to play a role UC because elevated levels of IL-13 and 
IL-5 detected (Fuss et al. 2004). However, there is no evidence of elevated levels of IL-4, a Th2 cytokine. 
Therefore, it has been proposed that natural killer T cells (NKT) cells are the predominant producers 
of IL-13, which causes altered expression of tight junctions and induces apoptosis (programmed cell 
death) in IECs (Heller et al. 2002); defective barrier function is characteristic to UC.  
A recent study showed elevated levels of IL-17A and IFNγ production in CD4+ T cells, which did not 
differ between CD and UC patients (Rovedatti et al. 2009). In addition, whole genome expression 
meta-analysis has not revealed convincing differences between CD and UC (Granlund et al. 2013). 
These challenge the concept that CD and UC can be categorised into Th1 or Th2-mediated 
inflammation.  
On the opposing side, inflammation in IBD is considered to arise from failure to regulate inflammatory 
responses. Tregs and Mφs are important components of the regulatory pathway in the intestine. Tregs 
(FOXP3+CD4+CD25+) are crucial in regulating intestinal inflammation as demonstrated in the T cell 
transfer model of colitis, in which the intestinal inflammation that develops after the transfer of CD4+ 
T cells into mice with severe combined immunodeficient (SCID; absence of lymphocytes) can be 
prevented by co-transferring Tregs (Hori et al. 2002). The protective effect of Tregs can be reversed 
by administering a transforming growth factor β (TGFβ)-specific antibody, suggesting that the 
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suppressive effects of Tregs are mediated through TGFβ. However, Tregs from TGFβ-deficient mice 
still mediates suppressor activity in vitro, demonstrating that additional mechanisms exist (Piccirillo et 
al. 2002). A population of IL-10 producing Tregs that are CD25- have been defined and termed T 
regulatory type 1 (Tr1) cells (Brockmann et al. 2017). The critical role of IL-10 in regulating intestinal 
inflammation will be discussed in section 1.8.  
Counterintuitively, more Tregs are present in the mucosa of IBD patients than healthy controls (Makita 
et al. 2004; Maul et al. 2005; H. H. Uhlig et al. 2006). However, effector T cells from inflamed mucosa 
display enhanced expression of SMAD7, which provides resistance to TGFβ-mediated suppression 
(Fantini et al. 2009). Therefore, Tregs are unable to suppress effector T cells within this context, 
consistent with a failure to regulate inflammatory responses in IBD. 
A population of Tregs with the capacity to produce IL-17A has been reported in the inflamed mucosa 
of CD patients but not UC patients or healthy controls (Hovhannisyan et al. 2011). This population is 
absent in the blood, suggesting that their development occurs in the intestine, and it is dependent on 
local mediators that are distinct to CD. It is unclear whether this population have a pro or anti-
inflammatory effect. 
Intestinal Mφs display a regulatory phenotype at steady-state; their features include resistance to TLR 
activation, removal of pathogens without producing pro-inflammatory cytokines, and constitutive 
production of IL-10 (reviewed by Mowat & Bain 2011). These properties have been shown to be critical 
in maintaining immune homeostasis in the intestine. The role of intestinal Mφs during steady-state 
and inflammation will be discussed further in section 1.6.   
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1.3.3.4 Treatment  
 
The goals of IBD treatment have shifted in recent years from a focus on relief from symptoms alone 
towards normalisation of inflammatory biomarkers and mucosal healing. There is increasing evidence 
that this approach improves outcomes in the longer term (Colombel et al. 2018). 
Most treatments used in IBD have anti-inflammatory effects, and the commonly prescribed agents are 
described below. There is overlap between the phenotypes of CD and UC and similar treatments are 
used in both conditions with important differences highlighted. Treatments are often divided into 
agents to induce remission (treatments which lead to rapid resolution of symptoms) and agents which 
maintain remission. 
Aminosalicylates, such as mesalazine, balsalazide and sulfasalazine, are the first line of treatment for 
UC to both induce and maintain remission. These drugs contain an active moiety (mesalazine) bound 
to a carrier molecule or encapsulated in a variety of coatings (e.g. MMX®, ethylcellulose) to ensure the 
majority of the active drug is delivered to the colon. Aminosalicylate anti-inflammatories are known 
to modulate the expression of genes involved in the NFκB pathway and cyclooxygenase 2 (COX2) 
(which is important in the generation of prostaglandins associated with inflammation). Recent meta-
analysis suggest these agents do not lead to a significant benefit in CD (Ford et al. 2011). 
Prednisolone and budesonide are corticosteroids commonly used to treat IBD. Corticosteroids bind to 
glucocorticoid receptors available in the cytoplasm of immune cells, which then translocate to the 
nucleus where they bind to the glucocorticoid response element and regulate gene expression. 
Inflammation can be suppressed using multiple targets, including the inhibition of NFκB (reviewed by 
Rhen & Cidlowski 2005). NFκB is involved in the production of pro-inflammatory cytokines, including 
TNFα, IL-1β, and IL-6 (reviewed by Lawrence 2009). Corticosteroid treatments are frequently used to 
induce remission but long-term use is ineffective and associated with multi-systemic side effects. 
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Immuno-modulators including thiopurines (azathioprine and mercaptopurine) and methotrexate are 
often used to maintain remission in CD and UC. Although recent evidence suggests methotrexate is 
not effective in UC (H. Herfarth 2018 abstract MERITUC). Thiopurines and methotrexate exert their 
anti-inflammatory effects by interfering with DNA synthesis, which proliferating immune cells are 
sensitive to. Metabolites of thiopurines are incorporated into DNA causing apoptosis (programmed 
cell death) as well as inhibiting purine synthesis (reviewed by Cara et al. 2004). Methotrexate is a folate 
analogue that interrupts the production of tetrahydrofolic acid and the synthesis of thymidine, which 
impairs RNA and DNA synthesis, and consequently white cell proliferation (reviewed by Tian & 
Cronstein 2007).  
Biological agents have transformed the treatment of IBD in the past 20 years, and this remains an 
evolving field. In the UK a number of anti-TNF agents and vedolizumab are licenced for the treatment 
of both CD and UC. While recently ustekinumab has been licenced for the treatment of CD. Anti-TNF 
agents like infliximab and adalimumab are monoclonal antibodies that exert their anti-inflammatory 
effect by binding to and neutralising TNFα as well as inducing apoptosis in activated T cells and 
monocytes (reviewed by Levin et al. 2016). Infliximab is a chimeric antibody that needs to be 
administered intravenously, while adalimumab is humanised monoclonal antibody that can be 
administered subcutaneously. Vedolizumab is a humanised monoclonal antibody that blocks entry of 
pro-inflammatory T cells into the intestine by binding α4β7 integrin, a homing receptor on the surface 
of immune cells, that interacts with MAdCAM-1 on the vascular endothelium (Singh et al. 2016). 
Ustekinumab binds the p40 subunit common to the cytokines IL-12 and IL-23. The IL-23 inflammatory 
pathway has been implicated in the aetiology of IBD (Hue et al. 2006; Holm H. Uhlig et al. 2006). These 
agents are used as long-term treatments to maintain remission and are sometimes used to induce 
remission alone or in combination with corticosteroids. 
Unfortunately, despite increased options for medical therapy, a significant minority of IBD patients do 
not respond or stop responding to medical interventions leading to recurring inflammation. Surgery 
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remains an important option for these patients. Surgery for UC involves a colectomy, which 
permanently removes the diseased colon. However, the patient will necessarily either have a stoma 
or internal pouch which does not function the same as a healthy colon. CD can affect anywhere in the 
gastrointestinal tract. Surgery for CD usually involves only removing the affected part of the bowel. 
Most patients experience a significant improvement in symptoms after surgery. However, recurrent 
inflammation affecting the anastomosis or a different part of the intestine is common in the long term 
(reviewed by Baumgart & Sandborn 2012).  
In some individuals, the combination of genetic factors and environmental exposures leads to 
dysregulation of the intestinal immune system, loss of control of the response to commensals and 
chronic T cell inflammation driven by bacterial antigens. Section 1.6 will discuss the role of Mφs in the 
intestine during steady-state and inflammation. 
1.3.3.5 Mouse models of colitis  
 
Much of what we understand about the immunological mechanisms underpinning intestinal 
inflammation come from animal models. This section will provide an overview of the animal models 
and their drawbacks. 
There are four main types of IBD models: inducible colitis, spontaneous colitis, transgenic, and 
adoptive transfer. The most widely used mouse model of IBD is the dextran sulphate sodium (DSS)-
induced colitis. DSS causes defects in the epithelial barrier by altering the expression of tight junction 
proteins, which causes enhanced epithelial cell apoptosis in concurrence with reduced proliferation 
(Poritz et al. 2007). Collectively, this causes an increase in gut permeability, which provides the 
opportunity for commensal bacteria to enter the mucosa and trigger an overwhelming inflammatory 
response. This reveals the critical role of the epithelial barrier in providing a protective barrier against 
external pathogens, helping maintain immune homeostasis in the intestine. In support of this, mice 
deficient in Muc2, which normally forms the mucous barrier that protects the epithelium, develop 
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spontaneous colitis upon exposure to commensal bacteria resembling UC (Heazlewood et al. 2008; 
Van der Sluis et al. 2006; Wenzel et al. 2014). 
DSS treatment can be used to induce an acute, chronic, or relapsing model of colitis by administrating 
one high dose or multiple smaller doses via the drinking water, which can be easily monitored; the 
molecular weight is critical in determining the severity and location of the inflammation (reviewed by 
Perše & Cerar 2012). Mice in the chronic phase of DDS-induced colitis display colonic dysplasia, which 
resembles changes in the intestinal mucosa reported in human UC (reviewed by Perše & Cerar 2012). 
Dysbiosis of the intestinal microbiota has also been reported in the acute and chronic phase of DSS-
induced colitis, which again is a feature of IBD in humans (Okayasu et al. 1990). Although there are 
histopathological features in common with UC, features that characterise CD, including transmural 
inflammation and granulomas, are rare in DDS-induced colitis, therefore, this model is recognised as 
more representative of UC (Alex et al. 2009).  
Environmental exposure can be controlled in mouse models enabling a definitive effect of the 
intervention. However, differences in susceptibilities and progression between mouse strains have 
been reported, e.g. DSS-treated C57BL/6 progress to chronicity but not BALB/c mice (Melgar et al. 
2005), much like humans. This has been attributed to the genetic makeup of the mouse strains 
revealing the critic role of genetics in susceptibility. The role of microbiota in intestinal inflammation 
was revealed in DSS-treated mice reared in GF conditions, where colitis was not induced (Hudcovic et 
al. 2001). However, conflicting results showed intestinal microflora was not necessary for intestinal 
pathology but DSS itself is destructive to the intestine (Kitajima et al. 2001). In support of Hudcovic et 
al. 2001, antibiotic treatment was shown to improve the outcomes of DSS-treated mice (Hans et al. 
2000). A study testing current therapeutic agents on DSS-treated mice showed efficacy in treating the 
colitis, arguing that DSS-induced models are relevant for the translation of mouse data to human 
disease (Melgar et al. 2008). Models of DSS-induced colitis have already helped identify inflammatory 
mediators that have provided therapeutic targets, such as anti-TNFα therapy.   
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Less commonly used mouse models of inducible colitis are trinitrobenzene sulfonic acid (TNBS)-
induced colitis and oxazolone-induced colitis. TNBS is dissolved in ethanol to disrupt the intestinal 
barrier and enable the interaction of TNBS with colon proteins (locally administered). TNBS acts as a 
hapten, when coupled with colonic proteins, makes them immunogenic eliciting an acute Th1-
mediated immune response; chronicity can be achieved by repeated administration. However, Balb/c 
mice appear to develop Th2 inflammation, which provides another demonstration of the variation 
between mouse strains (reviewed by Antoniou et al. 2016). The pathophysiological properties of 
TNBS-treated mice reflect human CD, including transmural inflammation and granulomas (reviewed 
by Antoniou et al. 2016). In addition, the involvement of NOD2 (a key CD susceptibility gene) has been 
shown to be important in the pathogenesis of TNBS colitis (Yang et al. 2008). Current therapeutic 
agents showed efficacy in treating TNBS-induced colitis, which emphasises its similarity with human 
disease (Selve & Wöhrmann 1992). Oxazolone is also a hapten but it elicits a Th2-mediated immune 
response instead of Th1. The pathophysiological properties of oxazolone-treated mice reflect human 
UC, including superficial ulceration in the distal colon (Heller et al. 2002; Wang et al. 2004). Current 
therapeutic agents also showed improvement in oxazolone-induced colitis, which again suggests that 
the model is a good representation of human disease and provides a way to test the efficacy of 
therapeutic agents (Kojima et al. 2004). 
Genetically modified mice have provided an invaluable resource for studying the interactions between 
microbiota, genetic, and immunogenic factors in IBD. Models based on genetic modifications can be 
grouped into depletion/deficiency, adoptive transfer, and transgenic. Mice deficient in IL-2, IL-10, or 
TGF-β develop spontaneous colitis, which reflects the critical role of immune-regulatory signals (Berg 
et al. 1996; Kühn et al. 1993). Loss of any one of these immune-regulatory molecules can alone induce 
intestinal inflammation, indicating important non-redundant roles of each molecule.  
The contribution of the microbiota in training intestinal immune cells towards regulatory responses is 
highlighted in the adaptive transfer model where CD4+ T cells collected from mice reared in GF or 
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conventional conditions were transferred into SCID mice, and mice receiving CD4+ T cells from the GF 
reared mice developed colitis (Strauch et al. 2005). This was shown to be due to the lack of Tregs 
detected as a consequence of not being exposed to commensal bacteria. The role of pro-inflammatory 
immune cells has also been explored using the adoptive transfer model briefly mentioned. CD45RB+ 
cells (naïve CD4+ T cells) are transferred into SCID mice inducing a Th1-mediated response, which can 
be prevented by co-transferring Tregs (Morrissey et al. 1993), which again highlights the importance 
of balancing pro-inflammatory and regulatory responses.  
TNFα is a pro-inflammatory cytokine detected at elevated levels in IBD patients.  In mice, deletion of 
AU-rich elements (ARE) enhances the stability of mRNA encoding TNFα resulting in an increase in 
production in these mice, which develop spontaneous colitis as well as arthritis (Kontoyiannis et al. 
1999). Transgenic mice have enabled the identification of important components of the pro-
inflammatory pathway, including IL-7 and STAT4. Overexpression of IL-7, which is important for 
differentiation and proliferation of T cells, leads to pathophysiological outcomes that resemble UC, 
and STAT4 favours the differentiation of Th0 cells into Th1 cells, whereby overexpression of STAT4 
leads to an increase in IL-12 production and as a consequence elevated levels of IFNγ, which favours 
a Th1-mediated inflammation  (reviewed by Jurjus et al. 2004). 
Studies in IBD patients and animal models of colitis have identified mononuclear phagocytes (MPs) as 
key players. This next section will define the origins of these populations before going on to discuss 
their role in intestinal inflammation.   
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1.4 Origin of MPs 
 
1.4.1 Origin of MPs in the mouse  
 
All tissue-resident Mφs were once believed to be solely derived from monocytes. However, fate-
mapping experiments have provided a better insight into the heterogeneity of the ontogeny of tissue-
resident Mφs. Yolk sac (YS)-derived myeloid progenitors seed the brain, liver, and skin giving rise to 
microglia, Kupffer cells, and Langerhans cells respectively. Microglial and Kuppfer cells are maintained 
through self-renewal during adult life (Ginhoux et al. 2010; Hashimoto et al. 2013; Hoeffel et al. 2012; 
Mass et al. 2016; Yona et al. 2013). The first hematopoietic stem cells (HSCs) emerge from the YS and 
aorta–gonad–mesonephros (AGM) region, which then seed the foetal liver (FL) and finally colonise the 
bone marrow (BM), where they are responsible for the maintenance of haematopoiesis thenceforth 
(reviewed by Kleer et al. 2014). 
FL-derived monocytes contribute to the Langerhans cell and intestinal Mφ pool (Hoeffel et al. 2012). 
They also form pre-alveolar Mφs in the lung prenatally that subsequently differentiate into alveolar 
Mφs after birth, which are able to self-maintain (Guilliams et al. 2013). Langerhans cells derived from 
FL monocytes proliferate after birth making up the majority of the Mφ pool in the epidermis, and are 
also able to self-maintain (Hoeffel et al. 2012). In contrast, it has been shown the intestinal Mφs pool 
requires constant replenishment by circulating blood monocytes (Yona et al. 2013; Bain et al. 2014). 
One explanation for the requirement of continuous monocyte recruitment could be that maintaining 
immune plasticity in the intestine becomes important due to the constant exposure to commensal 
bacteria. However, the Mφ pool in the heart, a sterile environment, also requires the recruitment of 
circulating monocytes (Epelman et al. 2014; Molawi et al. 2014). A more recent study has shown that 
the intestinal Mφ pool is made up of three distinct populations with heterogeneous ontogeny (Shaw 
et al. 2018). The key findings from Bain et al., 2014 and Shaw et al., 2018 will be discussed in section 
1.6. 
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Figure 1.3: Summary of the ontogeny of tissue-resident Mφs. Tissue-resident Mφs arise at different 
stages of development and are derived from different sources of progenitor cells. Adapted from Kleer 
et al., 2014.  
 
HSCs give rise to progressively more committed common monocyte progenitors (cMoP) and common 
DC precursor (CDP). cMoP differentiate into monocytes in the BM, which is dependent on colony 
stimulating factors (CSF1&2) (refer to figure 1.4), and are then released into the blood where they 
patrol for pathogens or can be readily recruited to most tissues during inflammation (detailed in 
section 1.7). Upon arrival to the tissue, monocytes have the capacity to differentiate into a variety of 
monocyte-derived cells (MDC) that include different types of tissue Mφs and moDCs (Guilliams et al. 
2014). MDCs can express F4/80 and CD64, are highly phagocytic and poor at migration like Mφs 
(Tamoutounour et al. 2012; Tamoutounour et al. 2013), but can also express CD11c and induce naive 
T cells like DCs (Cheong et al. 2011; Plantinga et al. 2013). In support of this, irradiated mice given 
MDCs were able to form cDCs and several tissue-resident Mφs (Fogg et al. 2006). Although monocytes 
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have the ability to differentiate into both Mφs and DCs, weather moDCs occur in a physiological setting 
remains controversial 
The majority of DCs are believed to be derived from CDPs. CDPs are subdivide into pre-classical DCs 
(pre-cDCs) and pre- plasmacytoid DCs (pre-pDCs). Pre-cDCs leave the BM and give rise to cDCs types 
1&2 in peripheral tissues, while pre-pDCs terminally differentiate into pDCs in BM before seeding 
tissues (Guilliams et al. 2014). Initially, DC development relies on the cytokine FMS-like tyrosine kinase 
three ligand (FLT3), differentiation into DC subtypes is then controlled by a distinct set of transcription 
factors (refer to Figure 1.4) (Guilliams et al. 2014).  
 
Figure 1.4: Summary of Monocyte and DC development. cMoP and CDP develop from HSCs and 
terminally differentiate in the BM or tissue. Adapted from Guilliams et al. 2014.  
 
1.4.2 Origin of MPs in humans  
 
The ontogeny of MPs occurs in humans via a similar progression to mice (Tavian & Peault 2005) but 
with a different time course as there is a difference in length of the gestational period. Studies on 
embryonic samples have furthered our understanding of haematopoiesis in humans, which will be 
described in this section. Embryos can be obtained at different gestational stages immediately after 
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voluntary terminations, and the foetal age estimated based on anatomic structures (Tavian & Peault 
2005). Human embryos are rare and difficult to acquire, therefore, the findings have been verified in 
avian and mouse embryos, demonstrating the conservation in higher vertebrate (Godin & Cumano 
2005).  
Studies of these embryos revealed that haematopoiesis begins with the YS by week three and lasts for 
three to six weeks, during which myeloid progenitors develop into embryonic Mφs in tissues of the 
brain, liver, and skin (Tavian & Peault 2005). Generation of HSC occurs in the AGM at around week six, 
before they seed the FL between 10 and 22 weeks (Tavian & Peault 2005). In support of this, 
proliferative Mφs have been identified in extravascular mesenchymal tissue and intravascular spaces 
before BM formation (Enzan 1986). However, it is not clear when the transition between FL and BM-
derived myeloid progenitors occurs. HSC begin to seed the BM by week 15 (Hann et al. 1983). High 
levels of circulating HSCs are observed before 32 weeks, which may reflect the active transfer of HSC 
from FL to BM (Clapp et al. 1989). The HSCs present in the BM are then responsible for the 
maintenance of haematopoiesis throughout adult life. 
There is evidence that tissue-resident Mφs in humans show similar self-renewing properties as in 
mouse. Patients with limb transplantations still present with the donors Langerhans cells ten years 
after the procedure (Kanitakis et al. 2011). In addition, patients with loss-of-function (LoF) mutations 
in GATA2 (a regulator of gene expression in HSCs) lack monocytes and DCs but display normal 
Langerhans cells and alveolar Mφs (Bigley et al. 2011). The blood-brain barrier restricts access of 
monocytes to the brain, therefore, microglial cells must have the capacity for self-renewal at steady 
state. The origin of intestinal Mφs in humans remains elusive without the applicability of fate-mapping 
techniques. A study assessing turnover of intestinal Mφs in donor-derived small intestinal segments 
transplanted along with pancreas tissue revealed that all donor-derived Mφ subsets were completely 
replaced by recipient cells over time (Bujko et al. 2017), consistent with findings by Bain et al., 2014. 
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However, distinct populations with different rates of replacement were identified, reflecting the 
findings by Shaw et al., 2018 in mice.  
Parallel DC cell populations characterised in mice have been defined in humans based on 
transcriptional, phenotypical, and functional homology, therefore, their ontogeny is inferred from 
mouse studies (reviewed by Guilliams et al. 2014). Human cMoP have recently been identified that 
give rise to monocyte but not DCs, which is consistent with the separation of moDCs from the 
ontogeny of CDP (Kawamura et al. 2017).  
1.5 Tissue-resident Mφs and their functions 
 
There are specialised Mφs that reside in every tissue of the body, including microglia in the brain, 
Kupffer cells in the liver, and alveolar Mφs in the lungs. As described earlier, these tissue-resident Mφ 
are derived from primitive YS or FL progenitors, which are self-maintained during steady-state 
(Ginhoux et al. 2010; Guilliams et al. 2013; Hashimoto et al. 2013; Hoeffel et al. 2012; Mass et al. 2016; 
Yona et al. 2013). Classically and alternatively activated Mφ give rise to M1 and M2 Mφ respectively 
(reviewed by Italiani & Boraschi 2014). M1 Mφ are activated by signals, such as IFNγ and TNFα, and 
display inflammatory properties including TNFα and NO production, whereas M2 Mφ are activated by 
signals such as IL-4 and IL-13, and display reparative properties, including efferocytosis (phagocytosis 
of dead/dying cells) and IL-10 production (reviewed by Italiani & Boraschi 2014). In the context of 
inflammation, monocytes are recruited to the tissue, where they undergo maturation via a series of 
intermediaries and eventually acquiring the typical properties of M1 or M2 Mφs, through a process 
sometimes referred to as the “monocyte waterfall” (Tamoutounour et al. 2013). The direction of 
maturation is determined by the environment. This demonstrates that monocytes are plastic cells 
which can give rise to populations with distinct functions depending on local signals 
Tissue-resident Mφs have distinct functions, which are considered to be influenced by the local 
environment but the determining factors remain largely unknown. Microglial cells are important 
during development of the brain and neural circuitry, as well as preserving synapses. Mutations in the 
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CSFR in humans leads to the loss of myelin sheaths and axonal destruction (reviewed by Wynn et al. 
2013). Kupffer cells are involved in iron recycling when clearing old red blood cells (RBCs), lipid 
metabolism, and toxin removal (reviewed by Wynn et al. 2013). Alveolar Mφs are important in 
surveillance, maintaining homeostasis, and clearing surfactants (reviewed by Davies et al. 2013). A 
common feature of tissue-resident Mφs is that they are critical in the development and maintenance 
of normal organ function. However, Mφs have also been associated with the pathogenesis of 
inflammatory and degenerative diseases, such as multiple sclerosis (MS) and liver fibrosis (reviewed 
by Wynn et al. 2013). Intestinal Mφs have distinct specialisations for their microbe-rich environment, 
which will be discussed in more detail below.  
1.5.1 Intestinal Mφs in the mouse  
 
Historically, studying the role of intestinal Mφs has proven challenging due in part to overlapping in 
expression of surface markers with DCs, making it uncertain how to differentiate between the two 
populations. As a result, findings can be ambiguous when interpreting the literature. This has driven 
the use of multi-parameter analysis combining expression of surface markers with functional 
characteristics. Surface markers used to identify Mφs include F4/80+, CD64+, and  high levels of CX3C 
chemokine receptor 1 (CX3CR1hi), in combination with MHCII and CD11b, while DCs are defined by 
CD11chi, CD103+, and MHCIIhi expression in the absence of CD64 (reviewed by Joeris et al. 2017). Mφs 
are phagocytic and bactericidal, while DCs have the capacity to migrate to the MLNs and activate naïve 
T cells (Rivollier et al. 2012; Schulz et al. 2009). It is unclear why Mφs highly express MHCII when they 
lack the capacity to migrate to MLNs and activate naïve T cells. A possible role is presenting antigens 
to local T cells; the IL-10 produced by Mφs may contribute to the secondary expansion and 
maintenance of Tregs and inhibition of effector T cell responses (Hadis et al. 2011; Kayama et al. 2012). 
This suggests a role of intestinal Mφs in inducing tolerance, which is consistent with their capacity to 
capture and present antigens and their regulatory properties.  
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Intestinal Mφs in the mucosa are positioned directly under the epithelium, making them the first line 
of defence and ideal to capture and destroy invading pathogens. Upon activation, Mφs initiate 
bacterial killing via the production of reactive oxygen species (ROS) (reviewed by Nathan & 
Cunningham-Bussel 2013). As described previously, mice deficient in ROS formed abscesses 
containing commensal organisms, highlighting the role of intestinal Mφs in controlling the intestinal 
microbiota (Shiloh et al. 1999). In addition, CX3CR1+ Mφ sample the intestinal lumen for soluble 
antigens and transfer them to CD103+ DCs (Mazzini et al. 2014), which have the unique ability to prime 
naive T cells (Schulz et al. 2009). These interactions are critical in training the adaptive immune cells 
to elicit the appropriate response when presented with beneficial bacteria vs invasive pathogens.   
At steady state, intestinal Mφs constitutively produce IL-10 (Bain et al. 2013; Rivollier et al. 2012), 
which has an important regulatory role (Denning et al. 2007; Krause et al. 2015). Moreover, intestinal 
Mφs downregulate their expression of TLRs and are able to mediate bacterial killing without the 
production of pro-inflammatory cytokines (Platt et al. 2010). Intestinal Mφs do produce IL-1β, which 
supports the development of pro-inflammatory Th17 cells in the mucosa (Shaw et al. 2012). Th17 cells 
are enriched in the LP at steady-state, and there is increasing evidence that they contribute to the 
defence against invading bacteria by their production of a number of signature cytokines, such as IL-
17, IL-22, and IL-21 (Annunziato et al. 2007; Wilson et al. 2007). IL-17 plays an important role in 
coordinating a response against pathogenic insults (reviewed by Witowski et al. 2004). IL-22 is a 
member of the IL-10 cytokine family, and it stimulates epithelial cells to enhance antimicrobial 
defence and epithelial barrier integrity (Zheng et al. 2008). However, Th17 cells are associated in the 
pathogenesis of IBD based on GWAS studies (e.g. CPEB4 loci is a transcriptional target of RORγt, a key 
determinant of Th17 cell differentiation), elevated levels of IL-17 production found in both CD and UC 
patients, and models of experimental colitis (reviewed by Wei et al. 2017).  
As mentioned earlier, tissue-resident Mφs have commonly been characterised as M1 or M2 based on 
mediators they produce. However, this method of characterisation is increasingly regard as too rigid 
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particularly for intestinal Mφs because subsets have been identified that display overlapping 
properties, which may reflect a developmental continuum (with the continuous recruitment of 
monocytes) that is progressively imprinted by their local environment giving rise to heterogeneous 
populations that cannot be classified into the simplistic M1-M2 paradigm (reviewed by Biswas & 
Mantovani 2010; Mosser & Edwards 2009). 
Consistent with the functions of other tissue resident Mφs, intestinal Mφs also perform a 
housekeeping role. Intestinal Mφs expression of CD36 (a scavenger receptor), which is involved in the 
clearance of dead cells and debris (reviewed by Smith et al. 2011). Prostaglandin E2 (PGE2) production 
by intestinal Mφs promotes the proliferation of epithelial progenitors in the intestinal crypts (Pull et 
al. 2004; Grainger et al. 2013), which highlights their role regulating the integrity of the epithelial 
barrier, involved in the pathogenesis of UC. Counter-intuitively, intestinal Mφs constitutively produce 
a low level of TNFα at steady-state (Bain et al. 2013), which indicates that this level of TNFα does not 
induce pro-inflammatory responses. It has been shown that the TNFα has a role in promoting 
enterocyte growth, regulating the permeability of the epithelium, and stimulating the production of 
tissue remodelling enzymes (Ma et al. 2004).  
Collectively, intestinal Mφ provide a critical defence against invading pathogens while maintaining 
their regulatory properties, and carrying out housekeeping roles that are important in preserving a 
stable environment and may promote local regulatory responses. All things considered, it is not 
surprising that selective depletion of intestinal Mφs results in increased susceptibly and severity of 
DDS-induced colitis (Qualls 2006). However, consistent with the other tissue Mφs, intestinal Mφs have 
also been implicated in intestinal inflammation. This will be discussed in detail in section 1.6.  
1.5.2 Intestinal Mφs in humans   
 
Human intestinal Mφs do not express F4/80 but do express CD64, CX3CR1hi and MHCIIhi (reviewed by 
Mowat & Bain 2011; Smith et al. 2011; Smith et al. 2005). CD64 expression on human Mφs can also 
be used to distinguish between intestinal Mφs and DCs (Langlet et al. 2012; Tamoutounour et al. 
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2012). Intestinal Mφs in humans are highly phagocytic and bactericidal but resistant to TLR stimulation 
and poor producers of pro-inflammatory cytokines, much like in mouse (Smythies et al. 2005). The 
bactericidal properties of human intestinal Mφs are independent of ROS (Mahida et al. 1989), and the 
mechanisms by which intestinal Mφs execute bacterial killing are unknown. There is conflicting data 
on the constitutive production of IL-10 in human intestinal Mφs depending on the anatomical site 
examined. Bujko et al., 2017 did not detect IL-10 production by human jejunal Mφs at baseline or 
upon TLR activation, which is in support of previous studies reporting a lack of IL-10 production by 
human jejunal Mφs (Smythies et al. 2005; Smythies et al. 2010), whereas human colonic Mφs have 
been shown to produce IL-10 (Kamada et al. 2008; Ogino et al. 2013). IL-10 producing Mφs have also 
been shown to be more frequent in the large intestine compared with small intestine in the mouse 
(Krause et al. 2015).  
The resistance of human intestinal Mφs to TLR stimulation can be partly explained by the 
downregulation in expression of TLRs or other molecules involved in microbial recognition, for 
example during the differentiation of blood monocytes into intestinal Mφs there is a downregulation 
of CD14 expression (Smith et al. 2001; Smythies et al. 2005). However, intestinal Mφs express TLR3 
and TLR5–9 but do not respond to stimulation with the corresponding TLR agonists (Smythies et al. 
2010), which indicates that there are other mechanisms facilitating their resistance to TLR stimulation. 
NFκB is a transcription factor that is activated upon TLR stimulation. During steady state, NFκB is 
retained in the cytosol by its association with the protein IκBα. Upon stimulation of TLRs, IκBα is 
phosphorylated and targeted for degradation, freeing NFκB to translocate into the nucleus where it 
promotes the transcription of pro-inflammatory cytokines (reviewed by Baldwin 1996). Intestinal Mφs 
have a reduced ability to phosphorylate IκBα in response to microbial stimulation and down-regulated 
adapter proteins MyD88 and TRIF (Smythies et al. 2010). Collectively, these components contribute 
to the regulatory properties of intestinal Mφs. The signals required to promote these regulatory 
properties during monocyte differentiation are discussed in section 1.6.  
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1.6 The role of Mφs in health and disease  
 
1.6.1 The role of Mφs in health and disease in the mouse  
 
A study by Bain et al., 2014 showed that self-renewing Mφ (embryonic precursors) are replaced by 
monocyte-derived Mφ during the neonatal period. In the absence of inflammation, newly recruited 
monocytes lose their inflammatory properties as they mature into ‘regulatory Mφs’, however, during 
inflammation this process is disrupted, and the recruited monocytes retain their inflammatory 
properties resulting in the accumulation of ’inflammatory Mφs’ (refer to Figure 1.5). This phenomenon 
has previously been reported but the inflammatory Mφs were labelled as DCs (Rivollier et al. 2012; 
Zigmond et al. 2012). Bain et al. 2013 were also able to demonstrate a context-dependent 
differentiation of Ly6Chi monocytes. It was first shown that resident Mφs did not change their 
properties during inflammation and that there was no distinct population of inflammatory Mφs 
carrying out a separate function. Instead, recruited monocytes were the source of both Mφ 
phenotypes (Weber et al. 2011; Bain et al. 2013). The data showed the transition of Ly6Chi monocytes 
into resident Mφs via intermediary phases, where the cells still retained their pro-inflammatory 
properties. During colonic inflammation, there was an accumulation of cells in the intermediate phase 
(Weber et al. 2011; Bain et al. 2013). This suggests that during inflammation the full maturation of 
Ly6Chi monocytes into non-inflammatory Mφs is disrupted, which results in an accumulation of 
inflammatory Mφs that further contribute to the inflammation. This context-dependent 
differentiation of Ly6Chi monocytes provides the plasticity for intestinal Mφs to respond to pathogenic 
insults. However, during chronic intestinal inflammation, there is a breakdown in the feedback 
mechanisms required to return to steady-state and begin repairs.  
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Figure 1.5: Monocyte recruitment to the intestine. In the absence of inflammation, Ly6Chi monocytes 
are continuously recruited to the intestine where they replenish the Mφ pool. These monocytes lose 
their inflammatory properties as they mature into regulatory Mφs. However, during inflammation, 
this process is disrupted, and the monocytes retain their inflammatory properties to mature into pro-
inflammatory Mφs. The figure is based on data from Bain et al. 2013.  
 
A recent study by Shaw et al., 2018 described three similarly sized intestinal Mφ populations, based 
on expression of Tim-4 (apoptotic cell uptake receptor) and CD4, with distinct replenishment rates. 
Tim-4+CD4+ Mφ were self-maintained, Tim-4-CD4+ Mφ displayed slow turnover from blood 
monocytes, and Tim-4-CD4- Mφ showed rapid replacement. In support of this, Tim-4+CD4+ cells were 
dominant in CCR2 KO mice (Shaw et al. 2018). These recent findings suggest there are locally 
maintained intestinal Mφ in addition to the monocyte-derived Mφ described by Bain et al., 2014, 
which may have been overlooked due to not being able to discriminate them from the monocyte-
derived population. Interestingly, exposure to commensal bacteria was required for the development 
of all three populations, independent of ontogeny (Shaw et al. 2018). This highlights the role of 
environmental cues in determining Mφ function. In support of this, a key study showed that YS-
derived Mφ (YS-Mφ), FL monocytes, and adult monocytes could all colonise an empty alveolar niche 
and differentiate into functional and self-maintaining AM (Van de Laar et al. 2016).  
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The environmental conditions that determine monocyte differentiation into regulatory or 
inflammatory Mφs are poorly understood but there are data to support a role for both IL-10 and TGF 
in the generation of the regulatory population. Conditional knock out (KO) mice were created in which 
the IL-10R was selectively deleted from Mφs using CX3CR1 to direct Cre recombinase enzymes to cut 
at LoxP sites on the IL-10R gene (Zigmond et al. 2014). These mice developed severe enterocolitis 
driven by exposure to commensal bacteria, with a phenotype similar to that observed in mice with IL-
10 deficiency. Immunofluorescence analysis showed an accumulation of Mφs with an inflammatory 
phenotype in the LP, which resembled the intermediate inflammatory cells previously described. This 
highlights that the ability of intestinal Mφs to respond to IL-10 is critical to maintaining immune 
homeostasis. In part, the role of IL-10 may be to directly promote the differentiation of newly arrived 
monocytes into regulatory Mφs. Alternatively, the accumulation of inflammatory Mφs may be a 
consequence of the inflammation that develops in IL-10R deficient animals rather than a direct 
consequence of the inability of these cells to respond to IL-10. In support of IL-10 being the critical 
signal, Shouval et al. 2014 showed IL-10Rβ KO mutations targeting innate immune cells impaired the 
generation and function of regulatory intestinal Mφs. 
TGFβ has also been shown to be a crucial signal in promoting monocyte differentiation into regulatory 
Mφs, as well as regulating the accumulation of monocytes in the intestine (Schridde et al. 2017). 
Importantly, Schriddle et al., 2017 showed that TGFβ and IL-10 imprint the distinct properties of 
intestinal Mφs by comparing the global transcriptome of TGFβR-deficient Mφs with that of published 
transcriptome from IL10R-deficient Mφs: TGFβ shapes their tissue repair and scavenging functions, 
and IL-10 downregulates their capacity to produce pro-inflammatory mediators. There is evidence 
that TGFβ is also important in the development and self-maintenance of alveolar Mφ and microglial 
cells (Butovsky et al. 2014; Yu et al. 2017). This is consistent with the concept that environmental cues, 
and not the developmental origin, are the major determinants of Mφ function.  
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Collectively, these studies show TGFβ and IL-10 act synergistically to control the inflammatory activity 
of newly arrive monocytes and imprint the regulatory phenotype of intestinal Mφ (refer to Figure 1.6).  
 
Figure 1.6: Mediators of intestinal Mφ development. The local signals required for monocyte 
differentiation into ‘regulatory’ Mφs during steady-state are unclear; IL-10 and TGFβ have both been 
shown to have important non-redundant roles. The figure is based on a collection of data from 
Zigmond et al., 2014, Shouval et al., 2014, and Smythies et al., 2005. 
 
1.6.2 The role of Mφs in health and disease in humans 
 
Bujko et al. 2017 identified four Mφ populations (Mf1-4) in human small intestine and tracked their 
turnover in patients who underwent a pancreatic transplant with an associated small intestinal 
segment; Mf1 and Mf2 showed rapid turnover and were phenotypically similar to blood monocytes, 
whereas Mf3 and Mf4 showed significantly slower replacement and displayed progressively similar 
properties typical of intestinal Mφ, which suggests a developmental relationship between monocytes 
and intestinal Mφs. The study by Bain et al., 2013 characterised Mφs isolated from the human ileum, 
and suggested a pattern of maturation from CD14hi cells to CD14lo cells through intermediate stages, 
similar to that found in mice. The distribution of these cell populations was compared in healthy ileum 
and ileum from a CD patient. An accumulation of CD14+ cells was observed in the ileum of the CD 
patient, reflecting the murine model of colonic inflammation (Bain et al. 2013). Multiple studies have 
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observed the same increase in the proportion of CD14+ cells isolated from the mucosa of CD patients 
in comparison to healthy controls (M. C. Grimm et al. 1995; Kamada et al. 2008; Lissner et al. 2015; 
Rugtveit et al. 1997; Thiesen et al. 2014; Magnusson et al. 2016; Jones et al. 2018). This suggests that 
the same disruption in monocyte differentiation into resident Mφsreported in mice may also occur in 
humans; the increase in the number of CD14+ cells in IBD may result in increased production of 
inflammatory mediators, and therefore perpetuating the intestinal inflammation. A study mapping 
transcriptional changes during monocyte differentiation in vitro, in the presence of CSF-1, showed 
that LPS-inducible genes were strongly enriched for those identified as IBD susceptibility loci in GWAS 
(Baillie et al. 2017). This indicates that dysregulation of monocyte differentiation in the intestine is a 
key process in the pathogenesis of IBD. However, the local signals that cause this disruption in 
monocyte maturation are unclear.  
There have been few studies on the factors that control the differentiation of Mφs within the human 
intestine but murine data suggest a potential role for TGFβ and IL-10. TGFβ produced by stromal cells 
has been shown to drive downregulation of both TLR expression and cytokine production in 
monocytes, resembling intestinal Mφs, during in vitro culture (Smythies et al. 2005). The induction of 
these regulatory properties is partly due to a reduced capacity to phosphorylate NFκB as a result of 
TGFβ signalling (Smythies et al. 2010). As mentioned earlier, enhanced SMAD7 expression has been 
observed in T cells extracted from inflamed mucosa (Fantini et al. 2009), which provides resistance to 
Treg-mediated suppression by interfering with SMAD2/3 mediated TGF signalling. A similar effect on 
signalling could also be true in monocytes, where a reduced TGFβ signal would favour their 
differentiation into inflammatory Mφs but this has yet to be tested. In mice, IL-10 has been shown to 
be important during monocyte differentiation into resident Mφs(Zigmond et al. 2014; Shouval et al. 
2014). If this is true in humans, then a reduced response of monocytes to IL-10 would shift the 
favourability of monocyte differentiation towards inflammatory Mφs. Accumulation of inflammatory 
Mφs in the intestine of IBD patients could be the exacerbating factor that sustains inflammation in 
these patients.  
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1.7 Monocyte subsets in health and disease   
 
Monocytes are highly plastic cells that can be imprinted by the environment and rapidly respond to 
inflammatory cues. Monocytes themselves are made up of heterogeneous populations that have 
distinct functions. Monocytes were considered to simply be progenitors of tissue-resident Mφs and 
some DCs. However only some tissue Mφs, including those in the intestine, are monocytes derived. 
This has driven investigations into the roles and characteristics of monocytes in as effector cells in 
their own right, and these will be detailed in this section.  
1.7.1 Monocyte subsets in the mouse  
 
Two main monocyte subsets have been characterised in mice based on their expression of lymphocyte 
antigen six complex locus C1 (Ly6C) (Geissmann et al. 2003). The function of Ly6C is poorly understood 
but it is known to be expressed in a lineage-specific manner, and therefore it is often used as a marker 
of differentiation (reviewed by Lee et al. 2013).  Ly6Chi monocytes leave the BM and enter the 
bloodstream, where a small proportion down-regulate their Ly6C expression to mature into Ly6Clo 
monocytes (Sunderkotter et al. 2004; Yona et al. 2013). C/EBPb drives Ly6Chi differentiation into Ly6Clo 
by promoting NR4A1, a master regulator of differentiation and survival of Ly6Clo monocytes (Hanna et 
al. 2011; Mildner et al. 2017). In a recent publication on monocyte nomenclature, the addition of an 
intermediary subset was proposed (Ziegler-heitbrock et al. 2014). However, this intermediary subset 
has not been well characterised in mice.  
Ly6Chi monocytes highly express C-C chemokine receptor type 2 (CCR2), which mediates monocyte 
release from the BM as demonstrated in CCR2 KO mice (Boring et al. 1997; Jia et al. 2008; Serbina & 
Pamer 2006; Tsou et al. 2007). However, the contribution of CCR2 in recruiting monocytes to sites of 
inflammation is unclear and may be tissue-specific. Through the use of fate-mapping, Bain et al. 2014 
showed that Ly6Chi monocytes are continuously recruited to the intestine in a CCR2-dependent 
manner. In support of this, CCR2-sufficient Ly6Chi monocytes fail to enter CCL2-deficient intestine 
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(Takada et al. 2010). During inflammation CCL2 expression is increased, indicating enhance 
recruitment of Ly6Chi monocytes (Nenci et al. 2007). The newly recruited monocytes differentiate into 
intestinal Mφ in a context-dependent manner, demonstrating their capacity to respond to 
environmental cues and that Ly6Chi monocytes are highly plastic cells (Schridde et al. 2017; Bain et al. 
2013). In addition, monocytes can enter tissues in steady-state and then recirculate to the lymph 
nodes (LNs) without differentiation into Mφs, challenging the concept that monocytes become tissue-
resident Mφ by default (Jakubzick et al. 2013).  
The main role of Ly6Clo monocytes is to remain in the bloodstream and patrol the endothelium, which 
is dependent on the integrin LFA-1 (Auffray et al. 2007). CX3CR1 is highly expressed in Ly6Clo 
monocytes, which mediates patrolling and rapid tissue invasion at the site of an infection, making 
them a part of the early inflammatory response (Auffray et al. 2007; Ancuta et al. 2003). Auffray et al., 
2007 showed in the first two hours of infection, Ly6Clo monocytes are the major source of TNFα, which 
was transiently produced and genes involved in tissue repair were turned on. The half-life of Ly6Chi 
monocytes is relatively short (20 hours), consistent with the concept that they are readily recruited to 
tissues, while Ly6Clo monocytes have a half-life of two days (Yona et al. 2013). 
1.7.2 Monocyte subsets in humans  
 
There are three major monocyte subsets in humans, which can be characterised based on their 
expression of CD14 and CD16 (FcγIII): classical (CD14++CD16-), intermediates (CD14++CD16+), and 
non-classical (CD14+CD16++) monocytes (Passlick et al. 1989; Ziegler-heitbrock et al. 2014). CD14 acts 
with TLR4 as a co-receptor for lipopolysaccharides (LPS), in the induction of pro-inflammatory 
responses (reviewed by Dobrovolskaia & Vogel 2002). CD16 is a low-affinity Fc receptor for IgG, which 
is expressed on a number of immune cells, including neutrophils and NK cells (Lisi et al. 2011).  
A study in macaques showed that the three monocyte subsets are not isolated populations, instead 
they represent a maturation pathway: classical monocytes are released from the BM into the 
bloodstream, where a proportion mature via an intermediate monocytes phase into non-classical 
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monocytes (Sugimoto et al. 2015). A more recent study, using in vivo deuterium labelling to follow 
monocytes in response to endotoxemia (LPS in the blood) and by analysis of humanised mice have 
identified a maturation pathway for human blood monocytes that is similar to mice (refer to Figure 
1.7) (Patel et al. 2017). Healthy volunteers were given deuterium-labelled glucose (incorporated into 
the DNA of dividing cells but not carcinogenic) drink at short intervals, and their monocyte subsets 
were then flow-sorted at sequential time points and analysed for deuterium incorporation. The 
sequence in which the monocyte subsets with deuterium incorporation appeared in the blood was 
used to predict their maturation using mathematical modelling. Healthy volunteers received a low 
dose of LPS intravenously, which causes monocytopenia and the sequence of recovery of the 
monocyte subsets in the blood was then followed. Finally, humanised mice were injected with classical 
monocytes, and their development was then tracked. The relative lifespan of human monocyte 
subsets are consistent with mice: classical monocytes have a short half-life (one day), while non-
classical monocytes have a half-life of seven days. Intermediate monocytes also display a short half-
life (four days), supporting the concept that they represent a transition between classical and non-
classical monocytes. 
Gene expression analysis comparing the monocyte subsets in humans and mice indicate that the 
classical monocytes resemble Ly6Chi monocytes, while non-classical monocytes resemble Ly6Clo 
monocyte (Figure 1.6)(Ingersoll et al. 2010). CCR2 is highly expressed on classical monocytes, drawing 
parallels with the mouse data discussed above, this is consistent with the concept that this subset is 
readily recruited to the intestine. Classical monocytes have also been labelled as ‘inflammatory’ 
monocytes because they display robust production of pro-inflammatory cytokines in response to 
various TLR agonists (Belge et al. 2002; Boyette et al. 2017; Cros et al. 2010; Thiesen et al. 2014).  
The intermediate subset was not recognised in mice until recently, and as a result, relatively little is 
known about this subset. Gene expression profiling revealed that 87% of genes and surface proteins 
in intermediate monocytes were expressed at levels between classical and non-classical monocytes, 
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consistent with their proposed intermediary nature (Wong et al. 2011). However, analyses of their 
transcriptome using SuperSAGE revealed unique identifiers of intermediate monocytes involving 
antigen presentation, activation, and angiogenesis, which provides genetic evidence for distinct roles 
(Zawada et al. 2011). Studies have shown that intermediate monocytes display a high capacity to 
produce pro-inflammatory cytokines in response to various TLR agonists in vitro (Belge et al. 2002; 
Boyette et al. 2017; Cros et al. 2010; Thiesen et al. 2014). In addition, an expansion in intermediate 
monocytes has been reported in acute infections, such as sepsis, as well as chronic inflammation, 
including IBD, rheumatoid arthritis (RA), and atherosclerosis (Fingerle et al. 2018; Nockher et al. 1998; 
Rossol et al. 2012; Schlitt et al. 2004; Thiesen et al. 2014). Collectively, these indicate that intermediate 
monocytes may not simply be a population transiting between classical and non-classical monocytes 
but may have functional activities distinct from either of the other subsets.  
Non-classical monocytes highly express CX3CR1, resembling Ly6Clo monocytes, which is consistent with 
the concept that this subset patrol the endothelium as CX3CR1 was shown to be critical in this role in 
mouse (Auffray et al. 2007; Thiesen et al. 2014). Studies have shown that non-classical monocytes 
respond poorly to various TLR agonists and have a low capacity to produce pro-inflammatory cytokines 
(Belge et al. 2002; Boyette et al. 2017; Thiesen et al. 2014; Cros et al. 2010). However, non-classical 
monocytes display a robust response to TLR7/8 (viral recognition) agonists, which suggest that this 
subset has the capacity to be pro-inflammatory in certain contexts (Cros et al. 2010).  
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Figure 1.7: Monocyte subsets and their function. Ly6Chi monocytes replenish the intestinal Mφ pool, 
while Ly6Clo monocytes remain in the bloodstream and patrol for pathogens. Gene expression analysis 
revealed similarities between Ly6Chi and classical monocytes, while Ly6Clo monocytes showed 
similarities to non-classical monocytes. These are not isolated populations but represent stages of 
differentiation. The figure is based on a collection of data from Bain et al., 2014, Auffray et al., 2007, 
Yona et al., 2013, Ingersoll et al., 2010, Patel et al.,. 2017. 
 
1.7.3 Role of monocytes in intestinal inflammation in the mouse 
 
An increase in CCL2 expression has been observed in mucosal inflammation indicating enhance 
recruitment of Ly6Chi monocytes, which may contribute to the persisting inflammation (Nenci et al. 
2007). In support of this, CCR2 KO mice display reduced susceptibility to DSS-induced colitis (Platt et 
al. 2010). A recent study further implicates monocytes in gut inflammation: Schippers et al. 2015 
showed that β7 integrin deficiency in mice was protective against DSS-induced colitis in Rag-deficient 
mice due to reduced monocyte recruitment. Injecting WT Ly6Chi monocytes but not β7 integrin-
deficient monocytes, caused an aggravation of the colitis in these mice. This again indicates that 
monocytes are a critical contributor of inflammation in already inflamed conditions. However, there 
has been no evidence yet that monocytes are the trigger of inflammation. 
Alternatively, studies have shown that monocytes have a regulatory role during inflammation. As 
mentioned previously, NOD2 mutations are associated with CD pathogenesis considered to be due to 
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the impaired clearance of pathogenic bacteria (Cooney et al. 2010; Kim et al. 2011). Stromal cells 
produce CCL2 in a NOD2-dependent manner, demonstrated by the reduced production of CCL2 in 
NOD2 KO mice (Kim et al. 2011). The subsequent reduction in monocyte recruitment results in 
impaired clearance of pathogens as adoptive transfer of Ly6Chi monocytes restored the clearance of 
pathogens (Kim et al. 2011). In addition, orally inoculated with Toxoplasma gondii, a parasite, showed 
that monocytes were primed for regulatory function in the BM by systemic inflammatory signals 
received from the intestine and relayed by NK cells (Askenase et al. 2015). This study demonstrates 
that the function of intestinal Mφs can be regulated at two levels: locally by the environment and 
systemically via the BM, and these can interact i.e. systemic signals from the intestine during 
inflammation can cause functional changes in progenitors in the BM, termed ‘trained immunity’. The 
concept of ‘trained immunity’ was considered to apply to mature myeloid cells but it is now evident 
that myeloid progenitors are also involved. Myeloid progenitors expand in the BM in response to β-
glucan (a component of the cell wall of bacteria and fungi), and these progenitors displayed functional 
changes, including elevated IL-1β, which coincided with a more robust response to secondary LPS 
challenge (Mitroulis et al. 2018). These observations demonstrate the benefits of ‘trained immunity’ 
for the host's defence against pathogens. Another study observed the same expansion of myeloid 
progenitors with greater capacity to produce pro-inflammatory cytokines in response to a high-fat diet 
(Christ et al. 2018). Thus, there is evidence that reprogramming of myeloid cell development in BM 
can both promote inflammatory activity (Christ et al., 2018; Mitroulis et al., 2018) and regulatory 
properties (Askenase et al., 2015) with the outcome likely to vary between different contexts and 
experimental models. The implication of trained immunity identified in the context of acute 
inflammation for chronic inflammatory diseases like IBD remains to be explored.  
1.7.4 Role of monocytes in intestinal inflammation in humans  
 
There is direct evidence that there is enhanced monocyte recruitment to inflamed mucosa: peripheral 
blood mononuclear cells (PBMCs) isolated from IBD patients were radiolabelled and re-injected before 
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abdominal scanning, which demonstrated monocyte uptake at actively inflamed regions  (Grimm et 
al. 1995). In addition, enhanced expression and production of CCL2 has been observed in IBD patients 
(Grimm et al. 1996), reflecting observations by Nenci et al., 2007 in the mouse. 
There is also evidence in humans that systemic signals from the intestine during inflammation cause 
functional changes to circulating cells. One study showed that the BCG vaccine given to volunteers 
improved their symptoms of viremia when a second vaccine with the live attenuated yellow fever 
vaccine (YFV) was given four weeks later compared to placebo, and PBMCs isolated from volunteers 
given the BCG displayed greater capacity to produce proinflammatory cytokines (Arts et al. 2018). 
Another study showed that monocyte-derived Mφ (moMφ) from CD patients displayed reduced TNFα 
production in response to E.coli compared to healthy controls (Smith et al. 2009). Furthermore, 
monocytes showed reduced retinaldehyde dehydrogenase (RALDH) activity in CD patients, which 
favours the differentiation of Mφ with an inflammatory phenotype in vitro (Sanders et al. 2014). The 
concept that systemic signals from the intestine during inflammation cause functional changes to 
circulating cells formed the rationale for studying blood monocytes, as the likely precursors of 
intestinal Mφ. The rationale for studying IL-10 response will be covered in the subsequent section. 
1.8 The importance of IL-10 in regulating intestinal inflammation   
 
IL-10 is mainly produced by leukocytes, including monocytes, Mφs, and Tregs (reviewed by Kole & 
Maloy 2014). The production of pro-inflammatory cytokines is inhibited by IL-10, and therefore, is 
considered an anti-inflammatory cytokine. IL-10 acts on both myeloid cells and lymphoid cells to 
suppress innate and adaptive inflammatory responses. It has been over 20 years since the observation 
that IL-10 deficient mice developed colitis upon exposure to commensal gut bacteria (Kühn et al. 
1993), which revealed an essential role for IL-10 in maintaining immune homeostasis in the intestine. 
The role of IL-10 in the steady-state and inflamed intestine will be examined in this section.  
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1.8.1 IL-10R signalling   
 
IL-10 signals through the IL-10R, which is a tetramer consisting of two α and two β chains; the α chain 
is specific to the IL-10R, while the β chain appears in other cytokine receptors, including IFNλ and IL-
22 receptors (reviewed by Moore et al. 2001). The α chain has been shown to be important in 
mediating high-affinity binding and signal transduction, while the β chain is mainly required for 
signalling (Kotenko et al. 1997). Upon binding of IL-10 onto IL-10Rα, IL-10Rβ is recruited, and the 
receptor becomes activated (reviewed by Mosser & Zhang 2008). The activation of the receptor 
triggers a phosphorylation cascade involving Janus kinase 1 (JAK1), TYK2, and STAT3 (Riley et al. 1999). 
Phosphorylated STAT3 molecules dimerise and translocate to the nucleus where they modify gene 
expression to bring about immune regulation but the events following DNA binding are poorly 
understood. Suppressor of cytokine signalling 3 (SOCS3) transcription is induced by STAT3, and is a key 
regulator of the activity of IL-10, including inhibition of the NFκB pathway, as well as negative feedback 
to suppress further IL-10 signalling (refer to Figure 1.8)(Mosser & Zhang 2008). The role of IL-10 in 
regulating intestinal inflammation will be discussed further in this section.  
 
Figure 1.8: IL-10R signalling pathway. Upon activation of the 
IL-10R, phosphorylated STAT3 undergoes dimerisation and is 
translocated to the nucleus where it promotes the 
transcription of SOCS3. SOCS3 inhibits the NFκB pathway, 
which prevents the release of inflammatory cytokines, 
including TNFα, IL-6, and IL-1β. The figure is based on a 
collection of data from Moore et al., 2001, Mosser & Zhang, 
and Riley et al., 1999 
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1.8.2 The role of IL-10 in the murine intestine 
 
IL-10 is a critical cytokine in preventing excessive inflammatory responses to innocuous agents, as 
demonstrated in murine models. IL-10 deficient mice developed chronic enterocolitis (inflammation 
of the small intestine and colon) driven by exposure to pathobiome (Berg et al. 1996; Kühn et al. 1993). 
Mice that are selectively deficient in MyD88 in Mφs, and therefore lack bacterial sensing do not 
develop colitis in an IL-10 deficient setting (Hoshi et al. 2012). These findings demonstrate that IL-10 
is important in preventing inflammatory responses against commensal bacteria. Treatment with IL-10 
prevents the development of colitis in IL-10 deficient mice and DSS-treated mice (Lindsay et al. 2003; 
Steidler et al. 2000). This further supports the importance of IL-10 in regulating inflammation even in 
the setting of induced inflammation. A recent study showed that IL-10-deficiency contributes to a loss 
of intestinal Mφ tolerance to bacteria as assessed by chromatin alterations mimicking inflammation, 
which is an initiating event in chronic intestinal inflammation (Simon et al. 2016). IL-10 has also been 
shown to be involved in promoting mitophagy (mitochondrial autophagy) that eliminates 
dysfunctional mitochondria; in IL-10 deficient mice and IL-10R-deficient patients, Mφs accumulate 
damaged mitochondria resulting in enhanced activation of the inflammasome and subsequent 
production of IL-1β (Ip et al. 2017). These provide mechanisms by which Mφs contribute to intestinal 
inflammation in the absence of IL-10 signalling. 
IL-10 has the potential to act on myeloid and lymphocyte populations to control inflammation, and 
until recently it was unclear which is the critical population whose response to IL-10 is essential in 
preventing the development of intestinal inflammation. Two studies by Shouval et al. 2014 and 
Zigmond et al. 2014, in which the IL-10R was selectively deleted in Mφs, support the concept that 
these cell populations are the critical targets of IL-10 as the mice developed spontaneous colitis. These 
studies also highlight the important role of Mφs in regulating inflammation in the intestine. 
 IL-10 has been shown to be critical in the ability of Mφs to regulate adaptive immune responses.  One 
study showed that the ability of CX3CR1hi cells, likely to be Mφs, to inhibit T cell responses and prevent 
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intestinal inflammation was abrogated in myeloid-specific STAT3-deficient mice, and the transfer of 
WT CX3CR1hi cells prevented the development of colitis in these mice (Kayama et al. 2012). In addition, 
CCR2 KO mice have a significantly depleted intestinal Mφ population and display more severe DDS-
induced colitis due to impaired IL-10 production (Takada et al. 2010). This highlights the importance 
of intestinal Mφs in maintaining homeostasis, and that both their production of IL-10 and their control 
by IL-10 are a crucial feature of their regulatory properties.  
1.8.3 The role of IL-10 in the human intestine  
 
Naturally occurring LoF mutations in the IL-10R gene are rare but have been identified in patients with 
very early-onset IBD (VEO-IBD), who display enhanced production of pro-inflammatory cytokines, 
including TNFα and IL-1β, from their PBMCs. VEO-IBD patients have a severe treatment-refractory 
phenotype and often require treatment by allogeneic BM transplantation (Begue et al. 2011; Glocker 
& Kotlarz 2009; Mao et al. 2012). This demonstrates the important non-redundant role of IL-10 
signalling in preventing inflammation in the human intestine. Patients with VEO-IBD also commonly 
suffer from auto-immune diseases, including psoriasis and RA, which highlights the importance of IL-
10 in establishing tolerance to self-antigens. In addition, a comparison of genes responsible for 
monogenic disease with IBD-like pathology and risk loci associated with IBD revealed that genes 
related to IL-10 (IL-10, IL-10RA, and IL-10RB) were the only ones common to both groups of patients 
(Uhlig 2013).  
GWAS have found IBD susceptibility variants in the genes for IL-10 and STAT3 (Franke et al. 2010; 
McGovern et al. 2010). However, the majority of IBD patients do not have LoF mutations or 
functionally significant variants in their IL-10R genes. Begue et al. 2011 investigated the concept of 
defective anti-inflammatory responses in IBD patients and showed patients with a severe relapse at 
the time of analysis displayed a reduced response to IL-10 inhibition of LPS-induced IL-8 production, 
which was restored once the patients achieved remission (Begue et al. 2011). However, immune 
populations were not specifically examined. Therefore, the possibility that these patients have 
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reduced responsiveness to IL-10 in critical populations has not been fully explored. There is evidence 
for a similar concept in T cells where cells from IBD patients are resistant to TGFβ-mediated 
suppression due to enhanced expression of SMAD7. 
IL-10 therapy showed promise in murine models of intestinal inflammation but did not show 
significant benefits in IBD patients (reviewed by Marlow et al. 2013). There are a number of 
explanations proposed for the failure of IL-10 therapy (reviewed by Marlow et al. 2013) but a sub-
optimal ability of critical cells to respond to IL-10 in IBD could contribute. Analogous to the targeting 
of SMAD7, with the anti-sense drug Mongersen, in order to enhance T cell responses to TGF 
(Monteleone et al. 2015), understanding the IL-10 response of IBD patients could lead to therapeutic 
interventions involving the IL-10 signalling pathway.   
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1.9 Hypothesis and Aims 
 
1.9.1 Hypothesis  
 
A sub-optimal response to IL-10 in critical populations gives rise to inflammatory cells that initiate or 
sustain inflammation in IBD.  
According to this hypothesis, individuals in the population fall within a spectrum of MP responsiveness 
to IL-10. At one end, healthy individuals with an optimal IL-10 response and at the other end, rare 
individuals with LoF mutations in their IL-10R who develop VEO-IBD. The majority of IBD patients lie 
in-between and are capable of responding to IL-10 but their response is suboptimal. 
 
Figure 1.9: Illustration of the spectrum of IL-10 response in the population.  
 
1.9.2 Aims  
 
The overall aim of the project is to compare IL-10 responses of Mo/moMφ in health and IBD and define 
mechanisms underlying any differences. Specifically, the objectives of this project are: 
1. Determine the ability of IL-10 to inhibit LPS-induced TNFα production in the monocyte subsets 
of healthy individuals; identify the mechanistic basis of the differences between monocyte 
subsets by investigating components along the IL-10 signalling pathway. 
2. Determine the ability of IL-10 to inhibit LPS-induced TNFα production in the monocyte subsets 
of healthy controls and IBD patients; assess differences in signalling components along the IL-
10 signalling pathway between health and IBD. 
3. Identify intestinal Mo/moMφs in health and IBD and determine their responsiveness to IL-10. 
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Chapter 2: Materials and Methods 
2.1 Materials  
2.1.1 Chemicals and Reagents  
 
• Ficoll-Paque Plus: is a high-density isotonic polysaccharide solution, which is used to separate 
PBMCs from whole blood on the basis of their densities (GE Healthcare, UK). 
• RPMI-1640 Medium (Dutch modification): is a tissue culture medium containing two 
buffering agents, sodium bicarbonate and 20mM HEPES, for maintaining optimal pH 
conditions (Sigma, USA). 
• HBSS (Hank’s balanced salt solution): is a tissue culture medium containing bicarbonate ions 
used as a buffer system (Sigma, USA). 
• FCS (fetal calf serum): is a supplement for complete medium, and it is used in FACS buffer to 
inhibit non-specific binding of antibodies during labelling (PAA, Austria). 
• L-glutamine: is an amino acid used as a supplement in complete medium (Sigma, USA). 
• Pen/Strep (Penicillin/Streptomycin): are antibiotics used in complete medium to control 
bacterial contamination (Sigma, USA). 
• Gentamicin: is an antibiotic used in complete medium to control bacterial contamination 
(Invitrogen, USA).  
• EDTA (ethylenediaminetetraacetic acid): is a chelating agent used in FACS buffer to prevent 
clustering of the cells by binding calcium ions, which interferes with cadherins and integrins. 
Also used to disassociate epithelial cells from intestinal tissue during LPMC extraction (Sigma, 
USA).  
• Dithiothreitol (DTT): is a reducing agent used to remove mucus and debris from intestinal 
tissue during LPMC extraction by disrupting disulfide bonds (Sigma, USA). 
• Deoxyribonuclease I (DNase I): is used to degrade cell-free DNA in order to prevent clumping 
of LPMCs during extraction (Roche, Switzerland).  
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• Collagenase D: is an enzyme used to extract LPMCs by digesting the intestinal tissue (Roche, 
Switzerland). 
• Sodium azide: is used in FACS buffer to prevent capping by inhibiting crosslinking, and 
therefore shedding or internalisation of the antibody-antigen complexes formed once the 
antibodies have bound to the surface marker during labelling (Sigma, USA).  
• Trypan blue solution (0.4%): dead cells take up the stain due to their disrupted membrane 
allowing them to be distinguished. Used during cell counting (Sigma, USA). 
• CTV (cell trace violet): is used for the labelling of cells to trace dividing populations using dye 
dilution by flow cytometry (ThermoFisher, USA).  
• LPS (lipopolysaccharide): is an endotoxin found in the outer membrane of Gram-positive 
bacteria, and is a TLR4 agonist (E. coli 0111: B4 from Sigma, USA).  
• Flagellin: is a protein that forms the filament in bacterial flagellum, and is a TLR5 agonist 
(Invivogen). 
• Pam3-Cys-Ser-Lys4 (Pam3CSK4): synthetic bacterial lipopeptide, and is a TLR1/2 agonist 
(Invivogen, USA) 
• Polyinosinic:polycytidylic acid (Poly(I:C)): a synthetic analogue of double-stranded RNA 
(dsRNA), and is a TLR3 agonist (Sigma, USA). 
• Monensin: widely used to disrupt the Golgi apparatus and retain newly synthesised cytokines 
within the Golgi apparatus by blocking vesicle transport.  The stock solution was prepared in 
ethanol at a concentration of 12mM and aliquots were stored at -80˚C (Sigma, USA). 
• PFA (paraformaldehyde): is used as a fixative by creating covalent bonds between 
intracellular proteins (Sigma, USA). 
• Leucoperm A and B: are used for intracellular cytokine staining. Leucoperm A is a fixative and 
Leucoperm B is a permeabilising agent (AbD Serotec, UK). 
• Methanol: alcohol used as a permeabilisation agent for intracellular staining.  
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• Flow-Count Fluorospheres: are count beads used to calculate absolute cell numbers on the 
flow cytometer (Beckman Coulter, USA). 
• TMI-005 (Apratastat): ADAM metallopeptidase domain 17 (ADAM17) inhibitor (Axon 
Medchem, Netherlands).  
• Fixable viability dye: enables identification of dead cells (eBioscience, USA) 
• Annexin V: binds to phosphatidylserine, which is a marker of apoptosis (Thermofisher, USA) 
• FcR blocking solution: blocks FcR-involved unspecific staining (Biolegend, UK). 
• IL-10R blocking antibody: blocks IL-10 signalling (Biolegend, UK). 
• Fluoresbrite® carboxylate microspheres: fluorescent microspheres that have carboxylate 
groups on their surfaces, used in phagocytosis studies (Polysciences Inc, US).  
• OptilyseC: used to lyse RBCs (Beckman Coulter, USA).  
2.1.2 Media and Buffers 
 
• Complete medium: RPMI-1640 Medium (Dutch modification) supplemented with 10% FCS, 
100ug/ml of penicillin, 100μg/ml of streptomycin, and 20mM of L-glutamine (25µg/ml of 
gentamicin included in LPMC culture)  
• PBS (phosphate buffered saline): a solution containing 137mM sodium chloride, 2.7mM 
potassium chloride, and 12mM phosphate in ultrapure water (Ca and Mg free).  
• FACS buffer: PBS containing 2% FCS, 1mM EDTA, and 0.2% (w/v) sodium azide. 
• PFA solution: PBS containing 1% PFA.  
• Brilliant stain buffer: recommended by BD to add 50µl when staining with more than one of 
their antibodies at the same time (BD Bioscience, UK).  
2.1.3 Antibodies  
 
The antibodies used for flow cytometry are detailed below in Table 1. The corresponding isotype 
controls are also listed and were used to exclude unspecific binding.  
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Antigen Fluorochrome Clone Isotype control Supplier 
HLA-DR APC L243 Mouse IgG2a Biolegend 
CD16 PerCP-Cy5.5 3G8 Mouse IgG1 Biolegend 
T-STAT3 PerCP-Cy5.5 M59-50 Mouse IgG2a BD 
CD192 (CCR2) PerCP-Cy5.5 K036C2 Mouse IgG2a Biolegend 
CD14 Pacific Blue  MFE2 Mouse IgG2a Biolegend 
CD16 PE 3G8 Mouse IgG1 Biolegend 
IL-10Rα PE 3F9 Mouse IgG1 Biolegend 
TNFα PE MAb11 Mouse IgG1 Biolegend 
CD45 PE HI30 Mouse IgG1 Biolegend 
IFNα [2b] PE 7N4-1 Mouse IgG1 BD 
pSTAT3 (pY705) Alexa Fluor 488 4/P-STAT3 Mouse IgG1 BD 
CD206 FITC 15-2 Mouse IgG1 Biolegend 
IL-1β FITC JK1B-1 Mouse IgG1 Biolegend 
CX3CR1 FITC 2A9-1 Rat IgG2b Biolegend 
IL-10 PE-Cy7 JES3-9D7 Rat IgG1 Biolegend 
TNFα PE-Cy7 Mab11 Mouse IgG1 Biolegend 
CD126 (IL-6Rα) PE-Cy7 UV4 Mouse IgG1 Biolegend 
CD64 APC-Cy7 10.1 Mouse IgG1 Biolegend 
Table 2.1: List of antibodies used for flow cytometry.  
 
2.1.4 Cytokines  
 
• IL-10 (interleukin-10): is a regulatory cytokine used to inhibit production of pro-inflammatory 
cytokines. The stock concentration was 50µg/mL, and the solution was prepared in sterile PBS 
containing 0.1% BSA and stored at -80˚C (R&D systems, UK). 
• IL-6 (interleukin-6): is a pro-inflammatory cytokine used to stimulate immune responses. The 
stock concentration was 100µg/mL, and the solution was prepared in sterile PBS containing 
0.1% BSA and stored at -80˚C (R&D systems, UK). 
2.1.5 Kits  
 
• PCR (Qiagen, Germany) 
o RNA extraction: RNeasy Micro Kit or Mini Kit 
o Reverse Transcription: QuantiTect Reverse Transcription Kit 
o SYBR Green real-time PCR: QuantiFast SYBR Green PCR Kit 
o QuantiTect primers: SOCS3 (QT00244580), SOCS1 (QT01157905), and GAPDH 
(QT00079247) 
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2.2 Methods 
2.2.1 Patient recruitment and sample collection  
 
IBD patients were recruited from The Royal London Hospital (ethical approval P/01/023 and 
15/LO/2127), and healthy controls were recruited from Barts and the London School of Medicine and 
Dentistry (ethical approval 05/Q0405/71). All study participants gave informed written consent. In line 
with ethical principles for medical research involving human subjects (World Medical Association 
Declaration of Helsinki) 
Intestinal biopsies were from patients attending The Royal London Hospital who were having a 
colonoscopy or a flexible sigmoidoscopy as part of their routine clinical care. Up to 8 biopsies were 
collected from either the colon or the ileum of IBD patients or non-IBD patients.  Non-IBD patients 
were typically under investigation for altered bowel habit or rectal bleeding, with no previous 
diagnosis of IBD and no evidence of macroscopic or histological intestinal inflammation. The tissue 
was collected in RPMI-1640 Dutch Modification (Sigma-Aldrich) and placed on ice. 
Peripheral blood was collected by venipuncture into 10ml sodium heparin Vacutainer tubes (BD) and 
mixed gently to prevent clotting.  
For detailed demographic information collected by a clinical fellow refer to the Appendix. 
2.2.2 Extracting lamina propria mononuclear cells (LPMCs) from intestinal tissue  
 
LPMCs extraction methods have been previously described (Hart et al. 2005). Briefly, the biopsies were 
added to a T25 tissue culture flask (BD) containing 1mM DTT (Sigma-Aldrich) in a total volume of 15ml 
made up with calcium and magnesium-free HBSS (Sigma-Aldrich) to incubate for 20 minutes at room 
temperature (RT). The flask was then manually shaken at regular intervals. A Pasteur pipette was used 
to aspirate the HBSS. The biopsies were then washed twice in 10ml of fresh HBSS, using a Pasteur 
pipette to aspirate the HBSS between each wash. The biopsies were incubated with 1mM EDTA 
(Sigma-Aldrich) in a total volume of 25mL made up with HBSS for 30 minutes in a heated shaker (37oC). 
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The EDTA was aspirated, and the biopsies were washed twice in HBSS followed by a further EDTA 
incubation and HBSS washes. The biopsies were then added to a new T25 flask containing 1 mg/ml 
collagenase D (Roche Applied Science), 2% FCS, and 20 μg/ml deoxyribonuclease I (Roche Applied 
Science) in a total volume of 15mL made up with HEPES buffered RPMI 1640 medium (Sigma-Aldrich) 
to incubate for a 1 hour in a heated shaker (37oC). The flask was then manually shaken at 5 minutes 
intervals for a further 15 minutes. The cell suspension was passed through a 70 μm cell strainer (Fisher 
Scientific) and washed with HBSS, centrifuging for 5 minutes at 300g at RT before discarding the 
supernatant. The cell pellet was then resuspended in complete medium (with the addition of 25µg/ml 
gentamicin).  
2.2.3 PBMC separation  
 
Whole blood was diluted 2:1 using RPMI-1640 Dutch Modification (Sigma-Aldrich). The diluted blood 
was layered onto 15ml of Ficoll-Paque Plus in a 50ml Falcon tube. The Falcon tube was centrifuged for 
20 minutes at 650g with the break off at RT. The interface containing PBMCs was collected into two 
15ml Falcon tubes, using a Pasteur pipette, and diluted 1:1 using RPMI-1640 Dutch Modification. The 
15ml Falcon tubes were then centrifuged for 10 minutes at 650g with the brake on. The cells were 
rewashed with complete medium, centrifuging for 5 minutes at 300g at RT before discarding the 
supernatant. The pellet was then resuspended in complete medium.  
2.2.4 Cell counting 
 
50μl of Trypan Blue (0.4%), 150μl of RPMI-1640 Dutch modification base medium, and 50μl of the cell 
suspension were mixed giving a 1:5 dilution to the cell suspension. The diluted cell suspension was 
then applied onto a Neubauer hemocytometer with a coverslip. The cells were counted three times in 
a four by four grid, and the average was taken to calculate the overall concentration of the cell 
suspension using the following equation: 
5 x (Average cell number of the three counts x 104) = cells/ml 
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2.2.5 Monoclonal antibody staining and flow cytometry 
 
2.2.5.1 Whole blood labelling 
 
Anti-coagulated whole blood was added at a volume of 100µL to FACS tubes (BD) for labelling. 
Fluorescent antibodies were used to label cell surface markers, as indicated in individual experiments. 
Each antibody was added at a predetermined optimal concentration directly onto the whole blood, 
gently mixed and left for 15 minutes at RT in the dark. To lyse the RBCs and fix the sample, OptilyseC 
(Beckman Coulter) was then added at a volume of 500µL to each FACS tube before mixing vigorously 
and leaving for 15 minutes at RT in the dark. The samples were washed twice in FACS buffer, 
centrifuging for 5 minutes at 300g at RT and the supernatant discarded between each wash. The cell 
pellet was then resuspended in 300µL of 1% paraformaldehyde (PFA). To determine absolute cell 
numbers, 20µL of Flow-count fluorospheres (Beckman Coulter) were added just before acquiring the 
samples on the flow cytometer (BD FACSCanto II). Method of calculation is described in section 2.2.5.5.   
2.2.5.2 Labelling of PBMC and LPMC 
 
Following PBMC or LPMC culture, the cells were harvested and washed once in FACS buffer. The 
samples were centrifuged for 5 minutes at 300g at RT, and the supernatant was discarded. The cell 
pellet was then resuspended in 100μl of FACS buffer for cell surface staining. Fluorescent antibodies 
were used to label cell surface markers required to identify cell populations. Each antibody was added 
at a predetermined optimal concentration and left for 20 minutes on ice in the dark. The cells were 
then washed with FACS buffer, centrifuging for 5 minutes at 300g at RT before discarding the 
supernatant. The cells were either staining for intracellular cytokines (Section 2.2.5.3) or resuspended 
in 300μL 1% PFA buffer and acquired on the flow cytometer (BD FACSCanto II) on the same day. To 
determine absolute cell numbers, 20µL of Flow-count fluorospheres (Beckman Coulter, USA) were 
added just before acquiring the samples on the flow cytometer (BD FACSCanto II). Method of 
calculation is described in section 2.2.5.5. 
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2.2.5.3. Intracellular cytokine staining 
 
Following cell surface staining (Section 2.2.5.2), cells were fixed in 100µL of Leucoperm A at 4oC for 20 
minutes in the dark.  The cells were washed once in FACS buffer, centrifuging for 5 minutes at 300g at 
RT, and the supernatant discarded before permeabilising with 100µL Leucoperm B at 4oC for 30 
minutes in the dark, while simultaneously staining for intracellular cytokines using fluorochrome-
conjugated antibodies (Table 1). The cells were washed once in FACS buffer, centrifuging for 5 minutes 
at 300g at RT, and the supernatant discarded. The cell pellet was resuspended in 300μL 1% PFA buffer, 
and the samples were acquired on the flow cytometer (BD FACSCanto II) on the same day. To 
determine absolute cell numbers, 20µL of flow-count fluorospheres (Beckman Coulter, USA) were 
added just before acquiring the samples on the flow cytometer (BD FACSCanto II). Method of 
calculation is described in section 2.2.5.5.   
2.2.5.4 PhosFlow  
 
One million PBMCs, suspended in 500μl of complete medium, were added to FACS tubes (BD) and 
washed with FACS buffer, centrifuging for 5 minutes at 300g at RT before discarding the supernatant. 
The cell pellet was then resuspended in 100μl of FACS buffer for cell surface staining (Section 2.2.5.2). 
The cells were then washed with FACS buffer, centrifuging for 5 minutes at 300g at RT before 
discarding the supernatant. The cell pellet was resuspended in 500μL FACS buffer before placing the 
FACS tubes (BD) in a 37oC water bath and stimulated for 15 minutes with IL-10 (100ng/ml), IL-6, 
(100ng/ml) or with phosphate buffered saline (PBS) as a control. 500ul of 4% PFA was then added to 
each tube to fix the cells rapidly, and left for a further 15 minutes in the 37oC water bath. The cells 
were washed once with PBS, centrifuging for 5 minutes at 300g at RT before discarding the 
supernatant.  The cell pellet was resuspended in 1mL of cold 70% methanol to permeabilise the cells 
and kept on ice for 30 minutes. The cells were then washed twice with FACS buffer, centrifuging for 5 
minutes at 300g at RT and discarding the supernatant between each wash. The cell pellet was 
resuspended in 100μl of FACS buffer and 50μl of brilliant stain buffer (BD) for intracellular staining. 
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Fluorescently labelled antibodies against STAT3 proteins or specific for phosphorylated forms of STAT3 
were added to the cells and left to incubate on ice in the dark for 30 minutes. The cells were washed 
once in FACS buffer, centrifuging for 5 minutes at 300g at RT before discarding the supernatant. The 
cell pellet was resuspended in 300μL 1% PFA buffer, and the samples were acquired on the flow 
cytometer (BD FACSCanto II) immediately.  
2.2.5.5 Flow-count fluorospheres 
 
Flow-Count Fluorospheres (Beckman Coulter, USA) are a suspension of fluorescent microbeads used 
to determine absolute cell numbers on the flow cytometer. A known volume of the beads (20µL) with 
a known concentration (Lot specific concentration: 1013 beads/µL of stock suspension) are added to 
the cell suspension just before acquiring the samples on the flow cytometer (BD FACSCanto II). The 
calculation is detailed below.  
Vol of original cell suspension 
Vol of beads
= 𝐀 
(
No. of cell events
No. of bead events x 𝐀
) × 1013 beads/µ𝐿 = cells per µL  
 
2.2.5.6 Flow Cytometry  
 
Labelled cells were acquired on BD FACSCanto II using the BD FACSDiva software. Single colour 
compensation controls were generated by labelling PBMCs with fluorochrome-conjugated anti-CD3 
or anti-CD4 monoclonal antibodies (Biolegend), which created positively and negatively stained 
populations for each fluorochrome used in a particular experiment. No less than 100,000 events were 
acquired for each sample. Once the data were collected as FSC files, they were analysed using Winlist 
3D version 8.0 (Verity Software House, Maine). Compensation was applied before data analysis using 
the WinList algorithm. Positive staining was determined by comparison with populations within 
samples stained with corresponding isotype control antibodies. 
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2.2.6 Cytokine production by blood monocytes and intestinal Mo/moMφs 
Two million PBMCs suspended in 1mL of complete medium, or a variable number of LPMCs suspended 
in 1mL of complete medium (with the addition of 25µg/ml gentamicin) were added to a 24 well plate 
(flat-bottom, VWR). Monensin at a concentration of 3µM was added to all wells. PBMCs were cultured 
for 3 hours at 37oC in medium alone or with several TLR ligands at variable concentrations as indicated 
in individual experiments. The ADAM17 inhibitor TMI-005 (Axon Medchem) was added 30 minutes 
before stimulation at a concentration of 50µM in some experiments (see below).  
To test the inhibitory effects of IL-10 on cytokine production, recombinant human IL-10 (0.016ng/ml-
10ng/ml) was added 30 minutes prior addition of TLR agonists in some experiments. At the end of 
incubation, cells were transferred to FACS tubes and washed with FACS buffer, centrifuging for 5 
minutes at 300g at RT and the supernatant discarded. The cell pellet was then resuspended in 100μl 
of FACS buffer. Cell surface staining with fluorochrome-conjugated monoclonal antibodies (Section 
2.2.5.2) was used to identify blood monocyte populations and intestinal Mo/moMφs as detailed in 
individual experiments. The cells were then washed with FACS buffer, centrifuging for 5 minutes at 
300g at RT before discarding the supernatant. Cytokines, including TNF, IL-1 and IFN, were 
detected by intracellular staining (Section 2.2.5.3). 
2.2.7 Cell sorting of blood monocyte populations 
 
Monocyte subset populations were cell sorted using the FACS Aria flow cytometer (Becton Dickinson) 
with the assistance of Gary Warnes, Flow Cytometry Core Facility, Blizard Institute. Before cell sorting, 
whole PBMCs were collected from up to 50ml of blood and combined into one FACS tube (BD). The 
cells were washed with FACS buffer, centrifuging for 5 minutes at 300g at RT before discarding the 
supernatant. The cell pellet was then resuspended in 100μl of FACS buffer for cell surface staining 
(Section 2.2.5.2). The cells were then washed with FACS buffer, centrifuging for 5 minutes at 300g at 
RT before discarding the supernatant. The cell pellet was resuspended in FACS buffer at a 
concentration of 20 million cells per ml for cell sorting. Single colour compensation tubes were 
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generated by labelling PBMCs with anti-CD3 or anti-CD4 antibodies (Biolegend) conjugated to the 
relevant fluorochromes. Compensation was applied in the cytometer before setting the sort gates and 
collecting monocyte populations. Classical monocytes (HLA-DR+CD14++CD16-), intermediate 
monocytes (HLA-DR+CD14++CD16+) and non-classical monocytes (HLA-DR+CD14+CD16++) were 
collected into separate FACS tubes (BD) and washed with FACS buffer, centrifuging for 5 minutes at 
300g at RT and then the supernatant was discarded. The cell pellets were resuspended in FACS buffer 
and divided into aliquots of 100,00 cells each to compare SOCS3 expression between subsets, and 
1x106 classical cells to compare SOCS3 expression between healthy controls and IBD patients. The 
1.5ml Eppendorf tubes were then centrifuged for 5 minutes at 400g before aspirating the supernatant. 
The cell pellets were resuspended in 350µL RTL lysis buffer and vortexed for 1 minute before placing 
in -80oC until further processing.  
2.2.8 Tracking phenotypic changes in monocyte subsets in vitro 
 
Monocyte subset populations were cell sorted using the FACS Aria flow cytometer (Becton Dickinson) 
with the assistance of Gary Warnes, Flow Cytometry Core Facility, Blizard Institute. Before cell sorting, 
whole PBMCs were collected from up to 50ml of blood and combined into one FACS tube (BD). The 
cells were washed with sterile PBS, centrifuging for 5 minutes at 300g at RT before discarding the 
supernatant. The cell pellet was resuspended in 500μl of warmed cell trace violet (CTV) dye and 
incubated at 37oC for 20 minutes. To stop the reaction, 500μl of cold FCS was added. The cells were 
washed with sterile FACS buffer (prepared with sterile PBS and EDTA, minus the sodium azide), 
centrifuging for 5 minutes at 300g at RT before discarding the supernatant. The cell pellet was then 
resuspended in 100μl of FACS buffer for cell surface staining (Section 2.2.5.2). The cells were then 
washed with sterile FACS buffer, centrifuging for 5 minutes at 300g at RT before discarding the 
supernatant. The cell pellet was resuspended in sterile FACS buffer at a concentration of 20 million 
cells per ml for cell sorting. Single colour compensation tubes were generated by labelling PBMCs with 
anti-CD3 or anti-CD4 antibodies (Biolegend) conjugated to the relevant fluorochromes. Compensation 
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was applied in the cytometer before setting the sort gates and collecting monocyte populations. 
Classical monocytes (HLA-DR+CD14++CD16-), intermediate monocytes (HLA-DR+CD14++CD16+) and 
non-classical monocytes (HLA-DR+CD14+CD16++) were collected into separate FACS tubes (BD) and 
washed with complete medium, centrifuging for 5 minutes at 300g at RT and then the supernatant 
was discarded. The cell pellet of classical monocytes was resuspended in complete medium at a 
concentration of 2 million cells per mL. The cell pellets of intermediate and non-classical monocytes 
were resuspended in 1mL of complete medium (100,000 cells). 500μL of each subset was added to 
two separate wells and topped up with 500μL of unlabeled PBMCs (suspended in complete medium 
at a concentration of 2 million cells per mL). Monensin at a concentration of 3µM was added to all 
wells. PBMCs were cultured for 3 hours at 37oC in medium alone or with 1ng/ml LPS. At the end of 
incubation, cells were transferred to FACS tubes and washed with cold FACS buffer, centrifuging for 5 
minutes at 300g at RT and the supernatant discarded. The cell pellet was then resuspended in 100μl 
of FACS buffer. Cell surface staining with fluorochrome-conjugated monoclonal antibodies (Section 
2.2.5.2) to identify blood monocyte populations as detailed in individual experiments. The cells were 
then washed with FACS buffer, centrifuging for 5 minutes at 300g at RT before discarding the 
supernatant. The cell pellet was resuspended in 300μL 1% PFA buffer and acquired on the flow 
cytometer (BD FACSCanto II) on the same day. 
2.2.9 Measuring cell viability  
 
Two million PBMCs suspended in 1ml of complete medium were added to a 24 well plate (flat-bottom, 
VWR). Monensin at a concentration of 3µM was added to all wells. PBMCs were cultured for 3 hours 
at 37oC in medium alone or with 1ng/ml LPS. One million PBMCs, suspended in 500μl of complete 
medium, were added to FACS tubes (BD) and washed with FACS buffer, centrifuging for 5 minutes at 
300g at RT before discarding the supernatant. The cell pellet was then resuspended in 100μl of FACS 
buffer for cell surface staining (Section 2.2.5.2). The cells were then washed with FACS buffer, 
centrifuging for 5 minutes at 300g at RT before discarding the supernatant. The cell pellet was 
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resuspended in 200µL PBS and placed on ice to prevent endocytic uptake. The viability dye was added 
to a final dilution of 1:10,000 and incubated for 30min in the dark. The cells were then washed with 
binding buffer, centrifuging for 5 minutes at 300g at RT before discarding the supernatant. The cell 
pellet was resuspended in 200µL PBS, and 10µL of the annexin V stain was added and incubated for 
15 minutes at RT. The cells were then washed twice with binding buffer, centrifuging for 5 minutes at 
300g at RT before discarding the supernatant. The cell pellet was resuspended in 300μL 1% PFA buffer 
and acquired on the flow cytometer (BD FACSCanto II) on the same day. For the compensation 
controls, two FACS tubes were prepared with PBMCs suspended in PBS. One tube was placed in a 
water bath at 55oC for 10 minutes. Once cooled, the two tubes were combined to provide a sample 
with both viable and dead cells. The sample was then divided into two FACS tubes. One tube was 
stained with fixable dye only, and the other tube with annexin V only.  
2.2.10 Measuring phagocytosis capacity 
 
One million LPMCs suspended in 1mL of complete medium (with the addition of 25µg/ml gentamicin) 
were added to two separate 24 well plates (flat-bottom, VWR). One plate was incubated at 4oC 
(control) and the other at 37oC for 15 minutes before adding the FITC-labelled microspheres 2.00µm 
(Polysciences Inc.) at a concentration of 10 microspheres per cell to incubate for a further 1.5 hours. 
One million LPMCs, suspended in 1mL of complete medium, were added to FACS tubes (BD) and 
washed with FACS buffer, centrifuging for 5 minutes at 300g at RT before discarding the supernatant. 
The cell pellet was then resuspended in 100μl of FACS buffer for cell surface staining (Section 2.2.5.2). 
The cells were then washed with FACS buffer, centrifuging for 5 minutes at 300g at RT before 
discarding the supernatant. The cell pellet was resuspended in 300μL 1% PFA buffer, and the samples 
were acquired on the flow cytometer (BD FACSCanto II) immediately.  
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2.2.11 Quantitative real-time PCR  
 
2.2.11.1 RNA extraction  
 
The RNeasy Micro Kit (Qiagen) was used in accordance with the manufacturer’s instructions. The 
samples stored at -80oC were defrosted at RT and vortexed. 350µL of 70% Ethanol was then added 
and the samples vortexed again. The solution was transferred to a spin column placed in a 2ml 
collection tube, which was centrifuged for 15 seconds at 8000g before discarding the flow through. 
700µL of RW1 buffer was then added and centrifuged again for 15 seconds at 8000g before discarding 
the flow through. The spin column was transferred to a new 2ml collection tube before adding 500µL 
of RPE buffer, centrifuging for 15 seconds at 8000g and discarding the flow through. 500µl of 80% 
ethanol was then added and centrifuged for 2 minutes at 8000g before discarding the flow through. 
The spin column was transferred to a new 2ml collection tube and centrifuged at 1600g for 5 minutes 
with the lids open to evaporate the alcohol. The spin column was then transferred to a new 1.5ml 
collection tube; 14µl of RNase-free water was added directly to the membrane and then centrifuged 
at 1600g for 1 minute to elute the RNA, which was used immediately for reverse transcription. 
The RNeasy Mini kit (Qiagen) was used in accordance with the manufacturer's instructions. The 
samples stored at -80oC were defrosted at RT and vortexed. The homogenised lysate was transferred 
to a genomic DNA (gDNA) Eliminator spin column placed in a 2ml collection tube, and centrifuged for 
30 seconds at 8000g. The column was discarded, and 350µL of 70% Ethanol was added to the flow-
through. The suspension was then transferred to a spin column placed in a 2ml collection tube and 
centrifuged for 15 seconds at 8000g before discarding the flow through. 700µL of RW1 was then added 
and centrifuged again for 15 seconds at 8000g before discarding the flow through. 500µL of RPE buffer 
was added and centrifuged for 15 seconds at 8000g before discarding the flow through. 500µl of RPE 
buffer was added again and centrifuged for 2 minutes at 8000g before discarding the flow through. 
The spin column was transferred to a new 2ml collection tube and centrifuged at 1600g for 1 minutes 
to further dry the membrane. Finally, the spin column was then transferred to a new 1.5ml collection 
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tube; 30µl of RNase-free water was added directly to the membrane and then centrifuged at 8000g 
for 1 minute to elute the RNA. The RNA was quantified using Nanodrop. The RNA was used 
immediately for reverse transcription. 
2.2.11.2 Measurement of RNA concentration  
 
NanoDrop uses the properties of RNA to measure concentration and purity. RNA absorbs ultraviolet 
(UV) light with a maximum absorption (λmax) wavelength of 260nm. The 260/280 ratio is used to 
assess RNA purity and should ideally be around 2.0. Each base has a characteristic λmax, therefore, 
the ratio will depend on the base composition of the RNA. However, a ratio that is much lower than 
2.0 may indicate the presence of contaminants, such as phenol that absorbs UV light at 230 nm and 
can contribute to an overestimation of DNA concentration in addition to inhibiting downstream 
reactions. The 260/230 ratio is a secondary measure of purity and should ideally be around 2.2. Using 
λmax and a known path length, the concentration of RNA can be calculated. However, very dilute 
samples lead to inaccurate ratios due to little differences between 260 nm and 280 nm absorbance 
and the similarity in absorption between RNA and DNA (λmax = 280) makes it challenging to determine 
DNA contamination (Desjardins et al. 2009). Therefore, nanodrop was used for RNA samples extracted 
using the RNeasy Mini kit (Qiagen). RNA-40 was selected on the NanoDrop software. 1μl of RNase-
free water was pipetted onto the lower measurement pedestal, and Blank was selected on the 
software. 1μl of the RNA sample was then pipetted onto the lower measurement pedestal, and the 
sample was measured.  
2.2.11.3 Reverse transcription  
 
The QuantiTect Reverse Transcription Kit (Qiagen) was used in accordance with manufacturer’s 
instructions. 12µl of the RNA samples extracted using the RNeasy Micro Kit (Qiagen) was transferred 
to a 200µl tube; 2µl of gDNA Wipeout Buffer was then added and mixed before incubating for 2 
minutes at 42°C to degrade the gDNA. The RNA samples extracted using the RNeasy Mini kit (Qiagen) 
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were diluted with RNase-free water to a normalised concentration (section 2.2.9.2), and 2µl of gDNA 
Wipeout Buffer was added before incubating for 2 minutes at 42°C. A reverse transcription master 
mix was made containing 1µl Quantiscript Reverse Transcriptase, 4µl Quantiscript RT Buffer, and 1µl 
RT primer mix per dose. 6µl of the master mix was added to the 14μl of RNA and mixed. This was 
incubated for 15 minutes at 42°C for the reverse transcription of the RNA into cDNA. The sample was 
then incubated for 3 minutes at 95°C to inactivate the Quantiscript Reverse Transcriptase. The cDNA 
was either used immediately for quantitative real-time PCR (qRT-PCR) or stored at -20 °C for future 
use. 
2.2.11.4 SYBR Green qRT-PCR 
 
This technique uses a highly specific, dsDNA binding dye to detect PCR product as it accumulates 
during PCR cycles. During the PCR, DNA Polymerase amplifies the target sequence that creates PCR 
product. The dye then binds to each new copy of dsDNA, which increases in fluorescence intensity 
proportionate to the amount of PCR product produced (Arya et al. 2005). The dye will detect all 
dsDNA, including non-specific reaction products, therefore, a well-optimised reaction is essential for 
accurate results. 
A master mix was made for each primer containing 12.5μl of SYBR Green PCR Mix, 2.5μl of the primer, 
and 8μl of RNase free water. 23μl of this master mix was added to a 96-well PCR plate in triplicates 
followed by 2μl of cDNA (replaced with RNase free water for no template control). The plate was 
sealed with Advanced Polyolefin StarSeal (Star Lab) and then centrifuged briefly to combine the liquids 
at the bottom of the well. The plate was then run immediately on the 7500 Real-Time PCR Systems 
(Applied Biosystems, USA), which used the 7,500 Software version 2.0.6. (Applied Biosystems, USA). 
The program was set in accordance with the manufacturer's instructions (Table 2).  
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Step  Temperature (oC) Time (seconds) Repeats 
1. Activation 95 300 1x 
2. Denaturing  95 10 40x 
3. Annealing & Extension  60 30 
4. Melt Curve  95 15 1x 
60 60 
95 30 
60 15 
 
Table 2.2: PCR program  
Data was collected of the cycle threshold (CT) values (the cycle number at which there’s a detectable 
signal). Relative gene expression of the genes of interest can be calculated using a reference gene 
(GAPDH), which are highly conserved and constitutively expressed, therefore, are used to normalise 
gene expression of target using the 2-deltaCt method (Livak & Schmittgen 2001), where deltaCt is the 
difference in CT number for target and reference gene.  
The samples run through qRT-PCR included RNA extracted from relatively few cells using the RNeasy 
Micro kit (Qiagen) in which exact quantification of RNA concentration using nanodrop was not 
possible. Therefore, a titration of classical monocytes was carried out to determine the lowest cell 
number that allows calculation of a reliable deltaCT, after which GAPDH expression is no longer linear 
These cells were titrated down past the cell number present in the experimental samples to be 
analysed and showed a reliable deltaCT could be calculated (refer to Appendix 1). The concentration 
of the RNA extracted with the RNeasy Mini kit (Qiagen) could be measured using Nanodrop and was 
normalised to 19.4ng/μL in subsequent experiments.  Before this, titration of a known concentration 
of RNA was carried out to determine the lowest RNA concentration that allows calculation of a reliable 
deltaCT, and 19.4ng/μL was within this range (refer to Appendix 2) 
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The purity and specificity of the amplified product was determined using melt curves. SYBR Green dye 
only fluoresces when bound to dsDNA, therefore can be used to determine the melting point of the 
PCR product. At the end of synthesis, all of the DNA is double-stranded, and SYBR Green is maximally 
bound producing the maximal relative fluorescence, as temperature increases, the DNA is denatured, 
and the fluorescence decreases following the same curve as the melting temperature. If the PCR 
product is pure, there will be a single peak (refer to Appendix 3). The appearance of an earlier peak is 
a sign of primer dimer formation (smaller fragments), while a peak later indicates genomic 
contamination (larger size). These samples were excluded because it affects the accuracy of the gene 
expression analysis.  
The primers were ordered from Qiagen, typically designed to be exon spanning to prevent 
amplification of contaminating gDNA. However, the SOCS genes consist of only two exons so the 
primers were within one axon, therefore, effective gDNA wipeout was critical. This was tested by 
replacing the reverse transcriptase with water during the RT-PCR reaction, and no signal was detected 
during the qRT-PCR reaction. 
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2.3 Statistics 
 
Statistical analyses were performed using Prism 6 (GraphPad Software, USA). t-tests were used to 
compare two groups of normally distributed data (paired and unpaired), with Welch’s correction for 
unequal standard deviations (SD) for unpaired data. A Mann-Whitney test was used to compare two 
groups of unpaired data that were non-normally distributed. A Wilcoxon tests was used to compare 
two groups of non-normally distributed paired data. Datasets containing more than two groups of 
unpaired and normally distributed data were compared using a one-way ANOVA with a Tukey test to 
correct for multiple comparisons. More than two groups of data that were unpaired and non-normally 
distributed were compared using a Kruskal-Wallis test with a Dunn’s test to correct for multiple 
comparisons. Paired datasets containing more than two groups of normally distributed data were 
compared using a repeated measures (RM) one-way ANOVA with the Greenhouse-Geisser correction 
and a Tukey test to correct for multiple comparisons. More than two groups of paired data that were 
non-normally distributed were compared using a Friedman test with Dunn’s test to correct for 
multiple comparisons. Paired datasets containing more than three groups of normally distributed data 
were compared using an RM Two-way ANOVA with a Tukey test to correct for multiple comparisons. 
Mean and SD are displayed for normally distributed data sets, while median and interquartile range 
(IQR) are displayed for non-normally distributed data sets. The normal distribution of the datasets was 
verified using three normality tests: D’Agostino-Pearson omnibus, Shapiro-Wilk, and Kolmogorov-
Smirnov. P-values were regarded as statistically significant when p < 0.05. 
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Chapter 3: Developing an assay to measure IL-10 response  
3.1 Chapter summary 
 
This chapter focusses on the development of an assay that could be used to measure IL-10 
responsiveness in human monocyte subsets. First, the monocyte subsets were defined based on CD14 
and CD16 expression: classical (CD14++CD16-), intermediate (CD14++CD16+), and non-classical 
(CD14+CD16++) monocytes, pre-gated on HLA-DR positive cells. Additional markers were used to 
confirm the identity of the monocyte subsets. To carry out functional experiments, PBMCs had to be 
separated from whole blood. However, culturing PBMCs ex vivo may impact monocyte subset 
distribution. To test this, monocyte subset distribution was compared between cells labelled in whole 
blood and PBMCs cultured for three hours. The data show little effect of short-term culture on 
monocyte subset distribution. 
The optimal stimulation conditions and cytokine readout with which to measure IL-10 response where 
then determined. Whole PBMCs were stimulated with LPS in the presence of increasing amounts of 
IL-10 to measure inhibition of TNFα production in the monocyte subsets. However, upon stimulation 
with LPS, there was an apparent loss of CD16+ cells that could not be dissociated from induction of 
TNFα production by adjusting LPS concentration or time course of stimulation or the use of alternative 
TLR agonists. The CD16+ cells did not show enhanced cell death or adherence to culture plates with 
LPS. A cell tracking experiment revealed a downregulation CD16 expression on the intermediate and 
non-classical monocytes. This downregulation was not due to internalisation of CD16 so was likely to 
be due to cleavage. In the presence of an ADAM17 inhibitor (TMI-005), CD16+ monocytes were still 
identifiable following LPS stimulation suggesting that CD16 is cleaved from the monocyte surface by 
this enzyme. The ADAM17 inhibitor was used in subsequent experiments to enable the IL-10 response 
to be determined in all three monocyte subsets in parallel. 
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3.2 Introduction 
 
The critical role of IL-10 in preventing excessive inflammatory responses to innocuous agents was 
discussed in depth in the introduction. Briefly, IL-10 deficient mice developed chronic enterocolitis 
upon exposure to commensal bacteria (Berg et al. 1996; Kühn et al. 1993), and in humans, patients 
with naturally occurring LoF mutations in the IL-10R genes develop VEO-IBD (Begue et al. 2011; 
Glocker & Kotlarz 2009; Mao et al. 2012). These studies highlight that IL-10 has a non-redundant role 
in regulating inflammation, and is especially important in maintaining immune homeostasis in the 
intestine where there is continuous exposure to external antigens. However, the majority of IBD 
patients do not have LoF mutations. The concept of defective anti-inflammatory responses in IBD 
patients has been previously investigated and showed patients with a severe relapse at the time of 
analysis displayed a reduced response to IL-10, which was restored once the patients achieved 
remission (Begue et al. 2011). However, specific cell types were not identified in this study. 
The critical target of IL-10 in regulating intestinal inflammation in humans was unclear. Recent murine 
studies by Shouval et al. 2014 and Zigmond et al. 2014 suggest that Mφs play a non-redundant role in 
IL-10 signalling: selective deletion of the IL-10R in this population caused spontaneous colitis with an 
accumulation of inflammatory Mφs (Shouval et al. 2014). These studies also highlight the critical role 
of Mφs in regulating inflammation in the intestine. Monocytes maintain at least some of the intestinal 
Mφ pool, therefore, regulating their inflammatory activity upon entry to the intestine would be 
critical.  
There is increasing evidence that systemic signals from the intestine during inflammation can cause 
functional changes to circulating cells formed the rationale for studying IL-10 response in blood 
monocytes (Arts et al. 2018; Askenase et al. 2015; Christ et al. 2018; Mitroulis et al. 2018; Sanders et 
al. 2014; Smith et al. 2009). The capacity of IL-10 to inhibit pro-inflammatory cytokine induction in 
monocytes has previously been reported, without taking into account monocyte subsets (Gasche et 
al. 2003). The monocyte subsets have distinct roles and characteristics, which should be considered 
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when investigating their response to IL-10. There was a need to develop an assay that could be used 
to measure IL-10 responses in the individual monocyte subsets in parallel to ensure the same culture 
environment.  
The aim of the work described in this chapter was to develop an assay that could be used to measure 
IL-10 responsiveness in human monocyte subsets. 
3.3 Aims 
 
1. Develop a gating strategy for the identification of well-defined human classical, intermediate, 
and non-classical monocytes.  
2. Establish stimulation conditions for the induction of cytokine responses in the monocyte 
subsets. 
3. Optimise methodology and analytical approach to quantify the impact of IL-10 on cytokine 
production by the monocyte subsets. 
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3.4 Results 
3.4.1 Identification of human monocyte subsets  
 
First, a robust gating strategy had to be defined to identify the monocyte subsets. Monocytes were 
labelled for HLA-DR, CD14, and CD16 in healthy donor whole blood. PBMCs were gated based on their 
forward scatter (FSC) and side scatter (SSC) properties (Figure 3.1 A). Doublet discrimination was 
carried out (Figure 3.1 B, C). HLA-DR labelling was then used to distinguish APCs (Figure 3.1 D). Finally, 
using an isotype control (Figure 3.1 E), CD14 and CD16 marker expression was used to distinguish the 
three monocyte subsets: CD14++CD16- (classical), CD14++CD16+ (intermediate), and CD14+CD16++ 
(non-classical) (Figure 3.1 F).  
 
 
Figure 3.1: Gating strategy for the identification of human monocyte subsets. Whole blood from a 
healthy donor was labelled with anti-HLA-DR, anti-CD14, and anti-CD16 antibodies; monocyte subsets 
were then identified using a flow cytometer. A) PBMCs were gated based on FSC and SSC. B and C) 
doublet discrimination was carried out. D) HLA-DR labelling was then used to distinguish APCs. E) 
isotype control for CD14 and CD16. F) the three monocyte subsets were distinguished based on their 
CD14 and CD16 expression: CD14++CD16- (classical), CD14++CD16+ (intermediate), and 
CD14+CD16++ (non-classical). 
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The phenotype of the monocytes was investigated further using additional subset-associated markers 
as well as markers of potential contaminating cell types (e.g. CD16+ NK cells) to confirm the identity 
of the gated monocyte subsets. Healthy donor PBMCs were labelled for HLA-DR, CD14, and CD16 to 
distinguish the monocyte subsets and the following markers: CD33 (expressed on monocytes), NKp46 
(used to exclude NK cells), CCR2 and CX3CR1 (hierarchy of expression is well characterised in the 
monocyte subsets). Expression levels of each marker in relation to the isotype control for the total 
monocytes were compared between the monocyte subsets using overlaid histograms. All three 
monocyte subsets were positive for CD33 but negative for NKp46, which confirmed the identity of the 
monocytes and ensured that the gating strategy excluded CD16+ cell populations that were not 
monocytes, e.g. NK cells. Expression of CCR2 (a chemokine receptor that facilitates monocyte release 
from the BM) was highest in classical monocytes and lowest in non-classical monocytes. In contrast, 
CX3CR1 (a chemokine receptor that facilitates endothelial adhesion, rolling, and migration) expression 
was lowest on classical monocytes and highest in non-classical monocytes. These findings are in 
agreement with previous reports on the hierarchy of expression of these markers in the human 
monocyte subsets (Boyette et al. 2017; Patel et al. 2017; Wong et al. 2011), therefore, the gating 
strategy can robustly identify monocyte subsets for further analysis. 
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Figure 3.2 Characterisation of the human monocyte subsets. Healthy donor PBMCs (n=1) were 
labelled with anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish the monocyte subsets. 
Additional markers were used to further characterise the monocyte subsets, including CD33, NKp46, 
CCR2, and CX3CR1. The sample was then acquired on the flow cytometer. The overlays represent the 
expression levels of each marker in relation to the isotype control for the total monocytes (grey 
histogram) and each monocyte subset (classical, intermediate, and non-classical). 
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Whole blood labelling minimises potential isolation-related changes to marker expression, making it 
highly suitable for phenotyping experiments but it is not suitable for many functional experiments, 
where separated PBMC are required. The assay for measuring IL-10 responsiveness would require 
separation of PBMCs from whole blood. To determine if all subsets are recovered equally well, 
monocyte labelling was compared between whole blood and separated PBMCs, cultured for three 
hours, from a healthy donor. The ratio of the monocyte subsets was similar whether determined in 
whole blood or PBMC.  
 
 
Figure 3.3: Comparing monocyte subset labelling in whole blood and separated PBMCs. A) whole 
blood from a healthy donor (n=1) was labelled with anti-HLA-DR, anti-CD14, and anti-CD16 antibodies 
to distinguish the monocyte subsets. B) PBMCs from the same donor were extracted, cultured for 
three hours, and labelled with the same set of antibodies before acquiring both samples on the flow 
cytometer. 
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3.4.2 Establishing stimulation conditions for induction of cytokine responses in 
monocytes subsets 
 
3.4.2.1 LPS induces apparent loss of CD16+ monocyte subsets 
 
Having confirmed the gating strategy, the next step was to define the stimulation conditions and 
cytokine readout. TNFα was chosen as the readout because it is clinically relevant in IBD, and LPS is 
known to stimulate a robust TNFα response in monocytes (Beutler 2000; Kontoyiannis et al. 1999). In 
order to establish a workable assay, the optimal LPS concentration for stimulation was determined by 
the ability to induce a robust TNFα response that could be measurably inhibited by IL-10 but not reach 
maximal TNFα production in all monocyte subsets that would diminish the sensitivity of the assay. To 
define this concentration, healthy donor PBMCs were stimulated with various concentrations of LPS 
(0.001-1000ng/mL) for three hours in the presence of monensin before staining for intracellular TNFα. 
TNFα production was quantified as a percentage of cells positive for TNFα above the unstimulated 
condition (Appendix 4a). Absolute cell numbers were calculated using Flow-Count Fluorospheres 
added to each sample immediately before acquisition. CD14 and CD16 expression was measured as 
mean fluorescence intensity (MFI) for staining with anti-14 or anti-CD16 antibody. 
Following culture for three hours in medium alone all three monocyte subsets remained identifiable, 
and there was little or no production of TNFα (Figure 3.4 A). In contrast, following stimulation with 
1ng/mL LPS, there was an apparent loss of CD16+ monocytes; the classical monocytes showed robust 
production of TNFα, the remaining intermediate cells were TNFα positive, and a small proportion of 
the remaining non-classical monocytes were also TNFα positive (Figure 3.4 B).  
To determine whether TNFα production and the apparent loss of specific monocyte populations could 
be dissociated by varying the concentration of LPS used for stimulation, LPS was titrated between 
0.001-1000ng/mL (Figure 3.4 C, D). The absolute number of classical monocytes was remained 
constant at lower concentrations of LPS but showed a gradual reduction above 1ng/mL, the 
concentration at which TNFα production was first detectable (Figure 3.4 C). The intermediate 
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monocytes showed maximal TNFα production at 1ng/mL but induction of TNFα production was closely 
associated with the apparent loss of this population (Figure 3.4 C). In non-classical monocytes, TNFα 
production increased with increasing concentrations of LPS and was greatest at to 100ng/mL. 
Although this response was less robust, it was again closely associated with the apparent loss of these 
cells from the cultures (Figure 3.4 C). The intermediate and non-classical cells remaining after 
stimulation showed a reduced level of CD16 expression with increasing LPS concentration (Figure 3.4 
D). There was little impact of LPS stimulation on CD14 expression by classical monocytes (Figure 3.4 
D). Figure 3.4 displays representative data; for pooled numerical data from repeated experiments 
refer to appendix 4b.  
TNFα production was detectable in all three subsets at LPS concentrations of 100pg/mL and above. 
Approximately 10-100-fold more LPS was required for maximal TNFα production by non-classical 
monocytes than by classical and intermediate monocytes (1-10ng/mL), and fewer non-classical 
monocytes were TNFα positive at this optimal LPS concentration than classical and intermediate 
monocytes (see also Chapter 4). A reduced proportion of monocytes were TNFα positive at super-
optimal concentrations of LPS in all three subsets.  
These data indicate that it is not possible to dissociate the apparent loss of CD16-expressing 
monocytes from stimulation of TNFα production by adjusting LPS concentration as the two 
phenomena are too tightly linked. 
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Figure 3.4: A representative of the effect of stimulation with LPS on the monocyte subsets. Healthy 
donor PBMCs were stimulated with increasing concentrations of LPS (0.001-1000ng/mL) for three 
hours in the presence of monensin. The PBMCs were then labelled for anti-HLA-DR, anti-CD14, and 
anti-CD16 antibodies to distinguish the monocytes subsets, fixed, permeabilised and labelling 
intracellularly with anti-TNFα antibody before acquiring on the flow cytometer. A) representative flow 
cytometry plots of monocyte subset distribution and TNFα production in unstimulated cultures. B) 
representative flow cytometry plots of monocyte subset distribution and TNFα production in cultures 
stimulated with 1ng/mL LPS. TNFα production was quantified as a percentage of cells positive for 
TNFα. Absolute cell number calculated using Flow-Count Fluorospheres. C) LPS-induced TNFα 
production with increasing concentration of LPS, and absolute numbers of the monocyte subsets. D)  
the level of CD14 and CD16 expression, measured as MFI, on monocyte subsets with increasing 
concentration of LPS.  
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A time course of LPS stimulation was also carried out to determine the kinetics of TNFα production 
and the ‘loss’ of CD16+ cells, and to assess whether these two effects of stimulation can be dissociated 
by careful selection of time points for analysis. Whole PBMCs from a healthy donor were stimulated 
with 1ng/mL LPS for one, three, six and 24 hours in the presence of monensin before staining for TNFα 
intracellularly. TNFα production was quantified as a percentage of cells positive for TNFα. Absolute 
cell number was calculated using Flow-Count Fluorospheres. CD14 and CD16 expression was 
measured as MFI for staining with anti-14 or anti-CD16 antibody. 
In unstimulated culture, the CD16+ cells displayed a gradual decline in CD16 expression over the first 
six hours of incubation but, interestingly, at 24 hours there was an increase in the double positive 
population (Figure 3.5 A). Upon stimulation, CD16+ cells were lost at all time points (Figure 3.5 B). In 
classical monocytes, TNFα production increased between one and six hours, but the response at 24 
hours was diminished; absolute numbers of classical monocytes showed a gradual reduction over the 
time course (Figure 3.5 C). TNFα production by intermediate monocytes increased between one and 
six hours but again was diminished at 24 hours; absolute numbers of intermediate monocytes were 
gradually lost over the six-hour stimulation but at 24 hours there was an apparent increase in the 
number of intermediate monocytes (Figure 3.5 C). In contrast, TNFα production by non-classical 
monocytes increased over the time course and was maximal at 24 hours; a loss in their cell numbers 
closely mirrored the production of TNFα (Figure 3.5 C). Time-dependent loss of CD16+ cells was 
mirrored by a reduced level of CD16 on the surface of the remaining cells (Figure 3.5 D).  
These data reveal a change in the phenotype of the monocyte subsets over a 24-hour culture reflected 
in marker expression and TNFα producing capacity. These data demonstrate that it is not possible to 
dissociated TNFα production and the apparent-loss of CD16+ cells by adjusting the duration of LPS 
stimulation.  
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Figure 3.5: Time course for LPS stimulation. Healthy donor PBMCs (n=1) were stimulated with 1ng/mL 
LPS for one, three, six, or 24 hours in the presence of monensin. The PBMCs were then labelled for 
anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish the monocytes subsets, fixed, 
permeabilised and labelling intracellularly with anti-TNFα antibody before acquiring on the flow 
cytometer. A) representative flow cytometry plots of monocyte subset distribution over the time 
course in unstimulated cultures. B) representative flow cytometry plots of monocyte subset 
distribution over the time course in cultures stimulated with 1ng/mL LPS. TNFα production was 
quantified as a percentage of cells positive for TNFα. Absolute cell number was calculated using Flow-
Count Fluorospheres. C) LPS-induced TNFα production with increasing time course of stimulation, and 
absolute numbers of the monocyte subsets. D) expression of CD14 or CD16, measured as MFI, on 
monocyte subsets stimulated with 1ng/ml LPS for 1-24 hours.  
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To determine whether the loss of CD16+ cells was specific to stimulation with LPS, the effect of other 
TLR agonists was investigated. Whole PBMCs from a healthy donor were stimulated with LPS a TLR4 
agonist (1ng/mL), Pam3CSK4 a TLR2 agonist (1000ng/mL), Poly(I:C) a TLR3 agonist (1000ng/mL), or 
Flagellin a TLR5 agonist (1000ng/mL) for three hours in the presence of monensin before staining for 
TNFα intracellularly. TNFα production was quantified as a percentage of cells positive for TNFα. 
Absolute cell number was calculated using Flow-Count Fluorospheres. CD14 and CD16 expression was 
measured as MFI for staining with anti-14 or anti-CD16 antibody. 
There was an apparent reduction in the absolute number of intermediate monocytes and to a lesser 
extent non-classical monocytes, upon stimulation with the all of the TLR agonists tested (Figure 3.6 
A). Like LPS, the other TLR agonists also caused a loss of CD16 expression on the residual intermediate 
and non-classical cells (Figure 3.6 B). There was a modest reduction in the absolute number of classical 
monocytes upon stimulation with the TLR agonists, but this seemed unrelated to the level of CD14 
expression (Figure 3.6 A, B). When comparing different TLR agonists, the ‘loss’ of monocytes was not 
always related to the level of TNFα production they induced. For instance, TNFα production was 
greater with LPS and Poly(I:C) stimulation than with Pam3CSK4 or flagellin but their effects on numbers 
of intermediate and non-classical monocytes and the level of CD16 expression was similar (Figure 3.6 
B, C).  
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Figure 3.6: The effect of stimulation with various TLR agonists on the monocyte subsets. Healthy 
donor PBMCs (n=1) were stimulated with LPS (1ng/mL), Pam3CSK4 (1000ng/mL), Poly(I:C) 
(1000ng/mL), or flagellin (1000ng/mL) for three hours in the presence of monensin. The PBMCs were 
then labelled for anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish the monocytes 
subsets before acquiring on the flow cytometer. A) absolute cell numbers, calculated using Flow-Count 
fluorospheres, of the monocyte subsets upon stimulation with the TLR agonists. B) expression of CD14 
or CD16, measured as MFI, on the monocyte subsets upon stimulation with the TLR agonists. C) TNFα 
production, quantified as a percentage of cells positive for TNFα, in the monocyte subsets upon 
stimulation with the TLR agonists.  
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3.4.3.2 The apparent loss of CD16+ cells is not due to cell death or adherence 
 
The apparent loss of CD16+ cells could be due to induced cell death upon TLR4 stimulation. To test 
this, the viability of the cells was investigated. Whole PBMCs from a healthy donor were stimulated or 
not with LPS (1ng/mL) for three hours in the presence of monensin and stained with fixable viability 
dye (enables identification of dead cells) and annexin V (binds to phosphatidylserine, a marker of 
apoptosis) to detect dead or dying cells within the three populations of monocytes.  
There was no shift in staining for fixable dye or annexin V in any of the monocyte subsets between 
unstimulated and LPS stimulated cultures, indicating no difference in the viability of the cells (Figure 
3.7). However, this approach can only assess the viability of the cells in the monocyte population 
remaining after stimulation and the viability of the cells that are ‘lost’ cannot be determined. 
Therefore, a contribution of cell death induced by TLR stimulation cannot be ruled out as an 
explanation for the loss of CD16+ cells.  
 
 
Figure 3.7: Viability of the monocyte subsets upon LPS stimulation. Whole PBMCs from a healthy 
donor (n=1) were stimulated or not with 1ng/mL LPS for three hours in the presence of monensin. The 
PBMCs were then labelled for anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish the 
monocytes subsets, and stained with annexin V and fixable viability dye to identify dead or dying cells. 
The sample was then acquired on the flow cytometer. Graphs show annexin V and fixable dye staining 
in classical (A; red), intermediate (B; blue), and non-classical (C; green) monocytes overlaying 
unstimulated culture (solid colour) and stimulated cultures (pale colour). 
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Upon activation, monocyte subsets may become adherent to tissue culture plastic to different extents. 
This raises the possibility that CD16+ monocytes could adhere to a greater degree leading to reduced 
recovery. To test this idea, stimulation assays were compared in low adhesive and standard tissue 
culture plates. Whole PBMCs from a healthy donor were stimulated with increasing concentrations of 
LPS (0.001-10ng/mL) for three hours in the presence of monensin. Absolute cell number was 
calculated using Flow-Count Fluorospheres. CD14 and CD16 expression was measured as MFI for 
staining with anti-14 or anti-CD16 antibody. 
The apparent loss of CD16+ monocytes upon LPS stimulation did not differ substantially between 
cultures in low adherence and standard tissue culture plates (Figure 3.8 A). The residual intermediate 
and non-classical monocytes were characterised by their reduced levels of CD16 expression with 
increasing LPS concentration whether they were cultured on standard or low-adhesive plates (Figure 
3.8 B). The modest loss of CD14+ classical monocytes in the absence of any effect on the level of CD14 
expression, previously observed, was observed in both types of plates (Figure 3.8 A, B). Nonetheless, 
results obtained using low adherence and standard plates were not identical; the recovery of both 
classical and intermediate monocytes was marginally higher in the low adherence plates compared 
with standard culture plates, consistent with a loss of small numbers of cells by adherence to the 
standard plate (Figure 3.8 A). This was reflected in their expression levels of CD14 and CD16 (Figure 
3.8 B). 
Overall, these data indicate that although there was a minor loss of both classical and intermediate 
monocytes on the standard plate, most likely due to adherence. The apparent loss of CD16+ subsets 
following LPS stimulation could not be attributed to adherence to the culture plate.  
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Figure 3.8: The effect of stimulation with LPS on the monocyte subsets cultured in standard or low-
adhesive plates. Whole PBMCs from a healthy donor (n=1) were stimulated or not in standard or low-
adhesive plates with increasing concentrations of LPS (0.001-10ng/mL) for three hours in the presence 
of monensin. The PBMCs were then labelled for anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to 
distinguish the monocytes subsets before acquiring on the flow cytometer. A) absolute cell numbers, 
calculated using Flow-Count fluorospheres, of the monocyte subsets upon stimulation with the TLR 
agonists. B) expression of CD14 or CD16, measured as MFI, on the monocyte subsets upon stimulation 
with the TLR agonists. 
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3.4.3.3 LPS stimulation causes loss of CD16 expression  
 
Thus far, the findings indicated that the loss of CD16+ cells upon LPS stimulation was unlikely to be 
explained by cell death or adherence to culture plates. Reduced expression of CD16 on the residual 
intermediate, and to a lesser extent non-classical monocytes following stimulation, suggested the 
alternative possibility that the CD16 marker was lost following stimulation. Thus, CD16+ monocytes 
may not be genuinely lost but instead undergo a phenotypic change upon stimulation such that they 
are no longer identifiable. To test this possibility, an approach was developed that allowed the fate of 
monocytes subsets to be tracked following stimulation independently of their continued expression 
of CD16 and CD14.  Whole PBMCs from a healthy donor were stained with CTV and then labelled for 
HLA-DR, CD14, and CD16 to distinguish the monocytes subsets for cell sorting on the FACS Aria. The 
separated subsets were spiked into unlabelled PBMCs and stimulated or not with 1ng/mL LPS for three 
hours in the presence of monensin. The level of CD14 and CD16 expression on the purified, labelled 
monocyte subsets were measured before and after culture. 
The level of CD14 expression on the classical monocytes was maintained after three hours of 
incubation with or without LPS stimulation (Figure 3.9 A, D). However, intermediate and non-classical 
monocytes showed a decline in CD16 expression after three hours of incubation even in the absence 
of LPS, and the level of CD16 expression was reduced further in LPS-stimulated cultures (Figure 3.9 B-
D). These observations suggest that the process of antibody labelling and/or sorting of the cells led to 
activation of the cells and reduced expression of CD16, and that this effect was further promoted by 
the addition of LPS. Although moderate, there was a further reduction in CD16 expression on the 
intermediate and non-classical monocytes upon LPS stimulation (Figure 3.10 B-D). 
Collectively, these data suggest that the apparent loss of CD16+ cells upon activation was due to 
changes in marker expression and not cell death or adherence.  
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Figure 3.9: Tracking monocyte subsets upon LPS stimulation. Representative of healthy donor PBMCs 
(n=4) were stained with CTV and then labelled for anti-HLA-DR, anti-CD14, and anti-CD16 antibodies 
to distinguish the monocytes subsets before cell sorting on the FACS Aria. The separated subsets were 
spiked into unlabelled PBMCs and stimulated or not with 1ng/mL LPS for three hours in the presence 
of monensin. The cultured cells were harvested and then labelled for HLA-DR, CD14, and CD16 before 
acquiring on the flow cytometer. A, B and C) representative flow cytometry plots of individual subsets 
at 0hrs, 3hrs, and 3-hour LPS stimulation. D) expression of CD14 or CD16, measured as MFI, on the 
monocyte subsets at 0hrs, 3hrs, and 3-hour LPS stimulation. 
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3.4.3.4 Loss of CD16 expression is not due to internalisation  
 
Tracking monocyte subsets as described above indicated that CD16 expression was rapidly lost from 
the cell surface upon activation. The possible mechanisms for this reduction in CD16 expression over 
a few hours are internalisation of CD16 or cleavage from the cell surface. First, the internalisation of 
the marker was investigated. Whole PBMCs from a healthy donor were stimulated with 1ng/mL LPS 
for three hours in the presence of monensin before staining for intracellular CD16 by permeabilising 
the cells before the addition of anti-CD16.  
Permeabilisation of LPS-stimulated cells before addition of anti-CD16 did not reveal a population of 
CD16+ intermediate or non-classical monocytes (Figure 3.10 A, B). This suggests that CD16 is not 
internalised following LPS stimulation and indicates that it must be lost from the surface by an 
alternative mechanism. 
 
Figure 3.10: Monocyte subset distribution upon LPS stimulation with intracellular CD16 labelling. 
Whole PBMCs from a healthy donor (n=1) were stimulated with 1ng/mL LPS for three hours in the 
presence of monensin. The PBMCs were then labelled for anti-HLA-DR, anti-CD14, and anti-CD16 
antibodies to distinguish the monocytes subsets, fixed, permeabilised and stained intracellularly for 
CD16 before acquiring on the flow cytometer. A and B) representative flow cytometry plots of 
monocyte subsets distribution under the two conditions. 
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3.4.3.5 LPS induces cleavage of CD16 via ADAM17 
 
The next step was to investigate the possible cleavage of CD16 from the surface of monocytes upon 
LPS stimulation. There is a precedent for this in NK cells as Romee et al. (2013) showed that CD16 was 
cleaved from the surface of NK cells upon stimulation and that this effect could be blocked by 
inhibitors of the metalloprotease ADAM17. To test whether monocytes cleaved CD16 in the same way, 
a specific ADMA17 inhibitor (TMI-005) was used. Whole PBMCs from a healthy donor were stimulated 
with LPS (1ng/mL) for three hours in the presence of monensin, and with or without ADAM17 inhibitor 
(50µM TMI-005 added 30min before LPS).  
Loss of CD16 expression was again observed upon LPS stimulation in the absence of the ADAM17 
inhibitor (Figure 3.11 A). However, in the presence of the ADAM17 inhibitor, CD16+ monocytes, both 
intermediate and non-classical subsets, were maintained following LPS stimulation (Figure 3.11 B). 
These findings indicate that CD16 is cleaved off the cell surface by ADAM17 upon TLR4 activation. 
Blocking ADAM17 also prevented the loss of CD16 expression when stimulating with other TLR 
agonists, including Poly(I:C), Pam3CSK4, and Flagellin (data not included), which suggests the 
downregulation of CD16 expression upon activation by various TLR agonists work via the same 
mechanism.  
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Figure 3.11: The effect of stimulation with LPS on the monocyte subsets cultured in the presence or 
absence of an ADAM17 inhibitor. Healthy donor PBMCs (n=1) were stimulated or not with LPS 
(1ng/mL), for three hours in the presence of monensin, and with or without ADAM17 inhibitor (TMI-
005 at 50µM added 30min before LPS). The PBMCs were then labelled for anti-HLA-DR, anti-CD14, and 
anti-CD16 antibodies to distinguish the monocytes subsets before acquiring on the flow cytometer. 
Graphs show representative plots of monocyte subset distribution upon TLR stimulation A) without 
ADAM17 inhibitor B) with ADAM17 inhibitor.  
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3.4.3 Optimising the assay for measuring monocyte responsiveness to IL-10  
 
Once the cleavage of CD16 could be blocked with an ADAM17 inhibitor, it was possible to reliably 
identify all monocyte subsets following LPS stimulation. ADAM17 is also involved in cleaving and 
release TNFα from the cell surface (Adrain et al. 2012), which could theoretically impact on the staining 
of cell-associated TNFα used as a readout for the response to LPS in this assay, therefore, it was 
important to ensure that that the addition of TMI-005 did not have a negative impact on the LPS-
induced TNFα response. Whole PBMCs from a healthy donor were stimulated with increasing 
concentrations of LPS (0.001-1000ng/mL) for three hours in the presence of monensin and ADAM17 
inhibitor (50µM TMI-005 added 30min before LPS) before staining for TNFα intracellularly. TNFα 
production was quantified as a percentage of cells positive for TNFα. Absolute cell number was 
calculated using Flow-Count Fluorospheres. CD14 and CD16 expression was measured as MFI for 
staining with anti-14 or anti-CD16 antibody.  
In the presence of ADAM17 inhibitor LPS induced TNFα production with the same hierarchy of the 
monocyte subsets and LPS dose-dependence previously noted in its absence (Figure 3.12 A). 
Therefore, ADAM17 does not appear to have a negative impact on TNFα as a readout, most likely 
because intracellular rather than secreted TNFα was measured in this protocol. 
The number of classical monocytes and CD14 expression was constant across the LPS concentrations 
(Figure 3.12 A, B). The number of intermediate and non-classical monocytes and CD16 expression was 
reduced at higher LPS concentrations even in the presence of TMI-005, suggesting that the protective 
effect of 50µM TMI-005 can be partially overcome if the strength of stimulation is sufficiently strong, 
but the magnitude of this effect was much lower than in the absence of ADAM17 inhibitor (Figure 3.12 
A). On the basis of these findings, TMI-005 was included in the assays going forward. 
Accordingly, 1ng/mL was determined as the optimal LPS concentration going forward as it was the 
minimum concentration required to produce a robust but sub-maximal TNFα response, measurable 
in all subsets, that should therefore provide sensitivity when assaying the inhibitory effects of IL-10. 
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Figure 3.12: LPS titration in the presence of ADAM17 inhibitor. Healthy donor PBMCs (n=1) were 
stimulated with increasing concentrations of LPS (0.001-1000ng/mL added 30min before LPS) for 
three hours in the presence of monensin and ADAM17 inhibitor (TMI-005 at 50µM added 30min 
before LPS). The PBMCs were then labelled for anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to 
distinguish the monocytes subsets, fixed, permeabilised and labelling intracellularly with anti-TNFα 
antibody before acquiring on the flow cytometer. TNFα production was quantified as a percentage of 
cells positive for TNFα. Absolute cell number calculated using Flow-Count Fluorospheres. C) LPS-
induced TNFα production with increasing concentration of LPS, and absolute numbers of the 
monocyte subsets. D)  the level of CD14 and CD16 expression, measured as MFI, on monocyte subsets 
with increasing concentration of LPS. 
 
Finally, to confirm the suitability of the assay for measuring the ability of IL-10 to inhibit LPS-induced 
TNFα production by the monocyte subsets, IL-10 was titrated into the assay. Whole PBMCs from a 
healthy donor were stimulated with 1ng/mL LPS and increasing concentrations of IL-10 (0.016-
10ng/mL added 30min before LPS) for three hours in the presence of monensin and ADAM17 inhibitor 
(50µM TMI-005 added 30min before LPS) before staining for TNFα intracellularly. TNFα production 
was quantified as a percentage of cells positive for TNFα.  
A dose-dependent reduction in TNFα production was observed with increasing concentrations of IL-
10 for each monocyte subset (Figure 3.13 A). The inhibition of TNFα production by IL-10 could be 
completely blocked by addition of an anti-IL-10R blocking antibody (Figure 3.13 B), confirming that the 
inhibitory action of IL-10 is a specific effect via the IL-10R.  
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Figure 3.13: Inhibition of LPS-induced TNFα production with increasing concentration of IL-10. 
Whole PBMCs from a healthy donor (n=1) were stimulated with 1ng/mL LPS and increasing 
concentration of IL-10 (0.4-10ng/mL added 30min prior to LPS) for three hours in the presence of 
monensin and ADAM17 inhibitor (TMI-005 at 50µM added 30min prior to LPS), and with or without 
IL-10R blocking antibody (5µg/mL added 30min prior to IL-10). The PBMCs were then labelled for anti-
HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish the monocytes subsets, fixed, 
permeabilised and labelling intracellularly with anti-TNFα antibody before acquiring on the flow 
cytometer. TNFα production was quantified as a percentage of cells positive for TNFα. A) LPS-induced 
TNFα production by monocyte subsets with increasing concentration of IL-10 in the absence of anti-
IL-10R blocking antibody. B) LPS-induced TNFα production by monocyte subsets with increasing 
concentration of IL-10 in the presence of ant-IL-10R blocking antibody. 
 
In summary, the final assay optimised in this chapter used unfractionated PBMCs stimulated with 
1ng/mL LPS and increasing concentration of IL-10 (0.016-10ng/mL added 30min before LPS) for three 
hours in the presence of monensin and ADAM17 inhibitor (TMI-005 at 50µM mL added 30min before 
LPS). The hierarchy of response to IL-10 inhibition for each subset is discussed in more detail in the 
next chapter.  
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5.5 Discussion  
 
The primary aim of this chapter was to develop an assay that could be used to measure IL-10 
responsiveness in human monocyte subsets. First, a gating strategy for the identification of the human 
monocyte subsets was established. The assay for measuring IL-10 responses in the monocyte subsets 
involved induction of TNFα production with LPS. However, this led to an apparent loss of CD16+ cells. 
This effect could be inhibited by an ADAM17 inhibitor (TMI-005), which enabled the IL-10 response of 
the monocyte subsets to be determined in parallel in the same culture environment.  
The method of monocyte subset identification was broadly based on previously published work by 
Thiesen et al. 2013. Importantly, CD33 and NKp46 labelling confirmed the identity of the monocytes 
and showed that CD16+ cell populations that are not monocytes (e.g. NK cells) were excluded from 
the non-classical monocyte gate as a result of pre-gating on HLA-DR+ cells. A recent study 
demonstrated in humans that the monocyte subsets are not isolated populations but represent stages 
of differentiation, along which the expression of various markers change (Patel et al. 2017). For 
instance, CCR2 is downregulated during the maturation of classical monocytes into non-classical 
monocytes, while CX3CR1 is upregulated (Patel et al. 2017). This expression profile was reflected in 
the analysis of the monocyte subsets identified with the gating strategy described in this chapter.  
The monocyte subsets could be identified using whole blood labelling, which was attractive for 
phenotyping because there is less manipulation of the cells. However, separated PBMCs had to be 
used for the functional experiments. The two methods were compared, and distribution of subsets 
within the monocyte population was similar in whole blood and separated PBMCs cultured short term, 
enabling the comparison of data produced from each method.   
It was decided to measure IL-10 responsiveness of monocyte subsets by stimulating whole PBMCs 
with LPS in the presence of increasing amounts of IL-10 and determining inhibition of TNFα 
production. TNFα was chosen as the readout because it is clinically relevant in IBD, and LPS is known 
to stimulate a robust TNFα response in monocytes (Kontoyiannis et al. 1999). However, upon 
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stimulation with LPS there was an apparent loss of intermediate monocytes, and to a lesser extent 
non-classical monocytes, which may be due to the greater induction of TNFα in intermediate 
monocytes compared to non-classical monocytes. The expression of CD16 on the residual 
intermediate and non-classical monocytes was also reduced with increasing concentration of LPS. The 
loss of CD16 expression upon TLR stimulation has previously been reported on NK cells (Romee et al. 
2013). The mechanism behind the apparent loss CD16+ cells will be discussed in more detail.  
The loss of CD14 expression upon activation has been previously described in monocytes (Bazil & 
Strominger 1991). In the data presented in this chapter, there was only a small reduction in the 
number of CD14+ classical monocytes, and a modest reduction in the level of CD14 expression at 
higher concentrations of LPS. The study by Bazil & Strominger 1991 used purified monocytes, which 
may account for the greater loss of CD14 expression reported. In addition, their study concluded that 
the loss of CD14 expression was due to shedding from the cell surface as they detected an increase in 
soluble CD14 in stimulated cultures (Bazil & Strominger 1991). Another study showed that the 
downregulation of TLR4 expression on human aortic endothelial cells was due to cleavage (Yang et al. 
2018). In contrast, a study by Kagan et al., 2008 showed that TLR4 activation induced CD14-dependent 
endocytosis of the TLR4 complex in Mφs. However, Rajaiah et al. 2015 showed endocytosis is CD14-
independent. Therefore, it appears that different cell types have different mechanisms for 
downregulating TLR4 expression. This phenomenon may demonstrate a negative feedback 
mechanism of endotoxin tolerance.  
A number of experiments were carried out in an attempt to dissociate the induction of TNFα 
production from the impact of stimulation on CD16+ monocytes. A time course was used to investigate 
the kinetics of LPS induced loss of the monocyte subsets and induction of TNFα production but both 
outcomes were tightly associated in time between one and six hours after stimulation. Following 
overnight culture, there was an apparent loss of classical monocytes that shift towards intermediate 
monocytes, with both populations displaying a diminished response to LPS. The upregulation of CD16 
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expression with overnight culture has not been previously described. However, this does not reflect 
the ‘monocyte waterfall’ of the maturation of classical monocytes into intermediate monocytes 
because of other phenotypic features (diminished LPS response). There is evidence that RBCs have a 
role in regulating CD16 expression (Schakel et al. 2006), therefore, the separation of PBMCs from 
whole blood during overnight culture could be the cause of the upregulated CD16 expression. The 
‘loss’ of non-classical monocytes was closely linked to TNFα production throughout the 24 hours of 
stimulated culture.  
The experiments so far had focused on LPS stimulation, which raised the question whether the ‘loss’ 
of CD16+ cells was TLR4-dependent. LPS signals down two pathways: MyD88-dependent and TRIF-
dependent (MyD88-independent) (Lu et al. 2008). Although there is cross-talk in these two signalling 
pathways, the former is associated particularly with activation of transcription factors such as NF-κB 
and production of pro-inflammatory cytokines including TNFα, whereas MyD88-independent 
signalling leads to the production of Type 1 interferons. To investigate the contribution of MyD88 
signalling to the ‘loss' of CD16+ cells, MyD88-dependent and -independent pathways were compared. 
LPS was compared with three other TLR ligands chosen to target these signaling pathways individually: 
Pam3CSK4 acts via TLR2 and Flagellin act via TLR5, both triggering the MyD88 pathway, whilst Poly(I:C) 
acts via TLR3 to activate TRIF (TLR3 is the only TLR not to activate MyD88-dependent signaling) (Akira 
& Takeda 2004). However, all the TLR agonists tested induced an equivalent ‘loss’ of the CD16+ cells, 
suggesting that both MyD88- and TRIF-dependent signalling are capable of inducing this effect. 
However, these two signalling pathways may not be completely independent as TNFα was induced by 
Poly(I:C) stimulation, indicating potential crosstalk between the two signalling pathways. The different 
TLR agonists induced variable levels of TNFα production but the ‘loss’ of the CD16+ cells was 
comparable, indicating that TNFα is unlikely to be solely responsible for the monocyte loss. 
Importantly, the viability of the monocytes was measured upon LPS stimulation to ensure that the 
monocytes were not impaired under the stimulation conditions. It is not known how long monocytes 
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survive in vitro after stimulation or if it varies between subsets. LPS stimulation did not affect the 
viability of the subset with the caveat that this could only be measured in the remaining cells. There 
is evidence that monocytes become more adherent upon activation (Tzeng et al. 1985), therefore, 
low-adhesive plates were used to ensure the monocytes were not being lost during cell harvesting. 
Although the low adhesive plates did not reverse the ‘loss' of CD16+ monocytes observed with 
increasing LPS concentrations, there was an overall improvement of cell recovery of classical 
monocytes, and of intermediate monocytes at lower concentrations of LPS confirming limited 
adherence to the standard plates. Non-classical monocytes did not show a noticeable difference in 
cell recovery with non-adherent plates. Although their role in patrolling the endothelium would 
suggest they are highly adherent, the surface of the plastic and the endothelium are not comparable 
(Auffray et al. 2007).  
Thus far, the apparent loss of CD16+ cells upon LPS stimulation could not be explained by induced cell 
death or adherence to culture plates, therefore, an alternative explanation that the changes in surface 
marker expression on the monocyte subsets upon stimulation was investigated. Cell sorted monocyte 
subsets were labelled with CTV to enable tracking once they were placed into culture with whole 
PBMCs (to maintain a consistent culture environment), with or without LPS stimulation. Expression of 
CD14 on classical monocytes was unaffected during the three-hour culture or by LPS stimulation. 
However, intermediate and non-classical monocytes showed a decline in CD16 expression during the 
three-hour incubation in the absence of stimulation. This suggests that the process of antibody 
labelling and/or cell sorting causes activation of the cells. Although moderate, there is a further 
reduction in CD16 expression on the intermediate and non-classical monocytes upon LPS stimulation. 
The moderate loss of CD16 expression upon LPS activation could be due to negative feedback 
mechanisms primed by the initial activation, as endotoxin tolerance is a well-known phenomenon 
(reviewed by Biswas & Lopez-Collazo 2009). Overall, these data suggest that the apparent loss of 
CD16+ cells upon activation is due to reduced cell surface expression. The most likely explanations for 
a reduction in CD16 expression over a few hours are internalisation or shedding of the marker from 
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the cell surface. However, there was no increase in intracellular CD16 staining in permeabilised cells 
suggesting that cleavage from the cell surface is the most likely explanation.  
Romee et al., 2013 showed that CD16 was shed from the surface of NK cells upon activation due to 
detecting an increase in soluble CD16 in stimulated culture, and this could be blocked by an ADAM17 
inhibitor. Therefore, a specific ADAM17 inhibitor (TMI-005) was used to investigate whether the same 
mechanism was present in monocytes. ADAM17 (also called tumor necrosis factor converting 
enzyme/TACE) is a metalloprotease first recognised for releasing membrane-bound TNFα to its active 
form, and is now understood to play a broader role (Adrain et al. 2012). In the presence of ADAM17 
inhibitor, CD16+ monocytes were still identifiable following stimulation, which indicates that CD16 is 
cleaved off the cell surface by ADAM17 upon TLR activation. There was still some cleavage of CD16 at 
higher LPS concentrations, which may suggest a suboptimal concentration of ADAM17 inhibitor or 
possibly that other protease could contribute to the loss of CD16. As mentioned, ADAM17 is also 
involved in cleaving TNFα, which is the readout for the LPS response, therefore, it was important to 
ensure that ADAM17 blockade did not have a negative impact on the LPS response. ADAM17 showed 
no negative impact on TNFα as a readout, which is most likely due to measuring intracellular TNFα 
production and not secretion. 
The use of an ADAM17 inhibitor enabled the measurement of IL-10 responsiveness of the monocyte 
subsets in parallel ensuring the same culture environment, and removed the need for cell sorting that 
appeared to activate the monocytes. TNFα production was measured via intracellular staining, which 
may differ to secretion that is regulated by ADAM17. The implications of CD16 shedding upon TLR 
activation are unclear. Downregulation of CD16 expression may limit cross-linking by immune 
complexes that induce ADCC (Romee et al. 2013; Schmitz et al. 2002), with the aim to maintain 
immune homeostasis. Shedding of CD16 could also be an artefact of in vitro stimulation. However, 
Picozza Picozza, Batistini, and Borsellino 2013 showed that stimulating whole blood with LPS induced 
the same effect. The concentration of LPS used may not be physiological, therefore, CD16 shedding 
115 
 
due to high LPS exposure cannot be ruled out. An environment where immune cells are continuously 
exposed to external antigens includes the intestine, where the function and origin of intestinal Mφs 
have been previously investigated. Although fate-mapping experiments in mice point to classical 
monocytes as the origin of intestinal Mφ in steady state, there may be circumstances in which other 
populations could contribute. In humans, a contribution of CD16+ monocytes to the intestinal Mφ 
pool may have been missed if CD16 is shed upon entry into the intestine making their identification 
challenging due to the lack of unique identifiers.   
5.6 Conclusion  
 
TLR stimulation leads to ADAM17 mediated cleavage of CD16 on monocytes and the apparent loss of 
intermediate monocytes, and to a lesser extent non-classical monocytes, from stimulated cultures. 
Addition of an ADAM17 inhibitor (TMI-005) to the cultures maintains CD16 expression and enables 
the responsiveness to IL-10 of the monocyte subsets to be determined in parallel in the same culture 
environment. The shedding of CD16 from the surface of populations of monocytes upon activation 
has important implications for the functions of these cells and also for the identification of moMφs 
within the intestine and other tissues. Caution should be applied when in interpreting an absence of 
CD16 expression as an absence of cells derived from intermediate or non-classical populations. 
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Chapter 4: Human monocyte subsets differ in their response to IL-10 
in healthy individuals  
4.1 Chapter summary  
 
In this chapter, the response of individual monocytes subsets to IL-10 was determined in healthy 
individuals. Response to IL-10 was measured using the ability of IL-10 to inhibit LPS-induced TNFα 
production. First, LPS-induced TNFα production was measured: intermediate monocytes showed 
greater TNFα production than classical monocytes, and non-classical monocytes showed the lowest 
TNFα production. IL-10 inhibition of this TNFα was greatest in classical monocytes, followed by 
intermediates, and least responsive were the non-classical monocytes despite low levels of TNFα 
production. Signalling components of the IL-10R signalling pathway were investigated to provide a 
possible explanation for the differences found in IL-10 response between monocyte subsets. These 
included IL-10Rα expression, STAT3 availability and phosphorylation, and SOCS3 mRNA expression. IL-
10Rα expression was highest in intermediate monocyte and lowest in classical monocytes, 
demonstrating that receptor expression was a poor indicator of the ability of IL-10 to inhibit pro-
inflammatory cytokine production in the different subsets. Classical and intermediate monocytes 
displayed equally high levels of STAT3, while non-classical monocytes displayed lower levels of STAT3, 
which correlated well with levels of STAT3 phosphorylation upon IL-10 stimulation. This may explain 
why classical monocytes are more responsive to IL-10 than non-classical monocytes but does not 
explain the difference between classical and intermediate monocytes. Classical monocytes also 
expressed higher levels of SOCS3 at steady-state than both intermediate and non-classical monocytes, 
as determined by qRT-PCR, which may provide another mechanism to explain their enhanced 
response to IL-10. This sensitivity to IL-10 may be particularly important in the intestine where 
regulatory signals must control recruited classical monocytes to limit their activation by commensal 
bacteria.   
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4.2 Introduction 
 
Most of our current knowledge about the role of monocytes and their subsets come from studying 
mice. However, striking similarities shown in gene expression analysis and expression of surface 
markers between monocyte subsets in mice and humans suggests one can draw parallels between 
their functions (Ingersoll et al. 2010; Geissmann et al. 2003). In brief, Ly6Chi cells in mice are analogous 
to classical monocytes (CD14++CD16+) in humans, as are Ly6Clo cells to non-classical monocytes 
(CD14+CD16++). The equivalent of intermediate monocytes has had little interest in mice, and as a 
consequence, not much is known about the role of these cells. In mice and now humans, it has been 
convincingly shown that the subsets of monocytes are not isolated populations, instead they 
represent stages of differentiation, where a small proportion of classical monocytes differentiate into 
intermediate monocytes, and finally non-classical monocytes (Patel et al. 2017; Yona et al. 2013; 
Sunderkotter et al. 2004). Ly6Chi cells at least in part maintain the intestinal Mφ pool during steady-
state, which has been shown to be CCR2-dependent (Bain et al. 2014; Takada et al. 2010; Yona et al. 
2013). In humans, classical monocytes highly express CCR2, and therefore are likely to perform similar 
roles (Appleby et al. 2013; Thiesen et al. 2014; Patel et al. 2017). Ly6Clo cells remain in the bloodstream 
and ‘patrol’ the endothelial wall, where CX3CR1 expression is critical in this role as well as rapid tissue 
invasion at the site of an infection (Ancuta et al. 2003; Auffray et al. 2007); non-classical monocytes in 
humans express a high level of CX3CR1 (Cros et al. 2010; Geissmann et al. 2003; Thiesen et al. 2014). 
Previous studies have shown that classical and intermediate monocytes are efficient producers of pro-
inflammatory cytokines upon stimulation with LPS, which was not seen in non-classical monocytes 
(Belge et al., 2002; Cros et al., 2010; Thiesen et al., 2014). It is critical that the inflammatory properties 
of the newly arrived monocytes are controlled as they differentiate into regulatory Mφs, which have 
been shown to play a critical role in maintaining steady-state in the intestine (Bain et al. 2013; Takada 
et al. 2010). The signals required for this process remain elusive but both IL-10 and TGFβ have been 
shown to have important non-redundant roles (Zigmond et al. 2014; Shouval et al. 2014; Smythies et 
al. 2005).  
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IL-10 is an important suppressor of inflammation. Mice and humans with deficiency in IL-10 or IL-10 
signalling components develop severe inflammation early in life (Begue et al. 2011; Gasche et al. 2003; 
Glocker & Kotlarz 2009; Grundtner et al. 2009; Kühn et al. 1993; Shouval et al. 2014; Zigmond et al. 
2014). The IL-10R is made up of two subunits: the alpha chain which facilitates specific binding of IL-
10, and the beta chain which is important for signal transduction (Kotenko et al. 1997). Upon activation 
of the IL-10R, proximal signalling events trigger a phosphorylation cascade involving JAK1, TYK2, and 
STAT3 (Riley et al. 1999). The p-STAT3 dimerise and translocate to the nucleus, where they regulate 
gene expression to bring about immune regulation (Donnelly et al. 1999), and therefore STAT3 
phosphorylation is often used as a marker of IL-10R activity.  
STAT3 has been shown to be critical in both IL-10 and IL-6 signalling using Cre-loxP recombination 
systems to show that IL-10 and IL-6 fail to induce a response in cells deficient in STAT3 (Akira 2000). 
However, it is not clear how activation of STAT3 with IL-10 causes inhibition of inflammatory 
responses, while IL-6 induces pro-inflammatory responses. A study by Yasukawa et al. 2003 suggests 
that SOCS3, induced by IL-10, is a key regulator of the divergent actions by selectively blocking 
signalling via IL-6. SOCS3 performs suppressive roles, such as inhibiting the NFkB pathway, as well as 
establishing a feedback loop to suppress further IL-10 signalling. LoupeTM cell browser (10X genomics) 
enables easy visualisation and analysis of 10x ChromiumTM Single Cell 5′ and 3′ gene expression data. 
The monocyte subsets were identified on the basis of CD14 and CD16 gene expression. Expression 
levels of selective genes along the IL-10R pathway were analysed in the monocyte subsets. SOCS3 was 
the only gene that showed significantly different expression levels between the monocyte subsets; 
classical monocytes showed the highest SOCS3 expression, followed by intermediates, and finally non-
classical monocytes (Appendix 5).   
The aim of the work described in this chapter was to determine the IL-10 responsiveness of monocyte 
subsets in healthy individuals. Signalling components of the IL-10R signalling pathway were measured 
to examine their relationship with the functional response to IL-10.  
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4.3 Aims 
 
To: 
4. Determine the ability of IL-10 to inhibit LPS-induced TNFα production in the monocyte subsets 
of healthy individuals. 
5. Identify the mechanistic basis of the differences between monocyte subsets by investigating 
the relationship between components of the IL-10 signalling pathway and TNF inhibition.  
6. Investigate the specificity of the subset difference in IL-10 response with respect to both 
modes of activation and cytokine read-out.  
4.4 Results  
4.4.1 Classical monocytes are most responsive to IL-10 inhibition in healthy 
individuals 
 
The response of monocyte subsets to LPS stimulation was compared in eight healthy individuals. 
PBMCs were stimulated with 1ng/ml LPS for three hours before staining for intracellular TNFα. TNFα 
production was quantified as a percentage of cells positive for TNFα and as the level of expression on 
a per cell basis, assessed as MFI. A significantly (p = 0.0183) higher percentage of intermediate 
monocytes produce TNFα than classical monocytes (Figure 4.1 A).  Fewer non-classical monocytes 
produced TNFα in response to LPS when compared to either classical (p = 0.0002) and intermediate 
monocytes (p < 0.0001). The level of TNFα production (MFI) in the TNFα positive cells was significantly 
higher in intermediate monocytes than classical (p = 0.0132) and non-classical (p = 0.0063) monocytes.  
The level of TNFα production in classical monocytes was significantly higher than non-classical 
monocytes (p = 0.0457) (Figure 4.1 B).  
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Figure 4.1: LPS-induced TNFα production in the monocyte subsets. PBMCs from healthy individuals 
(n=8) were stimulated with 1ng/ml LPS for three hours in the presence of monensin and ADAM17 
inhibitor (TMI-005). The PBMCs were then labelled with anti-HLA-DR, anti-CD14, and anti-CD16 
antibodies to distinguish the monocytes subsets, fixed, permeabilised and stained intracellularly for 
TNFα before acquiring on the flow cytometer. A) TNFα production was quantified as a percentage of 
cells positive for TNFα and B) level of expression on a per cell basis, assessed as MFI. Mean values and 
SD displayed. Data were analysed statistically by RM one-way ANOVA. p < 0.05* p < 0.01** p < 
0.001*** p < 0.0001****. 
 
The response of monocyte subsets to IL-10 was compared in eight healthy individuals. Responses to 
IL-10 were measured by determining the inhibitory effect of IL-10 on LPS-induced TNFα production. 
PBMCs were stimulated with 1ng/ml LPS in the presence or absence of increasing concentrations of 
IL-10 (0.016-10ng/ml IL-10), for three hours before staining for intracellular TNFα. Dose-response 
curves can be created, in which the percentage of cells positive for TNFα are reduced with increasing 
concentration of IL-10. These dose-response curves were compared between monocyte subsets 
(Figure 4.2A). A high proportion of classical and intermediate monocytes produced TNFα in response 
to LPS stimulation, whereas a smaller proportion of non-classical monocytes are stimulated to produce 
TNFα. Addition of between 0.016 and 0.4ng/ml IL-10 had no noticeable effect on TNF production by 
all three subsets. With further increases in IL-10 concentration, TNF production was inhibited. Visual 
inspection of dose-response curves indicated greater IL-10 inhibition of TNFα production by classical 
monocytes than by the intermediate cells, and non-classical monocytes showed the lowest response 
to IL-10. Although TNFα production by non-classical monocytes was lower than in the other two 
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subsets, this production was maintained in the presence of IL-10. As a result, TNF production by non-
classical monocytes was equivalent to that of the other two subsets at 10ng/ml IL-10.  
These differences were quantified more formally in two ways. Firstly, the concentration of IL-10 at 
which the frequency of TNFα producing cells was inhibited by 50% (effective dose 50/ED50) was 
calculated for each subset using MyCurveFit software. By this measure, classical monocytes required 
the lowest concentration of IL-10 to reach 50% inhibition of TNFα producing cells, followed by 
intermediate monocytes, and non-classical monocytes required the greatest mean concentration 
(Figure 4.2 C). However, formal statistical analysis of these data was problematic because in non-
classical and intermediate monocytes from some donors, 50% inhibition of TNFα production was not 
reached even at 10ng/ml IL-10, the highest concentration tested. Therefore, as an alternative 
approach, the percentage of inhibition at 2ng/ml IL-10 was used to compare monocyte subsets and 
carry out statistical analysis. At this concentration of IL-10, TNF production by classical monocytes 
was significantly more inhibited than production by intermediate (p = 0.0090) and non-classical (p < 
0.0001) monocytes. TNF production by intermediate monocytes was significantly more inhibited 
than non-classical monocytes (p = 0.0466) (Figure 4.2 C).  
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Figure 4.2: IL-10 responsiveness of monocyte subsets in health. PBMCs from healthy individuals (n=8) 
were stimulated with 1ng/ml LPS and increasing concentrations of IL-10 (0.016-10ng/ml) for three 
hours in the presence of monensin and ADAM17 inhibitor (TMI-005). PBMCs were then labelled with 
anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish the monocytes subsets, fixed, 
permeabilised and stained intracellularly for TNFα before acquiring on the flow cytometer. The 
resulting dose-response curves were compared between the monocyte subsets. A) TNFα production 
was quantified as a percentage of cells positive for TNFα and plotted along increasing concentrations 
of IL-10. B) the ED50 was calculated for each monocyte subset. Intermediate and non-classical 
monocytes from some donors did not reach 50% inhibition of TNFα production at 10ng/ml IL-10, the 
highest concentration tested, therefore, statistical analysis of these data was not conducted. Median 
and IQR are displayed. C) percentage inhibition of TNFα production at 2ng/ml IL-10 was used to carry 
out statistical analysis on. Mean values and SD displayed. Data were analysed statistically by RM one-
way ANOVA. p < 0.05* p < 0.01** p < 0.001*** p < 0.0001****. 
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Although all three subsets were assayed in parallel within whole PBMCs, and therefore exposed to the 
same assay environment, it was a theoretical possibility that autocrine IL-10 signalling could 
contribute to differences in IL-10 response by effectively increasing the local concentration active on 
some subsets. Indeed, endogenous IL-10 production and an increase in IL-10 production upon LPS 
stimulation in the monocytes has previously been observed (Malefyt et al., 1991) but individual 
subsets were not studied. To address this question in our system, endogenous as well as LPS-induced 
(1ng/ml for 3 hours) IL-10 production in the monocyte subsets was measured via intracellular staining 
in the same eight healthy individuals. IL-10 production was quantified as a percentage of cells positive 
for IL-10 and as the level of expression on a per cell basis, assessed as MFI.  
A significantly higher proportion of classical monocytes produced IL-10 in steady-state than both 
intermediates (p < 0.0001) and non-classical (p < 0.0001) monocytes but there was no difference 
between intermediate and non-classical monocytes (p = 0.3729) (Figure 4.3 B). Upon LPS stimulation, 
IL-10 production was significantly increased in classical monocytes (p = 0.0016) and intermediate 
monocytes (p = 0.0215), but not non-classical monocytes (p = 0.6355) (Figure 4.3 C, D).   
Taken together, these data suggest that IL-10 production by classical monocytes could contribute to 
their high responsiveness to the inhibitory effects of added cytokine by increasing the amount of IL-
10 in the culture. However, a parallel assessment of monocyte subsets within the same culture and 
environment is likely to minimise the impact of subset-specific autocrine effects. Moreover, the 
differential effect of exogenous IL-10 on intermediate and non-classical monocytes cannot be 
explained by a difference in their ability to produce IL-10.   
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Figure 4.3: Endogenous and LPS-induced IL-10 production in the monocyte subsets in health. PBMCs 
from healthy individuals (n=8) were stimulated with 1ng/ml LPS for three hours in the presence of 
monensin and ADAM17 inhibitor (TMI-005). PBMCs were then labelled with anti-HLA-DR, anti-CD14, 
and anti-CD16 antibodies to distinguish the monocytes subsets, fixed, permeabilised and stained 
intracellularly for IL-10 before acquiring on the flow cytometer. A) representative flow cytometry plots 
of IL-10 production in classical monocytes. IL-10 production was quantified as a percentage of cells 
positive for IL-10 and as the level of expression on a per cell basis, assessed as MFI. B) IL-10 production 
by monocytes subsets in the absence of stimulation. Mean values and SD displayed. Data were 
analysed statistically by RM one-way ANOVA. C, D) IL-10 production by monocytes subsets in LPS-
stimulated cultures. Mean values and SD displayed. Data were analysed statistically by paired t-test. 
p < 0.05* p < 0.01** p < 0.001*** p < 0.0001****.  
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4.4.2 Monocyte subset response to IL-10 is independent of TLR agonist and 
readout  
 
The next step was to determine if the differences in IL-10 response between monocyte subsets was 
dependent on the stimulus and/or readout (cytokine) measured. LPS engagement with TLR4 results in 
signalling down two pathways involving distinct adaptor molecules: MyD88 and TRIF (Lu et al. 2008). 
LPS was compared with two stimulants chosen to target these pathways: Pam3CSK4 triggers the 
MyD88 pathway, while Poly(I:C) activates TRIF. TNFα production was also compared to two readouts: 
IL-1β and IFNα induced predominately by MyD88 and TRIF pathways respectively (Akira & Takeda 
2004). Cytokine production was measured as a percentage of cells positive for the cytokine and as the 
level of expression on a per cell basis, assessed as MFI. Healthy PBMCs (n=7) were stimulated with 
1ng/ml LPS, 1000ng/ml Pam3CSK4, or 1000ng/ml Poly(I:C) and increasing concentrations of IL-10 (0.4-
10ng/ml IL-10) for three hours before staining for TNFα, IFNα, and IL-1β intracellularly. Percentage 
inhibition at 2ng/ml IL-10 was used to compare the responses as ED50 had limited sensitivity.   
A significantly greater proportion of intermediate monocytes produced TNFα than classical and non-
classical monocytes irrespective of the TLR agonist used for stimulation (Figure 4.4 A). Significantly 
more classical monocytes than non-classical monocytes produced TNFα in response to both LPS and 
Poly(I:C) stimulation but not in response to Pam3CSK4. LPS induced the greatest proportion of TNFα 
producing cells in all three monocytes subsets, despite using a concentration 1000x lower (Figure 4.4 
A). Poly(I:C) induced a greater proportion of TNFα producing classical and intermediate monocytes, 
but not non-classical monocytes, than were induced by Pam3CSK4 at the same concentration.  
Overall IFN responses were low compared with production of the other cytokines. Upon LPS 
stimulation, more classical and intermediate monocytes than non-classical monocytes produced IFNα. 
The low level of IFNα production following Poly(I:C) and Pam3CSK4 stimulation was not sufficient to 
allow differences between subsets to be determined (Figure 4.4B). In contrast, almost all classical and 
intermediate monocytes produced IL-1 irrespective of the agonist used. Significantly fewer non-
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classical monocytes produced IL-1β in response to all stimuli and the response to Poly(I:C) was 
significantly lower than to either LPS or Pam3CSK4 (Figure 4.4 C).  
The per cell level of cytokine production (MFI) in the cytokine positive cells was also determined in an 
attempt to improve sensitivity when the percentage of cells producing cytokine approaches 100%. 
Although the frequency of classical and intermediate monocytes producing IL-1β was similar (Figure 
4.4A), the MFI of intermediate monocytes was significantly higher irrespective of stimulus (Figure 
4.4B). This approach also revealed that LPS induced a greater IL-1 response than either of the other 
two stimuli in all monocyte subsets (Figure 4.4B)   
The degree to which each response was inhibited by addition of 2ng/ml IL-10 was calculated. The 
clearest differences between monocytes subsets with regard the inhibitory effects of IL-10 were 
observed when TNFα production was the read-out (Figure 4.4 C). Using this measure, IL-10 
responsiveness of non-classical monocytes was significantly lower than that of classical monocytes for 
all three stimuli tested. The response of intermediate cells was more similar to that of non-classical 
monocytes with Poly(I:C), to classical monocytes with Pam3CSK4, or as previously noted, intermediate 
between the two other subsets with LPS. Differences between monocyte subsets with regard to 
response to IL-10 were less when measuring IL-1β or IFNα production as read-outs. This may because 
the there is less resolving power when cytokine production is very high (IL-1β) or very low (IFNα); the 
intermediate TNFα response offers a greater resolution. Nonetheless, when measuring IL-1β, the 
response of non-classical monocytes to IL-10 was significantly lower than either subset. 
In summary, intermediate monocytes are the greatest producers of TNFα and IL-1β with the TLR 
agonists tested, followed by classical and then non-classical monocytes. IFNα production was too low 
using all agonists to enable clear conclusions about monocyte subsets to be drawn. When measuring 
TNFα production, the hierarchy of monocyte subset response to IL-10 inhibition was broadly similar 
irrespective of stimulation and consistently lower in non-classical monocytes. An intermediate level 
of cytokine production provides more sensitivity for resolving differences between subsets. 
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Figure 4.4: Monocyte subset responsiveness to IL-10 with various TLR agonists and readouts. PBMCs 
from healthy individuals (n=7) were stimulated with 1ng/ml LPS, 1000ng/ml Pam3CSK4, or 1000ng/ml 
Poly(I:C) and increasing concentrations of IL-10 (0.4-10ng/ml) for three hours in the presence of 
monensin and ADAM17 inhibitor (TMI-005). The PBMCs were then labelled with anti-HLA-DR, anti-
CD14, and anti-CD16 antibodies to distinguish the monocytes subsets, fixed, permeabilised and 
stained intracellularly for TNFα, IFNα, and IL-1β before acquiring on the flow cytometer. A) the 
proportion of TNFα, IFNα, and IL-1β producing cells with various TLR agonists for each monocyte 
subset. B) the level of cytokine expression on a per cell basis (MFI) with various TLR agonists for each 
monocyte subset. C) inhibition of TNFα, IFNα, and IL-1β production at 2ng/ml IL-10 with various TLR 
ligand for each monocyte subset. Mean and SD is displayed. Data were analysed statistically by a Two-
way ANOVA. p < 0.05* p < 0.01** p < 0.001*** p < 0.0001****. 
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4.4.3 Intermediate monocytes have the highest IL-10Rα expression   
 
The IL-10R is made up of two subunits: the alpha chains that facilitate specific binding of IL-10, and 
the beta chains which are important in signal transduction. The beta chains appear in other cytokine 
receptors including IL-22 and IFN-λ (reviewed by Moore et al. 2001), therefore, labelling for IL-10Rα 
enables the measurement of IL-10R expression specifically. Expression of IL-10Rα, the specific ligand 
binding component of IL-10R was measured on the individual monocyte subsets to determine the 
relationship between receptor expression and functional response to IL-10. The monocyte subsets 
from 15 healthy donors were labelled for IL-10Rα in whole blood to minimise isolation related 
changes. Receptor expression was quantified as percentage positive cells and MFI calculated as MFI 
for staining with anti-IL-10Rα antibody minus MFI for staining with an isotype-matched control 
antibody.  
Both the and proportion of IL-10Rα positive cells and level of IL-10Rα expression (MFI) differed 
between monocyte subsets (Figure 4.5 B, C). The proportion of IL-10Rα expressing cells was 
significantly higher in intermediate monocytes than in classical monocytes (p < 0.0001) and non-
classical monocytes (p < 0.0001), and comparable between classical and non-classical monocytes (p = 
0.1994) (Figure 4.5 B). The level of IL-10Rα expression was significantly higher on intermediate 
monocytes than on either classical (p < 0.0001) or non-classical (p < 0.0001) monocytes; non-classical 
monocytes expressed significantly higher levels of IL-10Rα than classical monocytes (p = 0.0370) 
(Figure 4.5 C). These data suggest that IL-10Rα expression level is a poor predictor of the ultimate 
functional response to IL-10 in the monocyte subsets.  
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Figure 4.5: IL-10Rα expression on the monocyte subsets in health. Whole blood from healthy donors 
(n=15) were labelled with anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish the 
monocyte subsets, and IL-10Rα before acquiring on the flow cytometer. A) representative histograms 
for the expression of IL-10Rα on each monocyte subset. The coloured histograms represent anti-IL-
10Rα staining for each monocyte subset (classical, intermediate, and non-classical) in relation to the 
corresponding isotype-matched control (grey histogram). IL-10Rα expression was calculated as B) 
percentage of cells positive for IL-10Rα and C) MFI calculated as MFI for staining with anti-IL-10Rα 
antibody minus MFI for staining with an isotype-matched control antibody for each monocyte subset. 
Mean values and SD displayed. Data were analysed statistically by RM one-way ANOVA. p < 0.05* p < 
0.01** p < 0.001*** p < 0.0001****. 
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4.4.4 STAT3 availability and STAT3 phosphorylation in response to IL-10 are 
lower in non-classical monocytes 
 
As mentioned above, the response of monocytes subsets to IL-10 did not correlate with their IL-10Rα 
expression. This led to investigations into the relationship between the availability of STAT3 and level 
of STAT3 phosphorylation in the individual monocyte subsets and how this relates to the functional 
response to IL-10. PBMCs from 10 healthy donors were stimulated with 100ng/ml of IL-10 for 15min 
before fixing and staining intracellularly for total (T-STAT3) and for p-STAT3 (p-STAT3) p-STAT3 using 
an antibody that binds specifically to STAT3 phosphorylated on Y705. T-STAT3 and p-STAT3 was 
quantified as a percentage of cells positive and MFI calculated as MFI for staining with anti-STAT3 and 
-p-STAT3 antibody minus MFI for staining with an isotype-matched control antibody. 
The percentage of cells positive for T-STAT3 and the level of STAT3 available (MFI) was comparable 
for classical and intermediate monocytes but lower in non-classical monocytes (p < 0.0001 versus 
classical monocytes; p = 0.0022 versus intermediate monocytes) (Figure 4.6 C).  Reassuringly, there 
was minimal background STAT3 phosphorylation in cells not exposed to IL-10 (data not shown). 
Following IL-10 stimulation p-STAT3 was detected. The percentage of cells positive for p-STAT3 upon 
IL-10 stimulation was equally high in classical and intermediate monocytes but was significantly lower 
than both of these in non-classical monocytes (p = 0.0016 versus classical monocytes; p = 0.0054 
versus intermediate monocytes) (Figure 4.6 D). These differences were reflected in MFI. Therefore, 
across the monocyte subsets, the level of p-STAT3 in response to IL-10 correlates with the availability 
of STAT3 within the cell but not IL-10 response.  
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Figure 4.6: STAT3 availability and phosphorylation levels upon IL-10 stimulation in monocyte 
subsets in health. PBMCs from healthy donors (n=10) were labelled with anti-HLA-DR, anti-CD14, and 
anti-CD16 antibodies to distinguish the monocyte subsets. PBMCs were stimulated with 100ng/ml IL-
10 before fixation, permeabilisation and intracellular staining for STAT3 and p-STAT3. Samples were 
then acquired on the flow cytometer. Representative histograms for the expression of A) T-STAT3 B) 
p-STAT3 for each monocyte subset. The overlays represent staining with anti-STAT3 and -p-STAT3 
respectively for each monocyte subset (classical, intermediate, and non-classical) in relation to their 
corresponding isotype-matched control antibody (grey histogram).  C, D) expression of STAT3 and p-
STAT3 was calculated as a percentage of positive cells and MFI calculated as MFI for staining with anti-
STAT3 and -p-STAT3 antibody minus MFI for staining with an isotype-matched control antibody. Mean 
values and SD displayed. Data were analysed statistically by RM one-way ANOVA. p < 0.05* p < 0.01** 
p < 0.001*** p < 0.0001****. 
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To further explore the relationship between low T-STAT3 in non-classical monocytes and their ability 
to phosphorylate STAT3 in responses to appropriate stimuli, their response to IL-6, a second cytokine 
that induces STAT3 phosphorylation, was tested. PBMCs from seven healthy donors were stimulated 
with 100ng/ml IL-6 for 15min before fixing and staining intracellularly for p-STAT3. STAT3 
phosphorylation was quantified as a percentage of cells positive for p-STAT3 and MFI calculated as 
MFI for staining with anti-p-STAT3 antibody minus MFI for staining with an isotype-matched control 
antibody. Again, there was minimal background STAT3 phosphorylation in the absence of stimulation 
(data not shown). Following stimulation with IL-6, the proportion of p-STAT3 positive non-classical 
monocytes was significantly lower than both classical and intermediate monocytes (p = 0.0011 and p 
= 0.0006 respectively; Figure 4.7A), which was also reflected in MFI (Figure 4.7B). This is consistent 
with a causal link between low T-STAT3 in non-classical monocytes and low capacity to phosphorylate 
STAT3. Interestingly, although the ability to phosphorylate STAT3 in response to IL-10 was similar in 
classical and intermediate monocytes, they differed in their response to IL-6. There was greater p-
STAT3 in response to IL-6 in classical than intermediate monocytes, despite similar levels of T-STAT3. 
This does not follow the same pattern of STAT3 phosphorylation induced with IL-10. Additional factors 
are likely to regulate IL-6 mediated STAT3 phosphorylation in these subsets. 
 
Figure 4.7: p-STAT3 upon IL-6 stimulation. Health PBMCs (n=7) were labelled with anti-HLA-DR, anti-
CD14, and anti-CD16 antibodies to distinguish the monocyte subsets. PBMCs were stimulated with 
100ng/ml IL-6 before fixation, permeabilisation and intracellular staining for STAT3 and p-STAT3. 
Samples were then acquired on the flow cytometer. A) STAT3 phosphorylation was calculated as a 
percentage of cells positive for p-STAT3. Median and IQR displayed. Data were analysed statistically 
by Friedman test. B) MFI calculated as MFI for staining with anti-p-STAT3 antibody minus MFI for 
staining with an isotype-matched control antibody. Mean values and SD displayed. Data were analysed 
statistically by RM one-way ANOVA. p < 0.05* p < 0.01** p < 0.001*** p < 0.0001****. 
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4.4.5 SOCS3 expression is highest in classical monocytes 
 
SOCS3 has been shown to be a critical component in the IL-10R signalling pathway (Yasukawa et al. 
2003), and SOCS3 was the only gene along the IL-10R pathway that showed significantly higher 
expression levels in classical monocytes in a recent single-cell RNA sequencing analysis (10X 
genomics). To verify this, expression levels of SOCS3 mRNA were measured in the monocyte subsets. 
PBMCs from 14 healthy donors were labelled with anti-HLA-DR, anti-CD14, and anti-CD16 antibodies 
to distinguish the monocyte subsets before sorting on the FACS Aria (BD). 100,000 cells were sorted 
for each population, and the relative gene expression of SOCS3 at resting level was measured using 
quantitative RT-PCR. SOCS3 expression in classical monocytes was significantly higher than in both 
intermediate and non-classical monocytes (p = 0.0422 and p = 0.0249 respectively). Intermediate and 
non-classical monocytes did not differ in their expression of SOCS3. Higher expression of SOCS3 in 
classical monocytes may contribute to their enhanced response to IL-10.    
 
Figure 4.8: SOCS3 mRNA expression in monocyte subsets in health. PBMCs from healthy donors 
(n=14) were labelled with anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish the 
monocyte subsets before sorting on the FACS Aria (BD). 100,000 cells were sorted for each population, 
and the relative gene expression of SOCS3 at baseline was measured using qRT-PCR. Median and IQR 
are displayed. Data were analysed statistically by Friedman test. p < 0.05* p < 0.01** p < 0.001*** p 
< 0.0001****. 
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4.5 Discussion  
 
The primary aim of this chapter was to determine IL-10 responsiveness of monocyte subsets in healthy 
individuals. First, LPS-induced TNFα production was measured. Intermediate monocytes showed 
greater TNFα production than classical monocytes, and non-classical monocytes showed the least 
TNFα production. The ability of IL-10 to inhibit this TNFα response was greatest in classical monocytes, 
followed by intermediates, and least responsive were the non-classical monocytes despite low levels 
of TNFα production. Signalling components along the IL-10R signalling pathway were measured to 
examine their relationship with the functional response to IL-10.   
In this chapter, there was no TNFα detected by intracellular staining in the unstimulated monocyte 
subsets. This is in agreement with the work of Cros et al., 2010, who reported a lack of secreted TNFα 
in unstimulated cultures of monocytes. However, Theisen et al., 2014 reported secretion of TNFα in 
unstimulated cultures of all three subsets. Cros et al., 2010 and Theisen et al., 2014 both measured 
TNFα secretion using supernatants, which requires separation of the subsets to enable the source of 
cytokines to be defined. Depending on the method of separation, this could result in unintended 
activation of the cells. Cros et al., 2010 used magnetic beads that are designed to avoid activation of 
monocytes, whereas Theisen et al., 2014 used FACS separation, which as described in the previous 
chapter can cause activation of the cells. Culturing the monocyte subsets separately also risks exposing 
them to distinct environments created by their own products. An additional limitation, culturing the 
monocytes subsets in the absence of other immune cells blocks their interactions, which is not 
representative of the immune diversity in the bloodstream.  
LPS-induced TNFα production in monocytes subsets has been previously investigated. The results in 
this chapter show that intermediate monocytes have the highest TNFα production, followed by 
classical monocytes, and least responsive to TLR4 activation are the non-classical monocytes. CD14 is 
a co-receptor for TLR4 (Beutler et al., 2000), therefore, its expression may explain the more robust LPS 
response in CD14hi monocytes. A greater proportion of intermediate monocytes produce TNFα than 
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classical monocytes, which may be due to the synergistic role of CD16 in CD14 signalling (Shalova et 
al. 2017). Although non-classical monocytes are more refractory to LPS stimulation, they do still retain 
some capacity to respond. This may be partly because non-classical monocytes still express low levels 
of CD14 as they mature from classical monocytes and/or due to the soluble CD14 reported to be 
present in FCS (Yang et al. 1996). A study that also measured intracellular TNFα showed a hierarchy of 
LPS response in classical monocytes and intermediate monocytes that is similar to the findings in this 
chapter except no TNFα production was detected in non-classical monocytes (Belge et al., 2002). 
Theisen et al., 2014 reported comparable levels of TNFα secretion by classical and intermediate 
monocytes, which is not consistent with the findings in this chapter. There are a number of possible 
explanations for this difference. Cytokine secretion may not correlate with levels of production 
detected by intracellular staining as secretory pathways can be independently regulated, for example 
cleavage of TNFα from the cell surface by ADAM17 may be regulated independently of production. 
Theisen et al., 2014 also used a much higher concentration of LPS and stimulated for a longer time, 
which may have maximised the LPS response in both subsets. Variation in levels of soluble CD14 
present in the culture may also contribute, and it is notable that Theisen et al., 2014 found no TNFα 
secretion by non-classical monocytes following LPS stimulation. Cros et al., 2010 reported yet another 
hierarchy of responses, with TNFα secretion being highest in intermediate monocytes, followed by 
non-classical monocytes, and finally classical monocytes. This diversity of findings demonstrates that 
the assay chosen to measure inflammatory properties can affect the outcome.  
As mentioned previously, human classical monocytes resemble Ly6Chi monocytes in mice based on 
gene expression profiles (Ingersoll et al. 2010). Ly6Chi monocytes have been shown to replenish the 
intestinal Mφ population in a CCL2-dependent manner in the steady-state intestine (Bain et al. 2014; 
Yona et al. 2013; Takada et al. 2010). High expression of CCR2 on classical monocytes supports the 
notion that they replenish intestinal Mφs, which have been shown to have a regulatory role in the 
mouse intestine (Thiesen et al. 2014; Bain et al. 2013; Takada et al. 2010; Yona et al. 2013; Appleby et 
al. 2013; Patel et al. 2017). However, it is not fully understood how the inflammatory properties of 
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these newly arrived monocytes are controlled during their differentiation into regulatory Mφs. A 
collection of studies described in the literature review indicate that IL-10 and TGFβ have important 
non-redundant roles (Zigmond et al. 2014; Shouval et al. 2014; Smythies et al. 2005).  
It has long been known that IL-10 inhibits pro-inflammatory cytokine production in monocytes 
(Malefyt et al. 1991). However, the capacity of each monocyte subset to respond to IL-10 inhibition 
has not been previously explored. IL-10 responsiveness of monocytes subsets was measured using the 
assay described in the previous chapter. Classical monocytes are most responsive to IL-10 inhibition 
despite their robust response to LPS stimulation. This supports the idea that a strong response to IL-
10 in classical monocytes is a critical mechanism by which their inflammatory properties can be 
controlled and may play an important role during their differentiation into regulatory intestinal Mφs 
(Bain et al. 2013; Takada et al. 2010). However, in the event of pathogenic insults to the intestine, 
there is a need for inflammatory responses to aid pathogen clearance. There is evidence that newly 
recruited monocytes provide this inflammatory response (discussed in the subsequent chapters). This 
plasticity in immune responses is especially important in the intestine where there is constant 
exposure to foreign antigens.  
As shown here and in previous studies (Belge et al. 2002; Cros et al. 2010; Thiesen et al. 2014) 
intermediate monocytes display a great capacity to respond to an inflammatory stimulus. Not only are 
these responses greater than those of classical monocytes but they are also less well controlled by IL-
10. The role of intermediate monocytes is poorly understood in part because the lack of identified 
counterparts in the mouse has hampered research. It is believed that intermediate monocytes only 
represent a stage of differentiation from classical monocytes into non-classical monocytes and do not 
play a major role in immune function, which is supported by their short half-life (Patel et al. 2017). 
However, data reported here show that intermediates have distinctive properties such as greater 
cytokine production and higher expression levels of IL-10Rα than either of the other subsets. 
Consistent with a distinct role they have been associated with inflammatory disorders such as RA 
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(Belge et al. 2002; Rossol et al. 2012). Collectively, these observations challenge the view that they are 
merely transitioning cells. Like classical monocytes, intermediate cells express CCR2 (Thiesen et al. 
2014; Appleby et al. 2013; Patel et al. 2017), and therefore may share the capacity to be recruited to 
the intestine. There has been no evidence of the existence of CD16+ Mφ populations in the human 
intestine. However, as demonstrated in the previous chapter, CD16 is readily cleaved upon TLR 
activation, and in the intestine, there is high potential for exposure to microbial agonist that induce 
loss of CD16 expression. The combination of strong pro-inflammatory properties and a suboptimal 
response to IL-10 inhibition may make intermediate monocytes, activated by microbial TLR ligands, 
important potential contributors to inflammatory pathology in the intestine and other tissues, even 
under conditions where their classical counterparts are constrained by IL-10.  
Non-classical monocytes have a poor response to IL-10 but as they produce low levels of TNFα in 
response to LPS, they may not be regarded as pro-inflammatory cells in many situations. This suggests 
that immune cell populations with a non-inflammatory phenotype have less restrictions on their 
activity. Although non-classical monocytes do not respond as aggressively to LPS stimulation as 
classical and intermediate monocytes in the absence of exogenous IL-10, when IL-10 is present, their 
response is maintained and can become equivalent to the other two subsets. Auffray et al., 2007 
showed that non-classical monocytes undergo rapid extravasation at sites of infection, making them 
part of the initial inflammatory response, during which restrictions on their inflammatory activity 
would be undesirable. In IL-10 rich environments such as the intestine, non-classical monocytes may 
become relevant during inflammation. In addition, Cros et al., 2010 showed that TLR7 and TLR8 
agonist are robust stimulators of pro-inflammatory cytokine production in non-classical monocytes, 
which suggests a capacity of these cells to contribute to inflammation under particular stimulatory 
conditions. Expression of CCR2 on non-classical monocytes is low (Thiesen et al. 2014; Patel et al. 
2017), and therefore unlikely to contribute to CCR2-dependent monocyte recruitment to the intestine 
under steady state conditions. However, changes to the vascular endothelium and chemokine 
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production induced by intestinal inflammation may enable extravasation of patrolling non-classical 
monocytes by alternative pathways.  
IL-10 production by LPS-stimulated monocytes has previously been observed (Cros et al. 2010; Malefyt 
et al. 1991; Thiesen et al. 2014). Malefyt et al., 1991 showed that the IL-10 produced had an auto-
regulatory role on the monocytes as TNFα production was increased in the presence of anti-IL-10 
neutralising antibody. However, this study did not identify the monocyte subsets individually. The 
findings in this chapter show that, under unstimulated conditions, IL-10 production is greatest in 
classical monocytes, while intermediate and non-classical monocytes display relatively low production 
of IL-10. Upon LPS stimulation, IL-10 production is increased in classical and intermediate monocytes 
but not in non-classical monocytes, which is in agreement with previous findings (Cros et al. 2010; 
Thiesen et al. 2014). LPS-induced IL-10 production by classical and intermediate monocytes may 
represent a negative feedback mechanism, restricting their activity, that is not active in non-classical 
monocytes. Thus, this mechanism of immune regulation is mainly focused on pro-inflammatory cells 
and is not necessary for the less inflammatory non-classical monocytes. It is possible that classical 
monocytes appeared more responsive to added IL-10 in the experiments reported here because there 
was an additive effect of the endogenous IL-10 production, which was less prominent in intermediate 
and non-classical monocytes. This is unlikely to be a major effect because the IL-10 produced by 
classical monocytes in the PBMC culture will diffuse freely with the potential to affect the other 
subsets in the same environment. However, in assays used by others, using purified cell populations, 
this effect would be particularly important. However, it is not possible to completely exclude some 
contribution of autocrine effects of IL-10 produced by classical monocytes.  
To determine whether differences in monocytes subset responses to IL-10 were specific to the mode 
of activation (LPS) or functional readout (TNFα production), additional TLR agonists and cytokines 
were compared. LPS signals down two pathways depending on the involvement of additional adaptor 
molecules: MyD88-dependent signalling following engagement of TLR4 at the cell surface and MyD88-
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independent TRIF-dependent signalling following triggering of endosomal TLR4 (Lu et al. 2008). 
Although there is cross-talk in these two signalling pathways, the former is associated particularly with 
activation of transcription factors such as NF-B and production of pro-inflammatory cytokines, 
including TNF and IL-1β, whereas MyD88-independent signalling leads to production of Type 1 
interferons, especially IFN, via the transcription factor IRF3/7 (Honda et al. 2005). To investigate the 
contribution of the MyD88 dependent and independent pathways, LPS was compared with two other 
stimulants chosen to target these signalling pathways individually; Pam3CSK4 acts via TLR2 to trigger 
the MyD88 pathway, while Poly(I:C) acts via TLR3 to activate TRIF. TLR3 is the only TLR not to activate 
MyD88-dependent signalling. To determine whether the differences observed between monocytes 
subsets were specific for TNF two other cytokine readouts were assessed: IL-1β and IFNα (an 
alternative Type 1 interferon chosen on the basis that anti-IFNβ antibodies are not commercially 
available) induced by MyD88 and TRIF pathways respectively (Akira & Takeda 2004).  
All three stimuli induced TNFα production but with different magnitudes of response. The hierarchy 
of response between monocyte subsets was broadly similar, which suggests that intermediate and 
classical monocytes are dominant responders to diverse TLR agonists regardless of the readout. The 
exception to this is that TNFα production by classical monocytes in response to Pam3CSK4 was 
relatively low. It has been previously reported that activating the MyD88 and TRIF pathways in 
isolation results in lower TNFα production suggesting that the two pathways act synergistically (Covert 
2005) with a role for the TRIF and Type I interferons in maximising TNFα production by classical 
monocytes. Non-classical monocytes display poor response to the TLR agonists tested regardless of 
readout. However, Cros et al., 2010 showed that TLR7 and TLR8 agonist induce a robust inflammatory 
response in non-classical monocytes. Therefore, further analysis with TLR7 and TLR8 agonists is 
required to determine whether non-classical monocytes can be stimulated to produce a robust 
response with an appropriate activator. 
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LPS induced the greatest production of all three cytokines tested. Production of IFN was low but the 
hierarchy of production across the monocyte subsets was similar to that observed for LPS-stimulated 
TNF and IL-1 with a greater proportion of cytokine-positive intermediate monocytes. The low type 
1 IFN response induced by Pam3CSK4 was expected as it does not signal through the TRIF pathway. 
However, Poly(I:C), which does signal down the TRIF pathway, also stimulated little IFNα production. 
As mentioned earlier, the TRIF pathway is mainly associated with IFNβ induction, and it is possible that 
IFN, which was chosen because of the availability of reagents, is not a useful read-out for this 
pathway. Almost 100% of classical and intermediate monocytes were induced to produce IL-1β with 
all three TLR agonists, while non-classical monocytes again were less responsive to activation. MFI was 
used to overcome the limitations in sensitivity for detecting subset differences when the percentage 
of cytokine-positive cells approaches 100%. The level of IL-1β production in the cytokine positive cells 
is significantly higher in intermediate than classical monocyte irrespective of stimulus, consistent with 
the hierarchy of responses.  
IL-10 inhibition of TNFα production induced by Pam3CSK4 and Poly(I:C) showed a similar hierarchy of 
response between the monocyte subsets as LPS. It is difficult to conclude with respect to differences 
in IL-10 inhibition of IFNα production between the monocyte subsets because the poor induction with 
all three TLR ligands means that the sensitivity of the assay is diminished. Conversely, IL-1β induction 
was very robust, and its inhibition by IL-10 inhibition was poor, again reducing the sensitivity of the 
assay and making it difficult to draw conclusions regarding differences between subsets. Overall, these 
data indicate that intermediate cytokine response gives the greatest ability to resolve differences 
between monocyte subsets. Both weak responses and very strong responses reduce the ability to 
resolve differences; weak responses (IFNα induction) are readily inhibited for all subsets, and very 
strong responses (IL-1β induction) are poorly inhibited even in classical monocytes. Of the read-outs 
tested, TNF production fulfilled this criterion best and using this, differences between subsets with 
respect to inflammatory properties and response to IL-10 were not dependent on the TLR agonist 
used. 
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The relationship between IL-10Rα expression and the response to IL-10 was investigated with the aim 
of finding a possible mechanism for the differences in IL-10 response between the monocyte subsets. 
Intermediate monocytes had the highest expression of the IL-10Rα measured as either the percent of 
cells expressing the receptor or MFI. It has been suggested that intermediate monocytes are simply a 
collection of cells captured as they transition from classical to non-classical monocytes (Patel et al. 
2017). Consistent with this view, expression of several markers, including CCR2 and CXCR1, 
intermediate monocyte falls between that of classical and non-classical monocytes. However, 
relatively high expression of IL-10Rα on intermediate monocytes in combination with their robust 
response to TLR activation suggests they are a distinct population. Classical monocytes expressed the 
lowest level of IL-10Rα even though they had the best functional response to IL-10. In summary, IL-
10R expression level does not correlate with functional response to IL-10, indicating that the level of 
receptor expression is a poor predictor of response.  
IL-10Rα expression could not explain the difference in IL-10 response between monocyte subsets, 
therefore, the relationship between proximal signalling events and response to IL-10 was investigated. 
As mentioned previously, STAT3 is phosphorylated upon IL-10R activation (Riley et al. 1999), and 
therefore STAT3 phosphorylation is commonly used as an indirect measure of IL-10R activity. The 
capacity of the individual monocytes subsets to phosphorylate STAT3 has not been previously 
examined. More classical and intermediate monocytes than non-classical monocytes were positive for 
T-STAT3, and the per cell level of T-STAT3 expression was also lower in non-classical cells. These levels 
correlate well with p-STAT3 in response to IL-10 and IL-6: classical and intermediate monocytes show 
comparable levels of p-STAT3 upon IL-10 stimulation, while non-classical monocytes display lower 
phosphorylation levels. At the monocyte population level, the relative level of receptor expression did 
not determine the degree of STAT3 phosphorylation in response to IL-10: p-STAT3 phosphorylation 
was high but receptor expression relatively low in classical monocytes. Again, this demonstrates that 
the level of IL-10Rα expression does not correlate well with the capacity of monocyte subsets to 
respond functionally to IL-10. Factors other than receptor expression that may influence the efficiency 
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of STAT3 phosphorylation are unclear. The relatively low availability of STAT3 and capacity to 
phosphorylate STAT3 in non-classical monocytes may explain their suboptimal response to IL-10 when 
compared to classical monocytes. However, intermediate monocytes were also less responsive to IL-
10 than classical monocytes despite displaying comparable levels of T-STAT3 and capacity to 
phosphorylate STAT3. Intermediate monocytes displayed greater TNFα production making it 
intrinsically harder to be inhibited by a given amount of IL-10, which may explain the lower response 
to IL-10. 
STAT3 does not directly suppress pro-inflammatory genes. Instead, SOCS3, as well as numerous other 
IL-10 regulated genes, are induced by p-STAT3 once it enters the nucleus. SOCS3 inhibits NFκB, 
blocking the production of pro-inflammatory cytokines such as TNFα and IL-6, as well as mitogen-
activated protein kinases (MAPKs) involved in TLR signalling (reviewed by Mosser & Zhang 2008). As 
mentioned earlier, SOCS3 was the only gene along the IL-10R pathway that showed significantly 
different expression levels between the monocyte subsets (10X genomics). In addition, Kontoyainnis 
et al., 2001 identified the existence of a pre-existing pool of SOCS3 available for rapid inhibition of 
inflammatory responses in the period during which STAT3 promotes gene expression and protein 
synthesis to generate new SOCS3 protein; differences in this pool could explain the differences found 
in IL-10 response between the monocyte subsets. This led to investigations into the expression of 
SOCS3 in the monocyte subsets. Unfortunately, it was not possible to measure protein levels with the 
small number of cells available so gene expression was determined instead. There was a higher SOCS3 
expression in classical monocytes than intermediate and non-classical monocytes, and if reflected in 
increased SOCS3 activity this could explain differences in their IL-10 response. In future work, it would 
be informative to also compare the level of IL-10 induced SOCS3 expression between the monocyte 
subsets.  
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4.6 Conclusion  
 
Classical and intermediate monocytes are robust producers of pro-inflammatory cytokines induced by 
diverse TLR agonists. The pro-inflammatory properties of classical monocytes can be effectively 
regulated by IL-10 which may be an important property of the cells that replenish the intestinal Mφ 
pool, preventing the development of bacterially driven inflammation. Fewer, non-classical monocytes 
produced inflammatory cytokines but in contrast to classical cells, this response was poorly controlled 
by IL-10, most likely because low STAT3 availability in this population limits STAT3 phosphorylation 
and downstream signalling. Thus, non-classical cells may contribute to inflammation in IL-10 rich 
environments. Similarly, although intermediate monocytes are similar to classical monocytes in their 
expression of proximal IL-10 signalling molecules, they were also less responsive to IL-10 and may 
contribute to inflammation in the presence of this cytokine. In terms of cytokine production and its 
control by IL-10, the properties of intermediate monocytes were distinct from those of classical and 
non-classical cells, suggesting that the view of them as simply a population transiting between the 
latter types of cell, is likely to be over-simplistic.   
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Chapter 5: Monocyte subsets and their responsiveness to IL-10 are 
altered in IBD 
5.1 Chapter summary  
 
The focus of this chapter is to investigate the responsiveness of monocyte subsets to IL-10 in health 
and IBD. Responsiveness to IL-10 was measured using the assay described in the previous chapters. 
First, the inflammatory capacity of the monocyte subsets was compared between healthy controls 
and IBD patients to ensure that IL-10 response was measured against the same inflammatory activity. 
There was no difference in LPS-induced TNFα production or spontaneous IL-10 production between 
health and disease. Classical monocytes, but not other subsets, were found to have a reduced 
response to IL-10 in IBD patients compared with healthy controls. Signalling components of the IL-10R 
signalling pathway were investigated to explore the possible mechanisms behind this reduced 
response to IL-10 in classical monocytes. Despite this reduced response to IL-10, classical monocytes 
from IBD patients express more IL-10Rα, which may explain their enhanced capacity to phosphorylate 
STAT3 in response to IL-10 despite comparable levels of STAT3 available within the cell. Thus, the 
proximal signalling components investigated so far do not suggest a mechanism for the reduced 
response to IL-10 in classical monocytes found in IBD patients. Downstream SOCS3, a key regulator of 
the activity of IL-10, also showed a trend towards increased mRNA expression in IBD patients. 
Additional properties of the IL-10 signalling pathway need to be explored.  
The distribution of the monocyte subsets in health and IBD was investigated, and a reduction was 
observed in both the number and proportion of non-classical monocytes in the circulating blood of 
two separate cohorts of IBD patients. There was no difference in numbers of classical or intermediate 
monocytes. This is in contrast to the previously reported increase in the proportion of intermediate 
monocytes as a percentage of total monocytes (Grip et al. 2006; Thiesen et al. 2014). The final section 
of this chapter will begin to explore the possible mechanisms for the loss of non-classical monocytes 
from the circulation.  
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5.2 Introduction  
 
Bain et al., 2014 showed that monocytes are continuously recruited to the intestine to replenish the 
Mφ pool. In addition, the same group showed that the newly recruited monocytes differentiate into 
Mφs in a context-dependent manner (Bain et al., 2013). In healthy mice, newly recruited Ly6Chi 
monocytes lose their inflammatory properties to give rise to regulatory Mφs, which have been shown 
to be critical in maintaining steady-state in the intestine (Takada et al. 2010; Bain et al. 2014). 
However, during inflammation, this pathway is disrupted, and the monocytes retain their 
inflammatory properties giving rise to pro-inflammatory Mφs that contribute to inflammation 
(Zigmond et al. 2012; Bain et al. 2013). The environmental cues that determine monocyte 
differentiation into regulatory or inflammatory Mφs are poorly understood. 
Numerous studies demonstrate the critical role of IL-10 in regulating inflammatory responses in the 
intestine (Begue et al. 2011; Kühn et al. 1993; Glocker & Kotlarz 2009; Gasche et al. 2003; Grundtner 
et al. 2009; Uhlig 2013). However, many immune cells can be influenced by IL-10, and until recently it 
was unclear which cell population(s) are the critical target of IL-10 for maintaining immune 
homeostasis in the intestine. There is growing evidence in mice that Mφs can drive intestinal 
inflammation but that their response is normally controlled in a non-redundant way by the action of 
IL-10 (Shouval et al. 2014; Zigmond et al. 2014). TGFβ has also been shown to be a crucial signal in 
promoting monocyte differentiation into resident Mφs (Smythies et al. 2010; Schridde et al. 2017). 
Importantly, Schriddle et al., 2017 showed that TGFβ and IL-10 imprint the distinct properties of 
intestinal Mφs; TGFβ shapes their tissue repair and scavenging functions, and IL-10 downregulates 
their capacity to produce pro-inflammatory mediators.  
There is evidence that systemic signals from the intestine during inflammation cause functional 
changes to circulating cells. For example, mice orally inoculated with Toxoplasma gondii, a parasite, 
showed that monocytes were primed for regulatory function in the BM by systemic inflammatory 
signals received from the intestine and relayed by NK cells (Askenase et al. 2015). In humans, moMφ 
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from CD patients displayed reduced TNFα production in response to E.coli compared to healthy 
controls (Smith et al. 2009) but whether this is the result of altered haematopoiesis or modulation of 
circulating monocytes is not known. Nonetheless, these observations suggest that systemic changes 
in circulating monocytes occur when the intestine is inflamed, and that these changes have 
consequences for the mucosal populations that are derived from them, which formed the rationale 
for studying blood monocytes, as the likely precursors of intestinal Mφ. 
The aim of the work described in this chapter was to determine whether IL-10 responsiveness of 
monocyte subsets is altered in disease, enumerate monocyte subsets in health and IBD, and explore 
possible mechanisms related to components of the IL-10R signalling pathway.  
5.3 Aims 
 
7. Determine the ability of IL-10 to inhibit LPS-induced TNFα production in the monocyte subsets 
of healthy controls and IBD patients. 
8. Assess differences in signalling components along the IL-10 signalling pathway between health 
and IBD. 
9. Investigate monocyte subset distribution and gut homing capacity in health and IBD.  
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5.4 Results 
5.4.1 The inflammatory capacity of monocytes subsets does not differ between 
health and disease 
 
The pro-inflammatory capacity of the monocyte subsets, assessed as TNF production, was compared 
between healthy controls and IBD patients to ensure that IL-10 response was measured against the 
same inflammatory activity. PBMCs from eight healthy controls and eight IBD patients with active 
disease (six CD and two UC) patients were stimulated with 1ng/ml LPS for three hours before staining 
for intracellular TNFα. TNFα production was measured as a percentage of cells positive for TNFα and 
as the level of expression on a per cell basis, assessed as MFI. The results show that there was no 
significant difference in TNFα production in any of the monocyte subsets of IBD patients compared 
with healthy controls (Figure 5.1). There were no detectable TNFα production in the monocyte subsets 
in unstimulated culture from healthy controls or IBD patients (data not shown). 
 
Figure 5.1: LPS-induced TNFα production by monocyte subsets in health and IBD. PBMCs were 
stimulated with 1ng/ml LPS for three hours in the presence of monensin and ADAM17 inhibitor (TMI-
005). The PBMCs were labelled with anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish 
the monocytes subsets, fixed, permeabilised, and stained intracellularly for TNFα before acquiring on 
the flow cytometer. TNFα production was compared between healthy controls (n=8) and IBD patients 
(n=8) with active disease. TNFα production was quantified as A) percentage of cells positive for TNFα 
and B) as the level of expression on a per cell basis, assessed as MFI, for each monocyte subset. Mean 
and SD are displayed for normally distributed data sets, while median and IQR are displayed for non-
normally distributed data sets. An unpaired T-tests was used to compare two groups of normally 
distributed data, while a Mann-Whitney test was used to compare two groups of data that were non-
normally distributed.   
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Next, the anti-inflammatory activity, assessed as IL-10 production, was compared between the same 
eight healthy controls and eight IBD patients with active disease. PBMCs were stimulated or not with 
1ng/ml LPS for three hours before staining for intracellular IL-10. IL-10 production was measured as a 
percentage of cells positive for IL-10 and as the level of expression on a per cell basis, assessed as MFI. 
There was no significant difference in the production of IL-10 at baseline or with LPS stimulation in the 
monocyte subsets from healthy controls and IBD patients.  
 
Figure 5.2: Endogenous and LPS-induced IL-10 production by monocyte subsets in health and IBD. 
PBMCs were stimulated or not with 1ng/ml LPS for three hours in the presence of monensin and 
ADAM17 inhibitor (TMI-005). The PBMCs were labelled with anti-HLA-DR, anti-CD14, and anti-CD16 
antibodies to distinguish the monocytes subsets, fixed, permeabilised, and stained intracellularly for 
IL-10 before acquiring on the flow cytometer. IL-10 production was compared between healthy (n=8) 
and IBD patients (n=8) with active disease. IL-10 production was quantified as a percentage of cells 
positive for IL-10 and as the level of expression on a per cell basis, assessed as MFI, for each monocyte 
subset in A, B) unstimulated and C, D) LPS-stimulated cultures. Mean and SD are displayed for normally 
distributed data sets, while median and IQR are displayed for non-normally distributed data sets. An 
unpaired T-tests was used to compare two groups of normally distributed data, while a Mann-Whitney 
test was used to compare two groups of data that were non-normally distributed.   
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5.4.2 Classical monocytes are less responsive to IL-10 in IBD patients compared 
with healthy controls 
 
The response of monocyte subsets to IL-10 was compared between the same eight healthy individuals 
and eight IBD patients with active disease. Responsiveness to IL-10 was measured using the assay 
described in Chapter 3, determining the ability of IL-10 to inhibit LPS-induced TNFα production. IL-10 
dose-response curves were compared between healthy controls and IBD patients for each monocyte 
subset (Figure 5.3 A). IL-10 response was quantified as either ED50 or as the percentage of inhibition 
measured at an IL-10 concentration of 2ng/ml (Figure 5.3 B, C).  
IL-10 at a concentration 0.08ng/ml had no significant impact on LPS-induced TNFα production by any 
monocyte subset (Figure 5.3 A). In classical monocytes, IL-10 at concentrations >0.08ng/ml caused a 
dose-dependent inhibition of TNFα production (Figure 5.3 A) but the inhibition was significantly lower 
in monocytes from IBD patients compared with healthy controls as assessed by ED50 (p = 0.0379) or 
by inhibition at 2ng/ml IL-10 (p = 0.0264) (Figure 5.3 B, C).  
In intermediate monocytes, IL-10 at concentrations >0.4ng/ml caused a dose-dependent inhibition of 
TNFα production (Figure 5.3 A). As previously noted in non-classical monocytes from healthy controls 
(Chapter 4), non-classical monocytes from IBD patients were also relatively resistant to control by IL-
10 despite poor TNFα production (Figure 5.1 A). It was not possible to accurately determine ED50 
values for intermediate and non-classical monocytes because inhibition did not reach 50% in cells from 
some donors even at the highest concentration of IL-10 tested (Figure 5.3 B). However, as determined 
by the response to 2ng/ml, the inhibitory effect of IL-10 did not differ between health and IBD in either 
intermediate and non-classical monocytes (Figure 5.3 C).  
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Figure 5.3: IL-10 responsiveness of monocyte subsets in health and IBD. PBMCs were stimulated with 
1ng/ml LPS and increasing concentrations of IL-10 (0.016-10ng/ml) for three hours in the presence of 
monensin and ADAM17 inhibitor (TMI-005). The PBMCs were labelled with anti-HLA-DR, anti-CD14, 
and anti-CD16 antibodies to distinguish the monocytes subsets, fixed, permeabilised, and stained 
intracellularly for TNFα before acquiring on the flow cytometer. A) IL-10 dose-response curves were 
compared between healthy controls (n=8) and IBD patients (n=8) with active disease for each 
monocyte subset. IL-10 response was quantified as B) ED50 and C) percentage inhibition of TNFα at 
2ng/ml IL-10 for each monocyte subset. Mean and SD are displayed for normally distributed data sets, 
while median and IQR are displayed for non-normally distributed data sets. An unpaired T-tests was 
used to compare two groups of normally distributed data, while a Mann-Whitney test was used to 
compare two groups of data that were non-normally distributed. p ≤ 0.05* p ≤ 0.01** p ≤ 0.001*** p 
≤ 0.0001****. 
 
5.4.3 IL-10Rα expression is increased in classical monocytes of IBD patients  
 
The underlying mechanism behind the reduced response to IL-10 was then investigated by examining 
proximal signalling components, including IL-10R expression. Whole blood from 15 healthy donors and 
31 IBD patients (15 active and 16 inactive; 21 CD, eight UC, and two IC) were labelled for IL-10Rα. 
Receptor expression was quantified as percentage positive cells and MFI calculated as MFI for staining 
with anti-IL-10Rα antibody minus MFI for staining with an isotype-matched control antibody. 
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There was no significant difference in the proportion of IL-10Rα expressing monocytes between 
healthy controls and IBD patients (Figure 5.4 A, B, and C). There was a significant increase in the level 
of IL-10Rα expression by the classical monocytes of IBD patients (p = 0.0207) (Figure 5.4 D). Therefore, 
the reduced response to IL-10 in classical monocytes from IBD patients cannot be explained by a 
reduced level of receptor expression. Instead, these data provide further evidence that the level of IL-
10R expression is a poor predictor of functional response to the cytokine. There was no significant 
difference in the level of IL-10Rα expression on intermediate and non-classical monocytes in health 
and IBD (Figure 5.4 E and F).  However, there was greater heterogeneity in the IBD group. Stratifying 
the IBD group into active and inactive, CD and UC, or treatment groups did not reveal any associations 
with IL-10R expression (Appendix 6). 
Figure 5.4: IL-10Rα expression on monocytes subsets in health and IBD. Whole blood from healthy 
donors (n=15) and IBD patients (n=31) were labelled with anti-HLA-DR, anti-CD14, and anti-CD16 
antibodies to distinguish the monocyte subsets, and IL-10Rα before acquiring on the flow cytometer. 
IL-10Rα expression was quantified as A) percentage of cells positive for IL-10Rα and B) MFI calculated 
as MFI for staining with anti-IL-10Rα antibody minus MFI for staining with an isotype-matched control 
antibody for each monocyte subset. Mean and SD are displayed for normally distributed data sets, 
while median and IQR are displayed for non-normally distributed data sets. An unpaired T-tests was 
used to compare two groups of normally distributed data, while a Mann-Whitney test was used to 
compare two groups of data that were non-normally distributed. p ≤ 0.05* p ≤ 0.01** p ≤ 0.001*** p 
≤ 0.0001****. 
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5.4.4 IL-10-induced STAT3 phosphorylation is more efficient in classical 
monocytes of IBD patients  
 
To test whether the increased IL-10Rα expression in IBD patients impacts on phosphorylation of 
STAT3, the capacity to phosphorylate STAT3 was measured in the monocyte subsets of 10 healthy 
controls and 11 IBD patients with active disease (six CD and five UC). Whole PBMCs were stimulated 
with 100ng/ml IL-10 for 15min before staining intracellularly for p-STAT3. STAT3 phosphorylation was 
quantified as a percentage of cells positive for p-STAT3 and MFI calculated as MFI for staining with 
anti-p-STAT3 antibody minus MFI for staining with an isotype-matched control antibody. The percent 
of cells positive for p-STAT3 was significantly enhanced in classical monocytes of IBD patients in 
comparison to healthy volunteers (p = 0.0029), which is reflected in MFI (p = 0.0032) (Figure 5.5 D). 
The increase in p-STAT3 positive cells may be explained by the enhanced surface expression of IL-10Rα 
in classical monocytes of IBD patients but does not explain the reduced functional response to IL-10 
in IBD patients. The proportion of p-STAT3 positive cells and the level of STAT3 phosphorylation did 
not differ between IBD patients and healthy controls in both intermediate and non-classical 
monocytes. However, as with IL-10R expression, there is greater heterogeneity in p-STAT3 expression 
the IBD group and elevated levels could be observed in some individuals.   
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Figure 5.5: STAT3 phosphorylation in monocyte subsets in health and IBD. PBMCs were labelled with 
anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish the monocyte subsets. The PBMCs 
were stimulated with 100ng/ml IL-10 before fixation, permeabilisation, and intracellular staining for 
p-STAT3. Samples from healthy donors (n=10) and IBD patients (n=16) with active disease were then 
acquired on the flow cytometer. STAT3 phosphorylation was calculated as A) percentage of cells 
positive for p-STAT3 and B) and MFI calculated as MFI for staining with anti-p-STAT3 antibody minus 
MFI for staining with an isotype-matched control antibody for each monocyte subset. Mean and SD 
are displayed for normally distributed data sets, while median and IQR are displayed for non-normally 
distributed data sets. An unpaired T-tests was used to compare two groups of normally distributed 
data, while a Mann-Whitney test was used to compare two groups of data that were non-normally 
distributed. p ≤ 0.05* p ≤ 0.01** p ≤ 0.001*** p ≤ 0.0001****. 
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In the analysis of STAT3 phosphorylation in the monocyte subsets in health, there was an association 
between with STAT3 availability and STAT3 phosphorylation in response to IL-10. To determine if the 
enhanced capacity to phosphorylation STAT3 observed in classical monocytes from IBD patients was 
also associated with a greater STAT3 pool, STAT3 availability was measured in the monocyte subsets 
of the same ten healthy controls and 11 IBD patients with active disease. STAT3 availability was 
quantified as a percentage of cells positive for STAT3 and MFI calculated as MFI for staining with anti-
STAT3 antibody minus MFI for staining with an isotype-matched control antibody. 
Figure 5.6 shows that there was no significant difference in the proportion of T-STAT3 positive cells or 
the level of T-STAT3 in any of the monocyte subsets in health and IBD. This suggests that STAT3 
availability is not contributing to the enhanced STAT3 phosphorylation observed in classical 
monocytes of IBD patients.  
 
Figure 5.6: STAT3 availability in monocytes subsets in health and IBD. PBMCs were labelled with anti-
HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish the monocyte subsets before fixation, 
permeabilisation, and intracellular staining for STAT3. Samples from healthy donors (n=10) and IBD 
patients (n=11) with active disease were then acquired on the flow cytometer. STAT3 availability was 
calculated as A) percentage of cells positive for T-STAT3 and B) and MFI calculated as MFI for staining 
with anti-STAT3 antibody minus MFI for staining with an isotype-matched control antibody for each 
monocyte subset for each monocyte subset. Mean and SD are displayed for normally distributed data 
sets, while median and IQR are displayed for non-normally distributed data sets. An unpaired T-tests 
was used to compare two groups of normally distributed data, while a Mann-Whitney test was used 
to compare two groups of data that were non-normally distributed.   
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5.4.5 SOCS3 mRNA expression in classical monocytes is enhanced in IBD 
patients compared to healthy controls 
 
The data presented so far in this chapter indicate that the reduced ability of IL-10 to inhibit LPS-
induced TNFα production in classical monocytes of IBD patients cannot be explained by proximal 
signalling events. Therefore, the next step was to look further downstream at SOCS3 mRNA 
expression.  Investigating SOCS3 protein levels directly was hindered by low cell numbers, therefore, 
baseline transcription level was used as a surrogate. In addition, low recovery of purified subsets 
meant that it was not possible to compare the level of IL-10 induced SOCS3 mRNA expression. PBMCs 
from 14 healthy donors and 16 IBD patients with active disease (eight CD, six UC, and two IC) were 
labelled with anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish the monocyte subsets 
before purification by sorting on the FACS Aria (BD). 1x106 classical monocytes were sorted, and the 
relative gene expression of SOCS3 was measured using qRT-PCR. SOCS3 mRNA expression in 
intermediate and non-classical monocytes was not compared between healthy individuals and IBD 
patients because sufficient cells could not be obtained from the volume of blood we were able to 
obtain under our ethical approval. However, the IL-10 response in these subsets did not differ in IBD 
patients (Figure 5.3), and therefore these subsets were unlikely to have been informative.  
A trend towards increased expression of SOCS3 mRNA expression in the classical monocytes of IBD 
patients was observed (p = 0.0695) (Figure 5.7), which is consistent with the increase in IL-10R 
expression and STAT3 phosphorylation reported above. However, a larger cohort is required to 
confirm this trend. 
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Figure 5.7: SOCS3 mRNA expression in classical monocytes in health and IBD. Whole PBMCs from 
healthy donors (n=14) and IBD patients (n=16) with active disease were labelled with anti-HLA-DR, 
anti-CD14, and anti-CD16 antibodies to distinguish the monocyte subsets before sorting on the FACS 
Aria (BD). 1x106 classical monocytes were sorted, and the relative gene expression of SOCS3 was 
measured using qRT-PCR. Median and IQR displayed; a Man-Whitney test was used.  
 
5.4.6 Fewer circulating non-classical monocytes are present in IBD patients  
 
The findings above together with other published work (Arts et al. 2018; Askenase et al. 2015; Christ 
et al. 2018; Mitroulis et al. 2018; Sanders et al. 2014; Smith et al. 2009) showed changes in the 
properties of blood monocytes during intestinal inflammation. Next, the distribution of the monocyte 
subset was examined. A comparison of monocyte subset distribution was made between 24 healthy 
controls and 41 IBD patients (21 active and 20 inactive; 28 CD, 11 UC, and two IC) using whole blood 
labelling. Each monocyte subset was assessed as both the proportion of total PBMCs and total 
monocytes as well as absolute cell number using Flow-Count Fluorospheres. There was a significant 
reduction in non-classical monocytes in IBD patients in comparison with healthy controls (Figure 5.8). 
This was true whether measured as a percentage of total PBMCs (p = 0.0202), as a percentage of total 
monocytes (p = 0.0025), and as absolute cell numbers (p = 0.0057). There were no significant changes 
in the proportion or cell number of the classical and intermediate monocytes between IBD patients 
and healthy controls. Stratifying the IBD cohort into active and inactive, CD and UC, or treatment 
groups did not reveal any significant associations (Appendix 7). This finding was in contrast to 
previously reported increase in the proportion of intermediate monocytes as a percentage of total 
monocytes (Grip et al. 2006; Thiesen et al. 2014). Therefore, the investigation into monocyte subset 
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distribution in health and IBD was repeated in a separate cohort of 18 healthy controls and 19 IBD 
patients with active disease (nine CD and ten UC) who were about to start vedolizumab treatment 
(Appendix 8a). In agreement with the findings in the first cohort, a significant reduction in the 
proportion and absolute cell number of non-classical monocytes was observed, and there was no 
difference in the proportion or number of classical and intermediate monocytes (Appendix 8b). 
 
Figure 5.8: Monocyte subset distribution in health and IBD. Whole blood from healthy donors (n=24) 
and IBD patient (n=41) were labelled with anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to 
distinguish the monocyte subsets before acquiring on the flow cytometer. Monocyte subset 
distribution was calculated as A) percentage of PBMCs, B) percentage of total monocyte, and C) 
absolute cell number. Mean and SD are displayed for normally distributed data sets, while median and 
IQR are displayed for non-normally distributed data sets. An unpaired T-tests was used to compare 
two groups of normally distributed data, while a Mann-Whitney test was used to compare two groups 
of data that were non-normally distributed. p ≤ 0.05* p ≤ 0.01** p ≤ 0.001*** p ≤ 0.0001****. 
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5.4.7 β7 is highly expressed in classical and intermediate monocytes  
 
Poor regulation of the inflammatory activity of intermediate and non-classical monocytes may be of 
relevance in inflammatory disorders of the intestine, where IL-10 plays a critical role in the prevention 
of bacterial driven inflammation (Kühn et al., 1993). Schippers et al. 2015 showed that β7 integrin 
deficiency in mice was protective against DSS-induced colitis due to reduced monocyte recruitment, 
and injecting WT Ly6Chi monocytes caused an aggravation of the colitis in these mice. This indicates a 
possible role of α4β7 in the recruitment of monocyte into the intestine. To test this, the expression 
levels of α4β7 was first measured on the monocyte subsets in 18 healthy individuals. The monocyte 
subsets in whole blood were labelled with anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to 
distinguish the monocyte subsets, and anti-CD103 to distinguish between α4β7 and CD103β7, both of 
which would label with anti-β7 antibody (Figure 5.9 A). β7 expression was quantified as a percentage 
of cells positive for β7 and MFI calculated as MFI for staining with anti-β7 antibody minus MFI for 
staining with an isotype-matched control antibody.  
A similar percentage (35-39%) of classical and intermediate monocytes were 47+ (identified as 
CD103-7+) (Figure 5.9 C) but the level of expression was significantly higher (p=0.0047) on the 
intermediate cells (Figure 5.9 D). Relatively low 7 expression was detected on the non-classical 
monocytes (Figure 5.9 D), and significantly fewer non-classical monocytes were positive for 4β7 than 
classical monocytes or intermediate monocytes (both p < 0.001) (Figure 5.9 C). These data show that 
intermediate monocytes display the potential capacity to be recruited to the intestine in a 4β7-
dependent manner, where the poor control of their inflammatory properties could contribute to 
intestinal inflammation. 
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Figure 5.9: β7 expression on monocyte subsets in health. Whole blood from healthy donors (n=18) 
were labelled with anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish the monocyte 
subsets (excluding CD103+ cells), and anti-β7 antibody before acquiring on the flow cytometer. A) 
gating strategy for assessing β7 expression on the monocyte subsets. B) representative histograms of 
β7 expression on the monocyte subset in relation to the isotype control for the total HLA-DR+ 
population (grey histogram) for illustration. β7 expression was quantified as C) percentage of cells 
positive for β7 and D) MFI calculated as MFI for staining with anti-β7 antibody minus MFI for staining 
with an isotype-matched control antibody for each monocyte subset in relation to their corresponding 
isotype control. Mean and SD are displayed for normally distributed data sets, while median and IQR 
are displayed for non-normally distributed data sets. Data were analysed statistically by Friedman test. 
p ≤ 0.05* p ≤ 0.01** p ≤ 0.001*** p ≤ 0.0001****.  
 
5.4.8 β7 expression on the monocytes subsets does not differ between health 
and IBD 
 
Next, expression levels of β7 on the monocyte subsets were compared between 18 healthy controls 
and 19 IBD patients with active disease (nine CD and ten UC). β7 expression was quantified as a 
percentage of cells positive for β7 (excluding CD103+ cells) and MFI calculated as MFI for staining with 
anti-β7 antibody minus MFI for staining with an isotype-matched control antibody.  
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No significant difference in either proportion of 47+ monocytes or level of β7 expression was seen 
on any of the monocyte subsets between healthy controls and IBD patients. However, there was 
greater heterogeneity in the IBD group most notably in the non-classical monocytes where a few 
individuals had an increased frequency of 47+ cells (Figure 5.10). Stratifying the IBD cohort into CD 
and UC patients or responders and non-responders did not reveal any significant association with 
disease type (Appendix 9). These data suggest that the loss of non-classical monocytes from the 
circulation of IBD patients is unlikely to be due to enhanced 47-dependent recruitment to the 
intestine during inflammation, at least in the majority of individuals.  
 
Figure 5.10: β7 expression on monocytes subsets in health and IBD. Whole blood from healthy 
donors (n=18) and IBD patient (n=19) were labelled with anti-HLA-DR, anti-CD14, and anti-CD16 
antibodies to distinguish the monocyte subsets (excluding CD103+ cells), and β7 before acquiring on 
the flow cytometer. β7 expression was quantified as A) percentage of cells positive for β7 and B) MFI 
calculated as MFI for staining with anti-β7 antibody minus MFI for staining with an isotype-matched 
control antibody for each monocyte subset. Mean and SD are displayed for normally distributed data 
sets, while median and IQR are displayed for non-normally distributed data sets. An unpaired T-tests 
was used to compare two groups of normally distributed data, while a Mann-Whitney test was used 
to compare two groups of data that were non-normally distributed.   
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5.4.9 Blockade of α4β7 in IBD does not impact upon circulating monocytes 
 
As previously described, monocytes have been implicated in intestinal inflammation using β7 integrin-
deficient mice (Schippers et al. 2015). In support of this, the data showed that monocytes subsets 
express 47. To assess the contribution of 47-dependent monocyte recruitment to the intestine 
during inflammation, monocyte subset distribution was monitored in patients undergoing 
vedolizumab treatment (an 47 blocking antibody). Whole blood from 19 IBD patients with active 
disease (nine CD and ten UC; seven responders and 10 non-responders) was collected at baseline and 
after two and six weeks of treatment. Monocyte subset distribution was assessed as the proportion 
of total PBMCs and total monocytes, and absolute cell number. Monocyte subset distribution was also 
assessed as a percentage of β7+ (excluding CD103+ cells) monocytes and β7+ monocytes per μL 
(Appendix 10a). 
No significant change was seen in proportion or absolute cell number of any of the monocyte subsets 
(Figure 5.11 A, B, C) over the six weeks of vedolizumab treatment. There was a trend towards an 
increase in the absolute number of classical cells and non-classical monocytes over the six weeks of 
vedolizumab treatment. However, a larger cohort is required to confirm this trend. Stratifying the IBD 
cohort into CD and UC patients or responders and non-responders did not reveal any significant 
associations (Appendix 10b).  
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Figure 5.11: The effect of vedolizumab therapy on circulating monocyte subset distribution. Whole 
blood from IBD patients (n=19) starting vedolizumab treatment were labelled with anti-HLA-DR, anti-
CD14, and anti-CD16 antibodies to distinguish the monocyte subsets before acquiring on the flow 
cytometer. Monocyte subset distribution and cell number were determined at baseline and after two 
and six weeks of treatment. Monocyte subset distribution was calculated as A) percentage of PBMCs, 
B) percentage of total monocyte, and C) absolute cell number. Mean and SD are displayed for normally 
distributed data sets, while median and IQR are displayed for non-normally distributed data sets. Data 
were analysed statistically by RM one-way ANOVA for normally distributed data sets, while a Friedman 
test was used for non-normally distributed data sets.   
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The presumed mechanism of action of vedolizumab is primarily to block effector T cell recruitment to 
the intestine. Therefore, we wished to determine whether an impact of vedolizumab on circulating T 
cells could be detected over the six weeks of treatment in this study. First, the distribution of β7+ 
(excluding CD103+ cells) CD45RA- T cells was compared between 16 healthy donors and 14 IBD 
patients with active disease. Next, the distribution of β7+CD45RA- T cells were assessed in the same 
14 IBD patients at baseline and after two and six weeks of treatment. 
A significant reduction in the number of β7 expressing CD8+ (p = 0.0300) and CD4+ (p = 0.0138) T cells 
compared with healthy controls was seen at baseline, which agrees with previous findings in IBD 
patients (Hart et al. 2004a; Hart et al. 2004b). Stratifying the IBD cohort into CD and UC did not reveal 
any significant associations (Appendix 11a).  
There was no significant change in either population after two weeks or six weeks of vedolizumab 
therapy (Figure 5.12). Stratifying the IBD cohort into CD and UC or responders and non-responders did 
not reveal any significant associations (Appendix 11b).  
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Figure 5.12: The effect of vedolizumab therapy on circulating β7+ CD4 and CD8 T cell distribution. 
Whole blood from healthy donors (n=16) and IBD patients (n=14) with active disease were labelled 
with anti-CD3, anti-CD45RA, anti-CD8, and anti-CD4 antibodies to distinguish CD45RA- CD8+ and CD4+ 
T cells (excluding CD103+ cells), and anti-β7 antibody before acquiring on the flow cytometer. The 
proportion of β7 expressing CD8+ and CD4+ T cells was calculated as a percentage of total T cells. A) 
gating strategy for assessing β7 expression on T cells. B) proportion of β7 expressing CD8+ and CD4+ 
T cells in health and disease. C) proportion of β7 expressing CD8+ and CD4+ T cells at baseline and 
after two and six weeks of treatment. Mean and SD are displayed for normally distributed data sets, 
while median and IQR are displayed for non-normally distributed data sets. Data were analysed 
statistically by RM one-way ANOVA for normally distributed data sets, while a Friedman test was used 
for non-normally distributed data sets. p ≤ 0.05* p ≤ 0.01** p ≤ 0.001*** p ≤ 0.0001****.  
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5.5 Discussion 
 
The primary aim of this chapter was to determine differences in IL-10 responsiveness of monocyte 
subsets between healthy individuals and IBD patients, and identify any differences in signalling 
components in the IL-10 signalling pathway between health and IBD. In addition, monocyte subset 
distribution was also compared between healthy individuals and IBD patients, and a potential role for 
47 integrin in monocyte recruitment to the intestine explored. 
Fate mapping techniques, as well as studies in CCR2-deficient mice, have shown that, at least in part, 
the intestinal Mφ pool requires constant replenishment by circulating monocytes (Yona et al. 2013; 
Bain et al. 2014). During steady-state, newly arrived Ly6Chi monocytes lose their inflammatory 
properties to give rise to regulatory Mφs, which display characteristics, including constitutive IL-10 
production and bacterial clearance without pro-inflammatory cytokine production, that would 
promote immune homeostasis (Bain et al. 2014). However, during inflammation, this pathway is 
disrupted, and the Ly6Chi cells become arrested at an intermediary stage of differentiation resulting in 
an accumulation of cells that retain their ability to respond to TLR ligands; these inflammatory Mφs 
are likely to be contributing to the inflammation (Bain et al. 2013). In humans, an expansion in the 
proportion of CD14+ Mφs that retain their capacity to respond to TLR stimulation has been reported 
in CD patients (M. C. Grimm et al. 1995; Kamada et al. 2008; Lissner et al. 2015; Rugtveit et al. 1997; 
Thiesen et al. 2014), which resembles the model of intestinal inflammation described in mice. The 
signals responsible for the fate of the newly recruited monocytes are unknown. The studies reviewed 
in the introduction demonstrate that TGFβ and IL-10 act synergistically to imprint the regulatory 
phenotype of intestinal Mφ.   
There is increasing evidence in both mice and humans that systemic signals from the intestine during 
inflammation cause functional changes to circulating cells (Arts et al. 2018; Askenase et al. 2015; Christ 
et al. 2018; Mitroulis et al. 2018; Smith et al. 2009; Sanders et al. 2014). Together with the data that 
IL-10 has a critical non-redundant role in IL-10 KO mice and VEO-IBD patients, sparked the interest in 
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investigating IL-10 response of intestinal Mφ and their precursors. Classical monocytes are said to be 
the human equivalent of LYC6hi cells based on gene expression profiles (Ingersoll et al. 2010), 
therefore, classical monocytes are likely to be a major source of intestinal Mφs (Bain et al. 2014). In 
the previous chapter, classical monocytes showed a robust response to IL-10, which suggests an 
important role for IL-10 in regulating their inflammatory properties once recruited to an IL-10 rich 
environment like the intestine. How this response changes in the context of intestinal inflammation 
was the subsequent area of interest.  
First, the inflammatory capacity of the monocyte subsets was compared between healthy controls 
and IBD patients to ensure that IL-10 response was measured against the same inflammatory activity, 
as suggested by experiments in which IL-1β was measured, stronger responses are harder to inhibit. 
Indeed inflammatory signals from the intestine have been shown to affect the phenotype of 
monocytes from development in the BM (Askenase et al. 2015). However, there was no significant 
difference in the capacity of monocytes from healthy controls and IBD patients to produce either TNFα 
or IL-10 following LPS stimulation. A low frequency of monocytes produced IL-10 but not TNFα in the 
absence of stimulation but again the was no difference between cells from patients and controls. The 
findings reported here agree with Thiesen et al., 2014 and Begue et al., 2011 who also found no 
significant differences in pro-inflammatory cytokine production by individual monocyte subsets in 
healthy controls and CD patients.  
A reduced response to IL-10 was found in classical monocytes of IBD patients. The release from IL-10 
control may be a ‘normal’ feature of immune responses allowing a response to be mounted against a 
real challenge. However, a reduction in IL-10 response could favour the accumulation of inflammatory 
Mφs, which may contribute to the sustainment of intestinal inflammation. The reduction in IL-10 
response in circulating classical monocytes reveals that systemic signals, as well as the local 
environment, can have an impact on monocyte fate. This is in support of previous observations of 
systemic changes in monocytes during intestinal inflammation (Arts et al. 2018; Askenase et al. 2015; 
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Christ et al. 2018; Mitroulis et al. 2018; Smith et al. 2009; Sanders et al. 2014). Intermediate and non-
classical monocytes showed no significant difference in their response to IL-10 between health and 
IBD. However, both of these subsets are relatively resistant to IL-10 inhibition in health compared with 
classical monocytes. Intermediate monocytes express CCR2 (Wong et al. 2011), indicating a potential 
capacity to be recruited to the intestine, via the CCR2-dependent process utilised by classical 
monocytes, where their pro-inflammatory properties and resistance to regulatory signals may favour 
differentiation into inflammatory Mφs. However, the contribution of intermediate monocytes to the 
intestinal Mφ pool and how this changes during inflammation has not been explored due to the lack 
of unique identifiers, as CD16 may be shed upon entry into the intestine making their identification 
challenging. Non-classical monocytes are likely to fulfil similar roles Ly6Clo cells, which have not yet 
been implicated in intestinal inflammation.  
The reduced response to IL-10 in classical monocytes of IBD patients is an important observation. 
However, the study consists of small numbers and the magnitude of the difference in response to IL-
10 between healthy individuals and IBD patients was also relatively small, therefore, a larger cohort is 
required to verify this finding. The genome of patients included in the cohort will be sequenced to test 
whether the donors express genetic variants along the IL-10R pathway that could impact IL-10 
response. However, a reduced response to IL-10 was a common feature of the IBD patients studied 
here, such genetic variation is unlikely to be a significant contributor to the differences observed. 
Proximal signalling components of the IL-10R signalling pathway were investigated for suboptimal 
activity in IBD patients that could explain the reduced IL-10 response in classical monocytes. In 
contrast to the functional response, classical monocytes showed enhanced expression of IL-10Rα in 
IBD patients. This again demonstrates systemic changes in monocytes caused by signals from the 
intestine during inflammation in support of previous observations (Arts et al. 2018; Askenase et al. 
2015; Christ et al. 2018; Mitroulis et al. 2018; Smith et al. 2009; Sanders et al. 2014). The enhanced IL-
10Rα expression in classical monocytes does not correlate with their functional response, providing 
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further evidence that the response to IL-10 is not determined by the level of receptor on the surface. 
The enhanced IL-10Rα expression may be an example of ‘negative feedback’ in which the immune 
system is attempting to control inflammation by upregulating the expression level of a receptor that 
respond to regulatory signals. However, if this is the case, this attempt by the immune system to 
enhance sensitivity to IL-10 seems to appear unsuccessful at least with regard to LPS-induced TNFα 
production, indicating the need to consider a defect further downstream. Phosphorylation of STAT3 
is also enhanced in classical monocytes of IBD patients, which is not due to greater STAT3 availability 
since staining for T-STAT3 was equivalent. These data indicate that in IBD, phosphorylation of STAT3 
in response to IL-10 exposure is further enhanced in classical monocytes as a result of IL-10Rα 
expression above the relatively low baseline level reported in Chapter 4. The expression levels of IL-
10Rα on intermediate and non-classical monocytes does not differ between IBD patients and healthy 
controls. A failure to enhance IL-10R in the face of inflammation may indicate that these cells are 
poorly controlled and can actively contribute to the disease process. The capacity of intermediates 
and non-classical monocytes to phosphorylate STAT3 remains unchanged in IBD patients, which 
reflects the unaffected expression levels of the IL-10Rα in both subsets.  
Differences in proximal signalling events do not explain the reduced response to IL-10 in classical 
monocytes in IBD, therefore, a target further downstream was investigated. As discussed in the 
previous chapter, a study by Kontoyiannis et al., 2001 speculated that the availability of a pool of pre-
formed SOCS3 protein could be a source of rapid inhibition of inflammatory responses in the period 
during which STAT3 promotes gene expression and protein synthesis to generate new SOCS3 protein. 
Investigating SOCS3 protein levels directly was hindered by low cell numbers, and therefore mRNA 
expression at baseline was used as a potential surrogate measure. SOCS3 mRNA levels showed a trend 
towards increased expression in IBD patients, which is consistent with the observed increase in IL-
10Rα expression and STAT3 phosphorylation but does not provide a mechanism for the reduced 
response to IL-10 in classical monocytes of IBD patients. It would also be worthwhile to investigate the 
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level of IL-10 induced SOCS3 mRNA or protein expression using pooled samples across donors to 
overcome the limitations of low cell numbers.  
The signalling components investigated thus far do not provide a clear mechanism for the reduced 
response to IL-10 in classical monocytes of IBD patients, indicating that unknown mechanisms are 
regulating IL-10 responsiveness. A global phosphoproteomic analysis could be used to identify other 
proteins that are phosphorylated following exposure to IL-10 and any differences between cells from 
healthy individuals and IBD patients. 
In humans, there is evidence that recruitment of monocytes is enhanced at sites of intestinal 
inflammation (M. Grimm et al. 1995) and this might be predicted to impact upon monocyte numbers 
or subset distribution in the circulation. To seek evidence of systemic changes to monocyte subset 
distribution, absolute cell numbers were compared between healthy controls and IBD patients. The 
observation that the non-classical monocytes, but not classical or intermediate cells, are significantly 
reduced in proportion and cell number in IBD patients, is in contrast to previous findings. Thiesen et 
al. 2013 and Grip et al., 2006 both reported an increase in the proportion of intermediate monocytes 
as a percentage of total monocytes but absolute cell numbers were not examined. Presenting the data 
as proportions and not absolute cell numbers means that the proportion of intermediate monocytes 
could be affected by changes in another subset. These conflicting observations could also be a result 
of the different gating strategies used to characterise the monocyte subsets: both Thiesen et al. 2013 
and Grip et al., 2006 did not exclude HLA-DR negative populations, therefore, could have NK cell 
contamination in the CD16+ gate. Another possible explanation could be that different types of 
patients were analysed: the cohort selected by Thiesen et al. 2013 and Grip et al., 2006 were CD 
patients with active disease, while the IBD cohort in this study included a combination of CD and UC 
patients that were active or in inactive. However, stratification of these data into the individual 
subgroups did not show any significant differences based on disease type or activity or even treatment 
groups. This suggests that the systemic effects of intestinal inflammation are long-lasting and 
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persistent into subsequent periods of inactive, which may explain the relapsing pattern common in 
IBD patients. Fewer non-classical monocytes were also observed in a separate cohort of IBD patients 
before starting vedolizumab treatment. The replicability of this observation further supports the 
robust nature of this observation. 
The reduction in circulating non-classical monocytes observed in IBD patients could be due to a 
number of reasons. One explanation may be that these cells are being recruited into the inflamed 
intestine as this population has been shown to be recruited into inflamed tissues, contributing initially 
to the inflammatory response before switching on reparative functions (Auffray et al. 2007). Another 
possible explanation for the loss of non-classical monocytes in blood could be that fewer classical 
monocytes are available to mature into non-classical monocytes. This could be explained by a surge 
in recruitment of monocytes into sites of intestinal inflammation (M. Grimm et al. 1995). No change 
in the abundance of classical monocytes was observed in IBD patients, which might have been 
expected if there was enhanced recruitment to the intestine. However, an increase in classical 
monocytes leaving the circulation could be compensated by enhanced monocyte development and 
release from the BM, in addition to arresting differentiation into non-classical monocytes. A rapid 
release of monocytes from the BM has been observed following systemic inflammation (Patel et al. 
2017). The impact of intestinal inflammation on the half-life of the monocyte subsets has not been 
studied but enhanced cell death of non-classical monocytes in the IBD patients could also account for 
their reduced abundance. Alternatively, changes to the endothelial wall induced by intestinal 
inflammation may make the non-classical monocytes more adherent to the surface and appear less 
abundant in the blood. This adhesion to the endothelial wall has been demonstrated by the selective 
mobilisation of CD14+CD16++ monocytes by exercise (Steppich et al. 2000). The loss of non-classical 
monocytes from the circulation could have important implications for tissue repair, as this is their 
ultimate function after recruitment, which may perpetuate tissue damage during intestinal 
inflammation (Auffray et al. 2007). The implications of altered numbers of circulating Ly6Clo 
monocytes has been demonstrated: mice fed a high-fiber diet showed enhanced generation of Ly6Clo 
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monocytes and a subsequent increase in the numbers of alternatively activated Mφs in the airways 
that displayed a limited capacity to produce CXCL1, which reduced neutrophil recruitment, thus 
limiting tissue immunopathology during infection (Trompette et al. 2018). 
It is difficult to understand the implications of any changes seen in the immune composition of the 
circulating blood in IBD patients. Fate mapping is not accessible for human intestinal studies, 
therefore, investigating the impact of therapies that target immune cell trafficking to the intestine, by 
following the immune composition of circulating blood from patients undergoing this treatment, is 
one way of gaining information about the key molecules involved in recruitment of different cell 
populations under inflammatory conditions. In mice, CCL2-depend recruitment has been implicated 
using anti-CCR2 antibodies to ablate Ly6Chi monocytes, which alleviated DSS-induced colitis (Zigmond 
et al. 2012). In humans, enhanced expression and production of CCL2 has been observed in IBD 
patients (Grimm et al. 1996). Monocytes recruited in an 47-dependent manner has also been 
implicated in intestinal inflammation in studies using β7 integrin-deficient mice (Schippers et al. 2015). 
However, expression of 47 by human monocyte subsets and its potential role in monocyte entry to 
the inflamed intestine had not been previously explored. The data presented in this thesis showed 
that classical and intermediate monocytes express 47. However, the data does not show if the 
integrin is in an active conformation, and therefore measuring binding to mucosal vascular addressin 
cell adhesion molecule 1/MAdCAM-1 (direct leukocytes into mucosal and inflamed tissues) would be 
informative. To assess the possible contribution of 47-dependent monocyte recruitment to the 
intestine during inflammation, monocyte subset distribution was monitored in patients undergoing 
vedolizumab treatment. The underlying assumption was that if blockade of 47 with vedolizumab 
impacted on monocyte recruitment to the intestine this would impact on populations in the 
circulation. However, no significant change was seen in proportion or absolute cell number of any 
monocyte subset over the six weeks of vedolizumab treatment irrespective of clinical response.  These 
data may be taken to indicate that 47 may not play a major role in monocyte recruitment to the 
intestine during inflammation or, if it does, that there is redundancy which means that other pathways 
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can operate when 47 is blocked. However, caution should be exercised before drawing this 
conclusion as no changes in blood T cells, the presumed primary target of Vedolizumab, were also 
observed over the course of the study. The assumption that blocking recruitment would lead to 
measurable changes in the blood may be incorrect, perhaps to compensatory homeostatic 
mechanisms or that such changes do occur but they take longer than six weeks, the last time-point 
analysed, to become evident. Patients achieve clinical remission after 14 weeks of vedolizumab 
therapy (Amiot et al. 2016; Shelton et al. 2015). An earlier time-point was chosen for our analysis in 
order to separate the direct effects of the drug on trafficking from later effects arising from resolving 
inflammation.  Although, based on animal studies, intestinal monocyte-derived populations turnover 
rapidly (Bain et al. 2014), six weeks may have been too early to detect any effect. In future 
experiments, patients may need to be followed for a longer time period to see the impact of 
vedolizumab treatment on populations of circulating immune cells.  
5.6 Conclusion  
 
Classical monocytes showed a reduced response to IL-10 in IBD patients. As the main source of 
replenishment for intestinal Mφs, the capacity to regulate the inflammatory properties of these 
precursors is important. The reduced response to IL-10 inhibition could favour the accumulation of 
inflammatory Mφs, which may contribute to intestinal inflammation. Amongst the monocyte subsets, 
it is only the classical monocytes, which have a reduced response to IL-10, supporting the importance 
of this ‘defect’ to responses in the mucosa. Signalling components, including IL-10Rα expression, 
STAT3 phosphorylation, and SOCS3 mRNA expression displayed differences between IBD patients and 
healthy control, supporting the concept that systemic changes occur in monocytes during intestinal 
inflammation but the direction of change (i.e. increase in IBD) was opposite to the functional response 
to IL-10, and therefore cannot explain the lack of response to IL-10 in IBD. Understanding how 
intestinal inflammation affects IL-10 responsiveness systemically in these cells and how this 
perpetuates intestinal inflammation may help generate new therapeutic targets.  
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Chapter 6: IL-10 response in intestinal Mo/moMφs  
6.1 Chapter summary  
 
In the previous chapter, classical monocytes (CD14+) were shown to have a reduced response to IL-10 
in IBD patients compared to healthy controls. The relevance of this finding in blood for CD14+ 
monocyte-derived cells in the intestinal mucosa was next explored. Firstly, Mo/moMφs were 
identified in LPMCs extracted from intestinal biopsies. Expression of HLA-DR, CD14, and CD64 was 
used to distinguish MP populations: P1 (HLA-DRhiCD14hiCD64+), P2 (HLA-DRhiCD14loCD64+), and P3 
(HLA-DRhiCD14-CD64-). The relative proportion of these Mo/moMφs was compared between mucosa 
from non-IBD patients and inflamed mucosa from UC and CD patients. The distribution of the 
Mo/moMφs in mucosa from non-IBD patients and inflamed mucosa from patients with UC were 
comparable, whereas inflamed mucosa from patients with CD had a significant increase in the 
proportion of P2 and decrease in P1.  
Both P1 and P2 in mucosa from non-IBD patients produced TNFα in unstimulated cultures, and this 
response was significantly enhanced in both populations following LPS stimulation. The proportion of 
TNFα+ cells and the level of TNFα production (MFI) were both significantly higher in both unstimulated 
and LPS-stimulated P1 compared to P2. The magnitude of the increase in the level of TNFα production 
upon stimulation was also greater in P1 than P2. IL-10 at 2ng/ml inhibited TNFα production by both 
P1 and P2. In contrast to findings with classical blood monocytes where inhibition was only partial at 
this concentration, the response of P1 and P2 was completely inhibited by IL-10 in cells from 50% and 
25% of samples respectively. There was also complete inhibition of TNFα production in the 
Mo/moMφs in inflamed mucosa from patients with CD and UC patients, limiting the sensitivity of the 
assay and making it difficult to conclude with respect to differences in response to IL-10 between 
health and disease. Reducing the concentration of IL-10 would increase the sensitivity of the assay 
and allow for a more meaningful comparison of IL-10 responses. 
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6.2 Introduction 
 
Human intestinal Mφs are characterised by their expression of surface markers including CD64+, 
CX3CR1hi, and MHCIIhi (reviewed by Mowat & Bain, 2011). Overlap in the expression of markers with 
DCs had previously made studying the role of intestinal Mφs challenging. This has driven the use of 
multi-parameter analysis combining expression of surface markers with functional characteristics. The 
functional characteristic of intestinal Mφs in humans include high levels of phagocytosis, bactericidal 
ability, and anergy to TLR activation (Smythies et al. 2005).  
In mice, fate-mapping experiments revealed that monocytes are continuously recruited to the 
intestine to replenish at least some of the Mφ pool in steady-state (Yona et al. 2013; Bain et al. 2014). 
In humans, turnover of Mφ in the small intestine was determined by analysing tissue from pancreas 
transplant patients who receive a small segment of the duodenum along with the transplanted 
pancreas (Bujko et al. 2017). All donor-derived Mφ subsets were completely replaced by recipient cells 
over time, although, distinct populations with different rates of replacement were identified, 
consistent with the mouse evidence for constant replenishment of at least some intestinal Mφ.  
Bain et al., 2013 also showed that the newly recruited Ly6Chi monocytes differentiate into Mφ in a 
context-dependent manner. In the absence of inflammation, these newly recruited monocytes 
acquire properties as they mature into regulatory Mφs, including constitutive IL-10 production and 
anergy to TLR activation. In the presence of inflammation, this process is disrupted, and the recruited 
monocytes get ‘stuck’ at an intermediate stage and retain their inflammatory properties. Similarly, in 
humans, phenotypic analysis of Mφs from the human ileum was consistent with the maturation of 
CD14hi cells through intermediate stages to CD14lo cells (Bain et al. 2013). An accumulation of the 
intermediary population was observed in the inflamed ileum of CD patients, reflecting the 
observations in mice (Bain et al. 2013). Multiple studies have observed an accumulation of CD14+ cells 
in the inflamed mucosa of CD patients compared to healthy controls (Kamada et al. 2008; Lissner et 
al. 2015; Rugtveit et al. 1997; Thiesen et al. 2014). This is consistent with the concept that during 
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inflammation a disruption in monocyte cell differentiation into resident Mφs occurs, perpetuating the 
intestinal inflammation. In addition, there is direct evidence that there is enhanced monocyte 
recruitment to the inflamed mucosa (Grimm et al., 1995). 
The environmental cues that determine monocyte differentiation into regulatory or inflammatory 
Mφs are poorly understood. IL-10 and TGFβ have been shown to provide crucial signals during 
monocyte differentiation into resident Mφs (Schridde et al. 2017; Shouval et al. 2014; Zigmond et al. 
2014; Smythies et al. 2010). Importantly, Schriddle et al., 2017 showed, by comparing the global 
transcriptome of TGFβR-deficient and IL10R-deficient Mφs, that TGFβ and IL-10 imprint distinct 
properties of intestinal Mφs. Collectively, these studies showed that TGFβ and IL-10 play important 
non-redundant roles in regulating intestinal inflammation with Mφs as targets.  
There have been few studies on the factors that control the differentiation of Mφs within the human 
intestine. TGFβ produced by stromal cells has been shown to be critical in inducing the regulatory 
properties of intestinal Mφ during monocyte differentiation in vitro (Smythies et al. 2005). Individuals 
with LoF mutations in the IL-10R gene develop VEO-IBD and display no suppressive effect of IL10 in 
purified CD14+ monocytes and MDCs after stimulation (Begue et al. 2011; Glocker & Kotlarz 2009; 
Mao et al. 2012). These support the concept that IL-10 and TGFβ perform important non-redundant 
roles in regulating intestinal inflammation with unknown targets. 
Identifying the factors that control the balance of inflammatory and regulatory functions in immune 
cells, can lead to new IBD therapies. For instance, T cells from inflamed mucosa displayed enhanced 
SMAD7 expression (Fantini et al. 2009), inhibiting their ability to respond to TGF, which has been 
targeted with an anti-sense drug (Mongersen) in order to restore responsiveness to TGF 
(Monteleone et al. 2015). Similarly understanding how IL-10 responsiveness is controlled in IBD 
patients could lead to therapeutic interventions involving the IL-10 signalling pathway.   
The aim of the work described in this chapter was to identify MP populations in the human intestine 
and determine their response to IL-10 in health and disease.  
176 
 
6.3 Aims 
 
1. Identify human intestinal MP populations.   
2. Compare the distribution of these populations in non-IBD and inflamed IBD mucosa. 
3. Determine the IL-10 responsiveness of intestinal Mo/moMφs in health. 
4. Compare the response to IL-10 in intestinal Mo/moMφs from non-IBD and inflamed IBD 
mucosa. 
 
6.4 Results  
6.4.1 Identifying intestinal Mo/moMφs  
 
First, a gating strategy was developed to identify human intestinal Mo/moMφs. LPMCs extracted from 
colonic biopsies from a patient with no history of IBD and no visible inflammation (non-IBD patient) 
were labelled with anti-CD45, anti-HLA-DR, and anti-CD14 antibodies. Leucocytes were gated based 
on CD45 expression (Figure 6.1 A). LPMCs were then gated based on FSC and SSC (Figure 6.1 B), 
excluding the dead cells using fixable dye (Appendix 12). Doublet discrimination was carried out 
(Figure 6.1 C and D). HLA-DRhi expression was used to distinguish large APCs (Figure 3.1 E). Finally, 
CD14 marker expression was used to distinguish three intestinal large HLA-DRhi populations: P1 
(CD14hi), P2 (CD14lo), and P3 (CD14-) (Figure 3.1 F). Corresponding isotype controls were used to gate 
each marker (Appendix 13). The distribution of P1 and P2 will be compared between non-IBD, UC and 
CD patients with active disease in Figure 6.5. 
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Figure 6.1: Gating strategy for the identification of human intestinal Mo/moMφs. LPMCs extracted 
from colonic biopsies from a non-IBD patient were labelled with anti-CD45, anti-HLA-DR, and anti-
CD14 antibodies; intestinal Mo/moMφs were then identified by flow cytometry. A) leucocytes were 
gated based on CD45 expression. B) live LPMCs were gated based on FSC and SSC. C, D) doublet 
discrimination was carried out based on size and granularity. E) HLA-DR labelling was then used to 
distinguish large APCs. F) three intestinal Mo/moMφs were distinguished based on their CD14 
expression labelled P1, P2, and P3. 
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The phenotype of P1, P2, and P3 was investigated further using additional markers to confirm their 
identity and purity. LPMCs from a non-IBD patient where labelled with anti-CD45, anti-HLA-DR, and 
anti-CD14 antibodies to distinguish the intestinal Mo/moMφs, and additional antibodies: anti-CD64, 
anti-CD206, anti-CCR2, and anti-CX3CR1. Expression levels of each marker were compared for each 
population to the isotype control for the total HLA-DR+ population using overlaid histograms (Figure 
6.2 A), and bar charts showing expression levels of each marker on the Mo/moMφs in relation to their 
corresponding isotype control. 
CD64 expression has been used to distinguish between intestinal Mo/moMφs (CD64+) and DCs (CD64-
) (Langlet et al. 2012; Tamoutounour et al. 2012). Both P1 and P2 express CD64 whereas P3 do not, 
suggesting that only P1 and P2 are Mo/moMφs. CD206, CX3CR1, and CCR2 were used as markers of 
MP maturation because CD206 and CX3CR1 are upregulated during monocyte differentiation into 
intestinal Mφs, and CCR2 is downregulated in mouse (reviewed by Mowat & Bain, 2011). However, all 
three markers are more highly expressed in P1 than P2. Collectively, these data suggest that P1 and 
P2 are MP populations but the direction of maturation cannot be clearly defined. The spread of the 
histograms indicates some contamination of the populations, which is expected with the overlap in 
marker expression between the APCs.  
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Figure 6.2: Characterisation of the human intestinal Mo/moMφs. LPMCs extracted from colonic 
biopsies from a non-IBD patient (n=1) were labelled with anti-CD45, anti-HLA-DR, and anti-CD14 
antibodies to distinguish the intestinal Mo/moMφs. Additional antibodies were used to further 
characterise the intestinal Mo/moMφs, including anti-CD64, anti-CD206, anti-CX3CR1, and anti-CCR2. 
The sample was then acquired on the flow cytometer. A) overlays represent the expression levels of 
each marker on the Mo/moMφs in relation to the isotype control for the total HLA-DR+ population 
(grey histogram) for illustration. B) expression levels of each marker on each Mo/moMφs population 
in relation to its population specific isotype-matched control.  
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Next, the functional characteristics of the intestinal Mo/moMφs were investigated. One functional 
characteristic of intestinal Mφs is that they are highly phagocytic (Smythies et al. 2005), and therefore 
the phagocytic capacity of the intestinal Mo/moMφs was investigated. LPMCs extracted from colonic 
biopsies from a non-IBD patient were incubated at 4oC (control) and 37oC in the presence of FITC-
labelled microspheres 2.00µm (Polysciences Inc.) at a concentration of 10 microspheres per cell for 
1.5 hours and detected via flow cytometry. Phagocytosis was quantified as the percentage of cells 
positive for FITC-labelled microspheres (above the control). P1 showed the highest proportion of 
phagocytic cells (Figure 6.3), indicating that P1 has a more Mφ phenotype.  
Figure 6.3: Phagocytic capacity of human intestinal Mo/moMφs. LPMCs extracted from colonic 
biopsies from a non-IBD patient (n=1) were incubated at A) 4oC B) 37oC in the presence of FITC-labelled 
microspheres 2.00µm (Polysciences Inc.) at a concentration of 10 microspheres per cell for 1.5 hours. 
The LPMCs were then labelled with anti-CD45, anti-HLA-DR, and anti-CD14 antibodies to identify the 
intestinal Mo/moMφs by flow cytometry.  
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The distribution of APC between P1, P2 and P3 was compared in LPMCs extracted from paired colonic 
and ileum endoscopic biopsies from the same non-IBD patient. There was a greater proportion of P1 
cells in the LPMCs extracted from colonic biopsies than from ileal biopsies, which are the population 
of interest (Figure 6.4). In addition, colonic biopsies were more readily obtainable, and therefore were 
the focus of analyses going forward.  
Figure 6.4: Distribution of intestinal Mo/moMφs from non-IBD colon vs ileum. LPMCs extracted from 
endoscopic biopsies from a non-IBD patient (n=1) were labelled with anti-CD45, anti-HLA-DR, and anti-
CD14 antibodies to distinguish the intestinal Mo/moMφs. The endoscopic biopsies were taken from 
A) the colon or B) the ileum.  
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6.4.2 P2 is increased proportionally in the inflamed mucosa of CD patients 
 
The distribution of HLA-DRhi cells between P1, P2, and P3 was compared between eight non-IBD 
patients, eight UC patients with active disease, and seven CD patients with active disease using LPMCs 
extracted from endoscopic biopsies. The distribution of the populations was assessed as a proportion 
of total HLA-DRhi cells. The proportion of P1, P2 and P3 cells in colonic LPMC from non-IBD patients 
and UC patients with active disease was similar (Figure 6.5 A, B). However, P2 cells were enriched (p 
= 0.0016) at the expense of P1 cells (p = 0.0215) in CD patients with active disease (Figure 6.5 A, B).  
Figure 6.5: Distribution of intestinal Mo/moMφs from non-IBD vs inflamed IBD colon. LPMCs 
extracted from endoscopic biopsies from non-IBD patients (n=8), UC patients (n=8) and CD patients 
(n=7) with active disease were labelled with anti-CD45, anti-HLA-DR, and anti-CD14 antibodies to 
distinguish the intestinal Mo/moMφs before acquiring on the flow cytometer. The distribution of the 
populations was calculated as a percentage of total APCs. A) representative flow cytometry plots 
showing the distribution of intestinal Mo/moMφs in non-IBD patients, CD and UC patients with active 
disease. B) distribution of intestinal Mo/moMφs in non-IBD patients, CD and UC patients with active 
disease. CD and UC patients were compared to non-IBD patients for P1 and P2 using an ordinary one-
way ANOVA. p ≤ 0.05* p ≤ 0.01** p ≤ 0.001*** p ≤ 0.0001****.  
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6.4.3 P1 have a higher capacity for TNFα production  
 
The response of the intestinal Mo/moMφs to LPS stimulation was compared in eight healthy 
individuals focusing on P1 and P2 but not P3 as this population was CD64 negative and unlikely to 
represent monocytes/Mφs. LPMCs were stimulated with 1ng/ml LPS for three hours before staining 
for intracellular TNFα. TNFα production was quantified as the percentage of cells positive for TNFα 
(above the isotype control), and as a per cell level of TNFα production in the TNFα positive cells (MFI). 
Figure 6.6 A, B show representative flow cytometry plots of TNFα staining in P1 and P2 in unstimulated 
and LPS-stimulated cultures respectively. There was detectable TNFα production in unstimulated 
cultures of LPMC which was significantly upregulated upon LPS stimulation. In both unstimulated and 
LPS-stimulated cultures, TNFα production was greater in P1 than in P2 as assessed by either percent 
positive or MFI (Figure 6.6 C). The magnitude of the increase in TNFα upon LPS stimulation was greater 
in P1 as determined on a per cell basis (MFI) but not in terms of the proportion of cells making cytokine 
(Figure 6.6 D), and as a per cell level of TNFα production in the TNFα positive cells (MFI). 
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Figure 6.6: LPS-induced TNFα production by intestinal Mo/moMφs from non-IBD colon. LPMCs 
extracted from endoscopic biopsies from non-IBD patients (n=8) were stimulated with 1ng/ml LPS for 
three hours in the presence of monensin and ADAM17 inhibitor (TMI-005). The LBMCs were labelled 
for anti-CD45, anti-HLA-DR, and anti-CD14 antibodies to distinguish the intestinal Mo/moMφs, fixed, 
permeabilised, and stained intracellularly for TNFα before acquiring on the flow cytometer. 
Representative flow cytometry plots of A) isotype control for TNFα B) baseline and C) LPS-induced 
TNFα production. TNFα production was quantified as a percentage of cells positive MFI. D) TNFα 
production at baseline and upon LPS stimulation. E) TNFα production upon LPS stimulation minus 
baseline TNFα production. Median and IQR is displayed. A paired Wilcoxon tests was used to compare 
two groups of non-normally distributed data. p ≤ 0.05* p ≤ 0.01** p ≤ 0.001*** p ≤ 0.0001***. 
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6.4.4 The IL-10 response of Mo/moMφs from non-IBD mucosa  
 
The response of intestinal Mo/moMφs to IL-10 was compared in eight non-IBD patients. Responses to 
IL-10 were measured by the inhibitory effect of IL-10 on LPS-induced TNFα production. Whole LPMCs 
were stimulated with 1ng/ml LPS with or without 2ng/ml IL-10, for three hours before staining for 
intracellular TNFα. Figure 6.7 A, B show representative flow cytometry plots of TNFα staining in P1 and 
P2 stimulated with LPS in the absence or presence of IL-10 respectively. IL-10 response was measured 
as percentage inhibition of LPS-induced TNFα production at 2ng/ml IL-10 (normalised to control; for 
raw values refer to Appendix 14). 
The proportions of TNFα positive P1 and P2 were both reduced in the presence of IL-10. In four of 
eight P1 samples and two (overlapping) of eight P2 samples, LPS-induced TNFα production was 
completely inhibited in the presence of 2ng/ml IL-10. In contrast, responses of blood monocytes were 
only partially inhibited at the same concentration (Figure 6.7 C). This may indicate that CD14+ cells in 
the steady-state intestinal mucosa have a greater sensitivity to IL-10 than their circulating monocyte 
precursors. 
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Figure 6.7: IL-10 responsiveness of intestinal Mo/moMφs from non-IBD colon. LPMCs extracted from 
endoscopic biopsies from non-IBD patients (n=8) were stimulated with 1ng/ml LPS and 2ng/ml IL-10 
for three hours in the presence of monensin and ADAM17 inhibitor (TMI-005). The LPMCs were 
labelled anti-CD45, anti-HLA-DR, and anti-CD14 antibodies to distinguish the intestinal Mo/moMφs, 
fixed, permeabilised, and stained intracellularly for TNFα before acquiring on the flow cytometer. 
Representative flow cytometry plots showing TNFα production in P1 and P2 upon LPS stimulation A) 
without IL-10 and B) with 2ng/ml IL-10. Percentage inhibition of TNFα production at 2ng/ml IL-10 was 
calculated (minus baseline TNFα production). P1 and P2 from some patients showed 100% inhibition 
of TNFα production at 2ng/ml IL-10, and therefore statistical analysis of these data were not 
conducted. Median and IQR is displayed. 
 
6.4. Comparing the IL-10 response of intestinal MPs from non-IBD and inflamed 
IBD mucosa 
 
One aim of this chapter was to compare TNFα production in intestinal Mo/moMφs and its ability to 
be inhibited by IL-10 in health and IBD. First, TNFα production was compared in P1 and P2 between 
health and IBD. Whole LPMCs from eight non-IBD patients, eight UC patients with active disease, seven 
CD patients with active disease, and four patients in remission (three UC and one CD) were cultured 
alone or stimulated with 1ng/ml LPS for three hours before staining for TNFα intracellularly. TNFα 
production was measured as a percentage of cells positive for TNFα, and as a per cell level of TNFα 
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production in the TNFα positive cells (MFI). Figure 6.8 A and C shows a trend towards increased 
production of TNFα by unstimulated cells from inflamed mucosa of CD patients but not UC patients 
compared to non-IBD patients, although this did not reach statistical significance with this small 
number of heterogeneous samples. This trend was most marked in P1 cells and was evident whether 
percentage positive or MFI was considered. There were no significant differences in the LPS-
stimulated TNFα production in the Mo/moMφs between non-IBD and UC or CD patients with active 
disease. However, this could be because LPS stimulation significantly (p = 0.0002 for P1; p= 0.0011 for 
P2) increased TNFα production in UC patients with active disease but not CD patients (data not 
shown), indicating Mo/moMφs from CD patients may be already maximally activated.  
Figure 6.8: Endogenous and LPS-induced TNFα production by intestinal Mo/moMφs from non-IBD 
and inflamed IBD colon. LPMCs extracted from biopsies from non-IBD patients (n=8), UC patients with 
active disease (n=8), CD patients with active disease (n=7), and four patients in remission (three UC 
and one CD) were stimulated with 1ng/ml LPS for three hours in the presence of monensin and 
ADAM17 inhibitor (TMI-005). The LPMCs were then labelled for anti-CD45, anti-HLA-DR, and anti-
CD14 to antibodies distinguish the intestinal Mo/moMφs, fixed, permeabilised, and stained 
intracellularly for TNFα before acquiring on the flow cytometer. TNFα production was quantified as a 
percentage of cells positive for TNFα, and as a per cell level of TNFα production in the TNFα positive 
cells (MFI). A, B) TNFα production by unstimulated P1 and P2. C, D) increase in TNFα production in P1 
and P2 upon LPS stimulation. Median and IQR is displayed. Data were analysed statistically by Kruskal-
Wallis test. 
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Next, the anti-inflammatory activity of the intestinal Mo/moMφs was compared between non-IBD and 
inflamed IBD mucosa. There is reason to believe that there is enhanced production of IL-10 in the 
inflamed mucosa (detailed in the discussion), therefore, IL-10Rα blocking antibody was used to test if 
endogenous production of IL-10 had a limiting effect on TNF production in unstimulated culture. In 
Chapter 3, this blocking antibody showed efficacy up to 10ng/ml IL-10. LPMCs from three non-IBD 
patients and three CD patients with active disease were cultured for three hours with or without IL-
10Rα blocking antibody before staining for TNFα intracellularly. TNFα production was measured as a 
percentage of cells positive for TNFα, and as a per cell level of TNFα production in the TNFα positive 
cells (MFI). TNFα production in the presence or absence of IL-10Rα blocking antibody was compared. 
There was no significant difference in TNFα production in the presence of anti-IL-10Rα blocking 
antibody in either P1 or P2 cells from both non-IBD and inflamed CD mucosa (Figure 6.9). In addition, 
no IL-10 production by these populations could be detected using intracellular staining. Taken 
together, these observations suggest that over the timespan of these experiments, IL-10 production 
by P1, P2 or other cells in the culture does not impact significantly on TNF production. 
 
Figure 6.9: The effect of IL-10Rα-blocking antibody on TNFα production by P1 and P2. LPMCs 
extracted from endoscopic biopsies from non-IBD patients (n=3) and CD patients with active disease 
(n=3) were cultured for three hours with or without IL-10Rα blocking antibody in the presence of 
monensin. The LPMCs were then labelled for anti-CD45, anti-HLA-DR, and anti-CD14 antibodies to 
distinguish the intestinal Mo/moMφs, fixed, permeabilised, and stained intracellularly for TNFα before 
acquiring on the flow cytometer. TNFα production was measured as a percentage of cells positive for 
TNFα, and as a per cell level of TNFα production in the TNFα positive cells (MFI). The difference in the 
proportion of TNFα positive cells and the percentage change in MFI was calculated for cultures with 
and without IL-10Rα blocking antibody. Median and IQR is displayed. 
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The response of intestinal Mo/moMφs to IL-10 was compared between the eight non-IBD patients, 
eight UC patients with active disease, seven CD patients with active disease, and four patients in 
remission (three UC and one CD). LPMCs were stimulated with 1ng/ml LPS and with or without 2ng/ml 
IL-10 for three hours before staining for intracellular TNFα. IL-10 response was measured as 
percentage inhibition of LPS-induced TNFα production at 2ng/ml IL-10 (normalised to control; for raw 
values refer to Appendix 15). 
P1 and P2 displayed enhanced sensitivity to IL-10 inhibition compared with blood monocytes, and 
multiple patients showed complete inhibition of TNFα production at 2ng/ml IL-10 in P1 and P2 (Figure 
6.9 A, B). Thus, the high sensitivity of intestinal cells to IL-10 discussed above for cells isolated from 
non-IBD tissues was also evident in Mo/moMφs from a number of IBD patients, which limited the 
ability to formally compare responsiveness between health and disease. Nonetheless, it is notable 
that the proportion of UC patients with active disease in which 2ng/ml IL-10 completely inhibited the 
TNFα responses was only half that of controls: 25% vs 50% for P1 cells and 12.5% versus 25% for P2 
cells. For CD patients with active disease, these values were 71% and 57% for P1 and P2 respectively. 
Median levels of inhibition were also lower in cells from UC patients with active disease compared 
with non-IBD patients and CD patients with active disease. In addition, both P1 and P2 cells from the 
three UC patients in remission were poorly controlled by IL-10, similar to those from UC patients with 
active disease, whereas the response of both types of cell from a CD patient in remission was 
completely inhibited, similar to those from CD patients with active disease. Thus, the possibility that 
P1 and P2 cells have an altered response to IL-10 in the different IBD groups merits further 
investigation. 
For patient information refer to Appendix 14. 
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Figure 6.10: IL-10 responsiveness of intestinal Mo/moMφs from non-IBD and inflamed IBD colon. 
LPMCs extracted from endoscopic biopsies from non-IBD patients (n=8), UC patients with active 
disease (n=8), CD patients with active disease (n=7), and four patients in remission (three UC and one 
CD) were stimulated with 1ng/ml LPS and 2ng/ml IL-10 for three hours in the presence of monensin 
and ADAM17 inhibitor (TMI-005). The LPMCs were labelled anti-CD45, anti-HLA-DR, and anti-CD14 
antibodies to distinguish the intestinal Mo/moMφs, fixed, permeabilised and stained intracellularly 
for TNFα before acquiring on the flow cytometer. Percentage inhibition of TNFα production at 2ng/ml 
IL-10 was calculated for A) P1 and B) P2. Median and IQR is displayed. 
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6.5 Discussion 
 
This chapter aimed to assess the impact of the suboptimal response to IL-10 in CD14+ classical blood 
monocytes on CD14+ cells derived from them, in the intestinal mucosa 
Fate mapping techniques, as well as studies in CCR2 deficient mice, have shown that at least part of 
the intestinal Mφ pool requires constant replenishment by circulating monocytes (Bain et al. 2014; 
Yona et al. 2013). During steady-state, newly arrived monocytes lose their inflammatory properties to 
give rise to resident Mφsthat promote immune homeostasis (Bain et al. 2014). During inflammation, 
an accumulation of cells that retain their inflammatory properties (inflammatory Mφs) have been 
described in mice, which are likely to be contributing to the inflammation (Bain et al. 2013). In humans, 
an expansion in the proportion of CD14+ Mφs that retain their capacity to respond to TLR stimulation 
has been reported in CD patients (Kamada et al. 2008; Lissner et al. 2015; Rugtveit et al. 1997; Thiesen 
et al. 2014; M. C. Grimm et al. 1995), resembling the models of intestinal inflammation described in 
mice. In addition, there is direct evidence that there is enhanced monocyte recruitment to the 
inflamed mucosa (Grimm et al. 1995).  
Individual groups have defined human intestinal Mφs using different methods. For example, Bain et 
al., 2013 defined CD14hi and CD14lo populations gated on CD45+Lin-CD103- cells, Bujko et al., 2017 
further sub-grouped the Mφ populations using CD11b expression, and Kamada et al., 2008 simply 
defined a population of CD33+ (MP marker) CD14+ cells. The lack of inconsistency in the criteria used 
to identify Mφs makes it difficult to compare different studies directly.  
The method chosen for characterising intestinal Mo/moMφs was optimised from a collection of the 
work described. CD45 expression was used to distinguish immune cells from non-immune cells and 
aid in eliminating debris. Dead cells and doublets were eliminated using a viability dye and FSC/SSC 
plots. HLA-DR expression was then used to distinguish large APCs, including monocyte, Mφs, DCs, and 
B cells. CD14 expression was finally used to distinguish populations of newly arrived monocytes and 
MDCs. Three populations were identified based on the level of CD14 expression: P1 (CD14hi), P2 
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(CD14lo), and P3 (CD14-). It has been suggested that CD14 is downregulated during monocyte 
differentiation into intestinal Mφs as one mechanism by which inflammatory responses are dampened 
(Smith et al. 2001; Smythies et al. 2005). According to this view, P1 may be the newly arrived 
monocytes, and P2 and P3 represent the stages of monocyte differentiation. However, P1 displayed 
autofluorescence when gated on an empty channel, a feature previously reported in human Mφ 
(Edelson et al. 1985; Li et al. 2012; Halldén et al. 1991), therefore, may appear to express higher CD14. 
Autofluorescence has previously been used to distinguish human alveolar Mφ in tandem with 
antibody labelling (Havenith et al. 1993; Viksman et al. 1994). P1 and P2 were positive for CD64, 
suggesting that P1 and P2 represent MP cells. Bain et al., 2013 alternatively used CD103 to exclude 
DCs, which is less powerful then positively gating for monocytes and MDCs. P3 is unlikely to represent 
MP populations due to absent CD64 expression and are likely to be a heterogeneous population, 
including DCs and B cells.  
The direction of a potential maturational pathway between P1 and P2 was explored by analysing 
additional markers: CD206, CX3CR1, and CCR2, the expression of which are reported to change during 
monocyte differentiation into intestinal Mφs (reviewed by Mowat & Bain, 2011). Enhanced expression 
of CX3CR1 and downregulation in CCR2 expression has been reported during monocyte differentiation 
into intestinal Mφs in mouse (Bain et al., 2013; Bain et al., 2014). However, in humans, there has been 
conflicting data: Bujko et al., 2017 assessed direction of maturation by comparing the transcriptional 
profile of blood monocytes to four MP populations (Mf1-4) and reported downregulation of both 
CX3CR1 and CCR2 from Mf1 to Mf4. CD163, CD209, CD11b, and CD206 are upregulated during 
monocyte maturation into Mφ in mice, and a reduction in their expression has been used 
interchangeably as an indicator of maturation (reviewed by Mowat & Bain 2011). However, all three 
markers tested were more highly expressed in P1 than P2. Collectively, these data suggest that P1 and 
P2 are MP populations but the direction of maturation cannot be clearly defined. The pro-
inflammatory properties of the two populations will be discussed below.   
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The phagocytic capacity of the intestinal Mo/moMφs was investigated because a functional 
characteristic of intestinal Mφs is they are highly phagocytic (Smythies et al. 2005). P1 showed the 
highest phagocytic capacity, indicating that P1 has a more Mφ phenotype. This is not consistent with 
the idea that CD14 is downregulated during monocyte differentiation into Mφ (Smythies et al. 2005).  
The distribution of the MP populations extracted from endoscopic biopsies was compared between 
the colon and the ileum. There was a greater proportion of P1 in the colon, and colonic biopsies are 
more readily accessible, therefore, colonic biopsies were used for subsequent experiments. Thiesen 
et al., 2014 also showed that was a greater proportion of HLA-DR+CD14+ cells in the uninflamed colon 
compared to the ileum. In mice, the higher rate of Mφ replenishment in the large intestine compared 
to the small intestine is considered to be due to the higher commensal burden in the colon compared 
with the small intestine, which is relatively devoid of commensal bacteria (Bain et al., 2014; Ginhoux 
& Guilliams, 2016; Ginhoux & Jung, 2014; O’Hara & Shanahan, 2006). 
The distribution of P1 and P2 was compared between non-IBD and inflamed mucosa from CD and UC 
patients. The distribution of P1 and P2 in non-IBD patients and UC patients with active disease were 
comparable, whereas CD patients with active disease displayed a significant increase in the proportion 
of P2 and a decrease in P1. Previous studies in CD patients reported an increase in the proportion of 
CD14+ Mφs (Kamada et al. 2008; Lissner et al. 2015; Rugtveit et al. 1997; Thiesen et al. 2014; M. C. 
Grimm et al. 1995) but they did not distinguish CD14hi and CD14lo populations, therefore, the reported 
increase in CD14+ cells could be attributable to an accumulation of P2 cells. A weakness in 
proportional data is that a change in one population leads to an opposing effect on another population 
and it cannot give information about changes in cell numbers.  
The inflammatory properties of P1 and P2 were measured by stimulating with LPS and detecting TNFα 
production. In contrast to blood monocytes, intestinal P1 and P2 both produced detectable TNFα in 
the absence of overt stimulation, which may reflect exposure during isolation or to activating 
components present in the intestine. Nonetheless, the addition of LPS significantly increased TNFα 
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production by both populations to a similar degree. This is not consistent with previous observations 
that human SI Mφs did not produce pro-inflammatory cytokines in response to TLR stimulation (Smith 
et al. 2001; Smythies et al. 2005). However, both studies used counterflow centrifugal elutriation to 
purify SI Mφs that were CD14- (Smith et al. 1997) and by definition CD14- cells were excluded from 
my analysis. CD14 is a co-receptor of TLR4, in the induction of pro-inflammatory responses 
(Dobrovolskaia & Vogel 2002), and in its absence response to LPS may be reduced or absent. P1 and 
P2 both express CD14, and this may explain their retained ability to respond to TLR4 activation and 
mandate active regulation by components such as IL-10 to prevent their inflammatory activation in 
the mucosa. Nonetheless, P1 had higher TNFα production, judged as the level of production in TNFα 
positive cells, in both unstimulated and LPS-stimulated cultures, suggesting these cells may have 
greater inflammatory potential, which may be consistent with the concept that these are newly 
recruited monocytes. Further characterisation of the Mo/moMφs is required using additional markers 
and functional properties, such as bactericidal activity, to better define the populations and to resolve 
the currently conflicting information about potential development relationships.  
The response of steady-state P1 and P2 cells to IL-10 was measured in cells from non-IBD patients. 
There were insufficient cells to test IL-10 across a range of concentration. Instead, a single 
concentration of 2ng/ml IL-10 was chosen because in earlier experiments on blood monocytes, this 
concentration caused an intermediate level of inhibition. However, in several intestinal samples, 
2ng/ml IL-10 completely inhibited TNFα production. This made it difficult to compare responsiveness 
across different cell populations. Nonetheless, it is notable that, in this small sample, complete 
inhibition was more frequent with P1 than P2 cells (50% versus 25%). Thus, as with blood monocyte, 
the population with high pro-inflammatory potential is more sensitive to control by IL-10. These 
results indicate that intestinal Mo/moMφs are more responsive to IL-10 than blood monocytes, and 
this may reflect an increased need to control their inflammatory activity in a microbe-rich 
environment. 
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Next, the pro-inflammatory capacity of P1 and P2 was compared between non-IBD patients and 
patients with active IBD by stimulating with LPS and measuring TNFα production. The proportion of 
TNFα producing cells and the level of TNFα production in unstimulated cultures and upon LPS 
stimulation did not differ between mucosa from non-IBD patients and inflamed mucosa from CD and 
UC patients in either P1 or P2. This is consistent with the findings in mouse where Bain et al., 2013 
showed that the phenotype of the existing Mφs did not change during intestinal inflammation, instead 
there was an accumulation of immature Mφs which retain their inflammatory properties. However, 
studies in humans have shown enhanced production of pro-inflammatory cytokines by CD14+ cells 
from inflamed mucosa compared with non-inflamed: Kamada et al., 2008 showed that the CD14+ 
population isolated from the inflamed mucosa of CD patients had enhanced mRNA expression and 
production of pro-inflammatory cytokines, including TNFα and IFNγ, upon stimulation but that only 
IL-6 mRNA was enhanced in CD14+ cells isolated from the inflamed mucosa of UC patients. Ogino et 
al., 2013 showed enhanced production of inflammatory cytokines, including TNFα and IL-6, as well as 
upregulation of anti-inflammatory genes IL-10 and TGFβ, in the CD14+ population isolated from the 
non-inflamed mucosa of IBD patients compared to non-IBD patients, and this capacity was further 
enhanced in the inflamed mucosa of IBD patients. The contrast between the findings in this chapter 
and these two studies may be explained by TNFα production being measured via intracellular staining 
in this assay but mRNA expression and excreted cytokine was measured by Kamada et al., 2008 and 
Ogino et al., 2013. TNF secretion is regulated at multiple levels. 
The anti-inflammatory activity of the intestinal Mo/moMφs was also compared between mucosa from 
non-IBD patients and inflamed mucosa from CD and UC patients by measuring IL-10 production. In 
mice, intestinal Mφs display constitutive production of IL-10 (Bain et al. 2013; Krause et al. 2015; 
Rivollier et al. 2012). However, there is conflicting data on the constitutive production of IL-10 by 
human intestinal Mφs. Bujko et al. 2017., did not detect IL-10 production by human jejunal Mφs at 
baseline or upon TLR activation, which is in support of previous studies reporting a lack of IL-10 
production by human jejunal Mφs (Smythies et al. 2005; Smythies et al. 2010). In contrast, human 
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colonic Mφs have been shown to produce IL-10 at baseline and upregulate upon activation (Kamada 
et al. 2008; Ogino et al. 2013). IL-10 producing Mφs have been shown to be more frequent in the large 
intestine compared with small intestine in the mouse (Krause et al. 2015). If this is true in humans, it 
could account for the different findings reported with jejunal and colonic Mφs. There is reason to 
believe that there is an increase in IL-10 production in the inflamed intestine. In humans, an increase 
in expression of mRNA for IL-10 has been observed in the CD14+ population isolated from the mucosa 
of CD patients compared with non-IBD patients (Ogino et al. 2013), which could reflect an increase in 
IL-10 production. To asses a potential role for IL-10 production in my cultures, an IL-10Rα blocking 
antibody was used to test whether endogenous IL-10 was affecting TNFα production by LPMCs.  
However, there was no increase in TNFα production in the presence of IL-10Rα blocking antibody in 
either P1 or P2 cells from non-IBD and inflamed IBD mucosa. Neither were IL-10 positive P1 or P2 cells 
detectable by intracellular staining. These data indicate that over the timespan of the cultures in these 
experiments, IL-10 production by CD14+ cells, or other populations is unlikely to influence TNF 
production, and therefore the apparent increase in sensitivity to IL-10 in intestinal cells cannot be 
attributed to production within the culture. 
Finally, the high sensitivity of intestinal Mo/moMφs to IL-10 in healthy individuals was also reflected 
in IBD patients, suggesting that there is not a gross loss in IL-10 response of Mo/moMφs in these active 
IBD patients. However, the sensitivity of the assay is reduced when responses of cells from donors are 
completely inhibited by IL-10 making it difficult to draw conclusions with respect to differences in 
response to IL-10 between health and disease. Nonetheless, it is notable that there is a trend 
suggesting that P1 and P2 from UC patients with active disease display a reduced response to IL-10 
inhibition when compared with non-IBD patient and CD patients with active disease, and this pattern 
is reflected in the inactive IBD cohort. Reducing the concentration of IL-10 used in these experiments 
would increase the sensitivity of the assay and allow for a more meaningful comparison of IL-10 
response between non-IBD patients and patients with active IBD.  
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6.6 Conclusion  
 
The implications of a suboptimal response to IL-10 inhibition in classical monocytes was investigated 
in CD14+ monocyte-derived cells in the intestine. Two populations were identified based on CD14 
expression: CD14hi (P1) and CD14lo (P2). Both populations spontaneously produce TNFα and 
production was enhanced with LPS stimulation. The intestinal populations were more sensitive to IL-
10 control than blood monocytes, making it difficult to draw conclusions with respect to differences 
in response to IL-10 between the two populations and health and IBD. These experiments are being 
refined to increase sensitivity and allow meaningful comparisons. 
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Chapter 7: Final discussion and future work 
 
The primary aim of the project was to identify MP populations in the blood and intestinal biopsies, 
determine their responsiveness to IL-10 and whether this response is altered in IBD patients, and 
finally begin to explore how such changes might contribute to the pathogenesis of IBD.  
First, an assay that could measure IL-10 responsiveness in human monocyte subsets was developed. 
The three monocyte subsets were distinguished based on CD14 and CD16 expression: classical 
(CD14++CD16-), intermediate (CD14++CD16+), and non-classical (CD14+CD16++) monocytes. The 
assay for measuring IL-10 response involved LPS induction of TNFα production, which lead to an 
apparent loss of CD16+ cells. Shedding of the CD16 marker upon activation had previously been 
reported in NK cells, which could be blocked by an ADAM17 inhibitor (Romee et al. 2013). Therefore, 
an ADAM17 inhibitor was added to the cultures and CD16 expression was maintained upon activation, 
which enabled the responsiveness to IL-10 of all three monocyte subsets to be determined in parallel. 
CD16 is an activating Fc receptor for IgG (reviewed by Guilliams et al. 2014), therefore, the process of 
CD16 shedding may help limit ADCC or further stimulation by cross-linking immune complexes. The 
shedding of CD16 from the surface of monocytes upon activation also has important implications for 
the identification of monocyte-derived cells within the intestine and other tissues that are constantly 
exposed to foreign antigens. Caution should be applied when interpreting an absence of CD16 
expression on cells in tissues as an absence of cells derived from intermediate or non-classical 
populations because CD16 may have been lost from the surface of such cells. 
Induction of TNFα production with LPS was compared between the monocyte subsets. Intermediate 
monocytes displayed the highest TNFα production, followed by classical monocytes, and least 
responsive to TLR4 activation were the non-classical monocytes. The hierarchy of LPS response can in 
part be explained by CD14 expression as the co-receptor for TLR4 (Beutler et al., 2000). The finding 
that classical and intermediate monocytes are robust responders to TLR stimulation and non-classical 
monocytes are poorly activated, is generally consistent with previously published studies using similar 
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agonists (Belge et al. 2002; Boyette et al. 2017; Cros et al. 2010; Thiesen et al. 2014). However, Cros 
et al., 2010 showed that TLR7 and TLR8 agonists, not tested in the current study, are robust activators 
of non-classical monocytes and stimulate the production of TNFα, IL-6, and IL-1β. This indicates that 
under appropriate stimulation these cells have a greater capacity to produce pro-inflammatory 
cytokines than was previously appreciated.  
The ability to inhibit LPS-induced TNFα production with IL-10 was then compared between monocyte 
subsets in healthy individuals. IL-10 inhibition of LPS-induced TNFα was greatest in classical 
monocytes, followed by intermediates, and least responsive were the non-classical monocytes despite 
low levels of TNFα production. The robust response of classical monocytes to IL-10 inhibition supports 
the concept that IL-10 is a critical mechanism by which their inflammatory properties can be controlled 
and may play an important role in acquiring regulatory properties during differentiation into intestinal 
Mφs (Bain et al. 2013; Kayama et al. 2012; Shouval et al. 2014; Takada et al. 2010; Zigmond et al. 
2014). The contribution of intermediate monocytes to the human intestinal Mφ pool remains unclear 
due to the lack of unique identifiers, and the possibility that CD16 is shed upon entry into the intestine. 
The robust response of intermediate monocytes to TLR activation in combination with a suboptimal 
response to IL-10 inhibition may make them important contributors to bacterial driven inflammation, 
including of IBD. Although non-classical monocytes respond relatively poorly to LPS stimulation in 
comparison to classical and intermediate monocytes in the absence of added IL-10, their response is 
maintained in the presence of IL-10 and under these conditions is equivalent to the other two subsets. 
Auffray et al., 2007 showed that non-classical monocytes undergo rapid extravasation at sites of 
infection and contribute to the initial inflammatory response. A lack of response to IL-10 in the tissues 
could enhance this response. In the context of intestinal inflammation, non-classical monocytes 
entering the mucosa would be poorly regulated by IL-10 and may perpetuate the inflammation.  
Next, the aim was to determine whether differences in monocytes subset responses to IL-10 were 
specific to the mode of activation (LPS) or functional readout (TNFα production). LPS signals down two 
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pathways: MyD88- and TRIF-dependent (Lu et al. 2008). LPS was compared to two stimulants chosen 
to target these signalling pathways: Pam3CSK4 triggers the MyD88 pathway, while Poly(I:C) activates 
TRIF. TNFα production was also compared to two additional readouts: IL-1β and IFNα induced by 
MyD88 and TRIF pathways respectively (Akira & Takeda 2004). Consistent with LPS-induced TNFα 
production, intermediate monocytes showed the highest cytokine production with all TLR agonists 
tested, followed by classical, and least responsive were the non-classical monocytes. Generally, the 
hierarchy of responses of the monocyte subsets to IL-10 inhibition of TNFα production is comparable 
between TLR agonists tested. The differential responses of the monocyte subsets to IL-10 inhibition 
was less evident when IL-1β and IFNα were used as readouts, most likely due to the limited sensitivity 
of the assay when the response was very high (IL-1β) or low (IFNα). Overall, these data show that the 
inflammatory properties of the monocyte subsets are not TLR-specific, and the capacity of IL-10 to 
inhibit TNFα production in the monocyte subset is also independent of the inducer. 
Signalling components of the IL-10R signalling pathway were investigated to provide a possible 
explanation for the differences found in IL-10 response between monocyte subsets. These included 
IL-10Rα expression, STAT3 availability and phosphorylation, and SOCS3 mRNA expression. IL-10Rα 
expression was highest in intermediate monocyte and lowest in classical monocytes, which makes IL-
10Rα expression a poor indicator of the ability of IL-10 to inhibit pro-inflammatory cytokine 
production. Relatively high expression of IL-10Rα on intermediate monocytes in combination with 
their robust response to TLR activation provides evidence that their phenotype is distinct from both 
classical and non-classical monocytes, and therefore challenges the concept that intermediate 
monocytes are merely a population transiting between classical and non-classical monocytes.  
Classical and intermediate monocytes expressed high and equivalent levels of STAT3, while non-
classical monocytes expressed lower levels of STAT3, which correlated well with levels of STAT3 
phosphorylation upon IL-10 stimulation. This may explain why non-classical monocytes are less 
responsive to IL-10 than the other two subsets but does not explain the difference between classical 
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and intermediates. The difference in IL-10 response between classical and intermediate monocytes 
could be due to higher TNFα production in intermediate monocytes because as suggested by the 
experiment in which IL-1β was measured, stronger responses are harder to inhibit. In addition, PCR 
data show that classical monocytes also express higher levels of SOCS3 mRNA at steady-state than 
both intermediate and non-classical monocytes. One role of SOCS3 protein is inhibiting the NFκB 
pathway, therefore, increased expression may provide a mechanism behind enhanced IL-10 
responsiveness. Investigating SOCS3 protein levels directly was hindered by low cell numbers, and 
therefore mRNA expression at baseline was used as a potential surrogate measure. SOCS3 protein 
levels remain to be assessed, and pooling of samples across donors could be used to overcome the 
limitations of low cell numbers in future experiments. It would also be worthwhile to investigate the 
level of IL-10 induced SOCS3 mRNA or protein expression.  
The IL-10 responsiveness of the monocytes subsets was compared between healthy individuals and 
patients with active IBD to determine whether this response is altered in the presence of intestinal 
inflammation. Classical monocytes were the only subset that displayed a reduced response to IL-10 in 
IBD patients compared with healthy controls. This may have important implications in IBD as fate-
mapping experiments in mice point to classical monocytes as the origin of intestinal Mφ (Bain et al. 
2014). Bain et al. 2013 demonstrated a context-dependent differentiation of newly arrived monocytes 
in mice. The inflammatory properties of the newly arrived monocytes are downregulated during 
differentiation into resident Mφs in steady-state. However, during intestinal inflammation, this 
pathway is disrupted causing an accumulation of cells that retain their ability to respond to TLR ligands, 
and these inflammatory Mφs are likely to perpetuate the inflammation (Bain et al. 2013). In humans, 
an expansion in the proportion of CD14+ Mφs that retain their capacity to respond to TLR stimulation 
has been reported in CD patients (M. C. Grimm et al. 1995; Kamada et al. 2008; Lissner et al. 2015; 
Rugtveit et al. 1997; Thiesen et al. 2014), which resembles the situation described in intestinal 
inflammation in mice. The signals responsible for the fate of the newly recruited monocytes are poorly 
understood. The studies described previously by Zigmond et al., 2014 and Shouval et al., 2014 indicate 
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that IL-10 has an important non-redundant role during monocyte differentiation into ‘regulatory’ Mφ. 
In support of this, classical monocytes showed a robust response to IL-10, suggesting an important 
role for IL-10 in regulating their inflammatory properties. The reduction in IL-10 response could favour 
the accumulation of inflammatory Mφs, which may contribute to the sustainment of intestinal 
inflammation. In vitro models, such as those used by Smythies et al. 2005, could be used to further 
investigate the role of IL-10 in during monocyte maturation into intestinal Mφ. 
There is increasing evidence in both mice and humans that systemic signals from the intestine during 
inflammation cause functional changes to circulating cells (Arts et al. 2018; Askenase et al. 2015; Christ 
et al. 2018; Mitroulis et al. 2018; Sanders et al. 2014; Smith et al. 2009). This formed the rationale for 
studying blood monocytes, as the likely precursors of intestinal Mφ. The reduction in IL-10 response 
observed in circulating classical monocytes of IBD patients is consistent with the concept that systemic 
signals, as well as the local environment, can have an impact on monocyte fate.  
Signalling components of the IL-10R signalling pathway were investigated to explore the possible 
mechanisms behind the reduced response to IL-10 in classical monocytes from IBD patients. The 
reduced response to IL-10 was despite increased IL-10Rα expression. Higher expression of Il-10Rα may 
explain the enhanced capacity to phosphorylate STAT3 following IL-10 stimulation in classical 
monocytes from IBD patients despite comparable levels of T-STAT3 within the cell. In addition, 
baseline SOCS3 mRNA levels showed a trend towards increased expression in IBD. These IBD-
associated changes may demonstrate negative feedback mechanisms conditioned to return the 
immune system to steady-state. However, the signalling components investigated thus far do not 
provide a mechanism for the reduced response to IL-10 in classical monocytes of IBD patients, 
indicating that unknown mechanisms are regulating IL-10 responsiveness. Global phosphorylation 
analysis could be used to look at IL-10 signalling components globally and compare health and disease 
to expose changes that may account for the reduced response.  
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Figure 7: Summary Diagram. 
The distribution of the monocyte subsets in health and IBD was investigated. Non-classical monocytes, 
but not classical or intermediate cells, were significantly reduced in proportion and cell number in IBD 
patients in two separate cohorts. This is in contrast to Thiesen et al. 2013 and Grip et al., 2006 who 
both reported an increase in the proportion of intermediate monocytes in CD patients. The contrasting 
results could be because different gating strategies were used to identify the monocyte subsets.  
The loss of non-classical monocytes in circulating blood could be due to increased recruitment to the 
inflamed intestine as this population has been shown to be recruited into inflamed tissues, initially 
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contributing to the inflammatory response before switching on reparative functions (Auffray et al. 
2007). Alternatively, changes to the endothelial wall induced by intestinal inflammation may make the 
non-classical monocytes more adherent to the surface and appear less abundant in the blood. 
Enhanced death of non-classical monocytes in the IBD patients could account for fewer circulating 
cells but the impact of intestinal inflammation on the half-life of the monocyte subsets has not been 
studied. Another possible explanation for the loss of non-classical monocytes in circulating blood could 
be that fewer classical monocytes are available to mature into non-classical cells due to enhanced 
recruitment into the inflamed intestine (Grimm et al., 1995). Regardless of the precise mechanism, 
any loss of non-classical monocytes from the circulation could have important implications for tissue 
repair as this is their ultimate function after recruitment (Auffray et al. 2007). Reduced recruitment of 
reparative monocytes could contribute to tissue damage and inflammation in IBD.  
The implications of a suboptimal response to IL-10 inhibition observed in classical monocytes was 
investigated in CD14+ monocyte-derived cells in the intestine. First, these cell populations were 
identified in LPMCs extracted from intestinal biopsies. Expression of HLA-DR, CD14, and CD64 was 
used to distinguish two CD14-expressing populations both of which expressed the Mo/Mφ marker 
CD64: P1 (HLA-DRhiCD14hiCD64+) and P2 (HLA-DRhiCD14loCD64+).  
LPS-induced TNFα production was measured using LPMCs extracted from intestinal biopsies from non-
IBD patients. Both P1 and P2 were responsive to LPS stimulation but less than in blood monocytes, 
which supports the concept that inflammatory responses of newly arrived monocytes are regulated. 
In contrast to blood monocytes, intestinal P1 and P2 produced detectable TNFα in the absence of LPS, 
which may reflect the constant exposure to external antigens in the intestine. Addition of LPS 
significantly increased TNFα production by both populations to a similar degree. In both unstimulated 
and LPS-stimulated cultures, TNFα production was greater in P1 than in P2 as assessed by either 
percent positive or MFI, which suggests these cells have greater inflammatory potential indicating 
newly recruited monocytes. However, P1 was more phagocytic than P2 indicating that P1 has a more 
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Mφ phenotype. Further characterisation of the two populations is required using functional properties 
such as bactericidal activity. Although P2 expressed less CD14, their capacity to respond to LPS was 
not diminished, which is not consistent with the concept that newly arrived monocytes downregulate 
TLR expression and become anergic to activation during maturation into intestinal Mφ (Smith et al. 
2001; Smythies et al. 2005). However, it is not known that P2 is derived from P1. 
TNFα production at baseline and upon LPS stimulation did not differ in P1 and P2 between non-IBD 
and inflamed IBD mucosa. This compliments the findings by Bain et al., 2013 in mice that showed the 
phenotype of the resident Mφ did not change, instead, there is an accumulation of immature Mφ 
which retain their inflammatory properties. However, in humans, studies have shown enhanced 
production of pro-inflammatory cytokines in CD14+ cells from inflamed mucosa compared to non-
inflamed (Kamada et al. 2008; Ogino et al. 2013). The contrasting results could be because Kamada et 
al., 2008 measured secreted cytokine and Ogino et al., 2013 measured mRNA expression.  
The distribution of P1 and P2 was compared between non-inflamed and inflamed mucosa. The 
distribution of P1 and P2 in non-IBD patients and patients with active UC were comparable but 
patients with active CD displayed a significant increase in the proportion of P2 and a decrease in P1. 
This is in contrast to previous findings in CD patients that showed an increase in the proportion of 
CD14+ Mφs (Grimm et al., 1995; Rugtveit et al., 1997; Kamada et al., 2008; Thiesen et al., 2014; Lissner 
et al., 2015). The contradicting results could be due to the lack of consistent markers used to 
characterise intestinal Mφ populations in humans. 
Finally, the capacity of IL-10 to inhibit LPS-induced TNFα production was measured in P1 and P2 using 
2ng/ml IL-10 chosen on the basis of experiments carried out on blood monocytes. However, in 
multiple samples, there was 100% inhibition, and therefore it was difficult to conclude with respect to 
differences in IL-10 response between P1 and P2. These data may also indicate that intestinal CD14+ 
cells have an enhanced response to IL-10 compared with circulating monocytes, their putative 
precursors. Whether this enhanced response to IL-10 is directly due to greater sensitivity to lL-10 itself 
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or because the lower response to LPS observed with intestinal cells is more readily inhibited cannot 
be distinguished currently. There was no evidence that IL-10 production by intestinal cells in the 
culture contributed. A lower concentration of IL-10 is required to increase the sensitivity of the assay 
and allow meaningful comparisons between health and IBD.  
Overall, this thesis has demonstrated that IL-10 is a critical mechanism by which the inflammatory 
properties of classical monocytes can be controlled but it may play a less prominent role in the control 
of responses by other subsets. Understanding the environmental cues determining the fate of 
monocyte-derived cells in the intestine and how these cues differ between health and disease is likely 
to be a key area for future research. Modulating monocyte maturation to favour differentiation into 
regulatory Mφ may provide new therapeutic targets for treating IBD. 
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Appendix 
 
 
Appendix 1: Example of a melt curve. Purity of the amplified product was verified by melt curve 
analysis. For the SOCS3 amplified product there is a single discrete change in fluorescence at a specific 
temperature indicating a pure product. 
 
 
Appendix 2: Titration of cell number input. Whole PBMCs from a healthy donor were labelled with 
anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish the monocyte subsets before sorting 
on the FACS Aria (BD). 1x106 classical monocytes were sorted and titrated (800,000-12,500 cells) down 
past the cell number present in the experimental samples to be analysed (>50,000 cells) and showed 
a reliable deltaCT could be calculated above 25,000 cells.  
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Appendix 3: Titration of RNA input concentration. Whole PBMCs from a healthy donor were labelled 
with anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish the monocyte subsets before 
sorting on the FACS Aria (BD). 1x106 classical monocytes were sorted and the concentration of RNA 
measured using Nanodrop. A titration of a known concentration of RNA (100-3.125ng/μL) was used 
to determine the lowest RNA concentration that allowed calculation of a reliable deltaCT, and showed 
a reliable deltaCT could still be calculated at the lowest concentration of RNA tested.  
 
 
Appendix 4a: Representative flow cytometry plots of TNFα isotype controls. Healthy donor PBMCs 
were stimulated or not with 1ng/ml LPS for three hours in the presence of monensin. The PBMCs were 
then labelled for anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish the monocytes 
subsets, fixed, permeabilised and labelling intracellularly with corresponding isotype controls for anti-
TNFα antibody before acquiring on the flow cytometer.   
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Appendix 4b: Marker expression and cell numbers of monocyte subsets upon LPS stimulation. 
Healthy donor PBMCs (n=21) were stimulated with LPS (0.1/1ng/ml) for three hours in the presence 
of monensin. The PBMCs were then labelled with anti-HLA-DR, anti-CD14, and anti-CD16 antibodies 
to distinguish the monocytes subsets before acquiring on the flow cytometer. A) absolute cell 
numbers of classical, intermediate, and non-classical monocytes upon stimulation with 0.1/1ng/ml 
LPS. Median and IQR is displayed for non-normally distributed data sets. The data were analysed 
statistically by Kruskal-Wallis test. p ≤ 0.05* p ≤ 0.01** p ≤ 0.001*** p ≤ 0.0001***. B) level of CD14 
and CD16 marker expression (MFI) on the monocyte subsets upon stimulation with 0.1/1ng/ml LPS 
normalised to control (where unstimulated cells represent 100% expression).  
 
 
Appendix 5: Analysis of 10x ChromiumTM Single Cell 5′ and 3′ gene expression data using LoupeTM 
cell browser (10X genomics). The monocyte subsets were identified on the basis of CD14 and CD16 
gene expression. Expression levels of selective genes along the IL-10R pathway were analysed in the 
monocyte subsets.  
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Appendix 6a: Patient data. Several IBD patients were receiving combination therapies at the time of 
blood collection.  
 
Appendix 6b: Stratification of IL-10Rα expression data from IBD cohort into CD vs UC. Whole blood 
from 21 CD and 8 UC patients were labelled with anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to 
distinguish the monocyte subsets, and IL-10Rα before acquiring on the flow cytometer. IL-10Rα 
expression was quantified as A) percentage of cells positive for IL-10Rα and B) MFI calculated as MFI 
for staining with anti-IL-10Rα antibody minus MFI for staining with an isotype-matched control 
antibody for each monocyte subset. Mean and SD are displayed for normally distributed data sets, 
while median and IQR are displayed for non-normally distributed data sets. An unpaired T-tests was 
used to compare two groups of normally distributed data, while a Mann-Whitney test was used to 
compare two groups of data that were non-normally distributed.  
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Appendix 6c: Stratification of IL-10Rα expression data from IBD cohort into active vs inactive. Whole 
blood from 15 active and 16 inactive patients were labelled with anti-HLA-DR, anti-CD14, and anti-
CD16 antibodies to distinguish the monocyte subsets, and IL-10Rα before acquiring on the flow 
cytometer. IL-10Rα expression was quantified as A) percentage of cells positive for IL-10Rα and B) MFI 
calculated as MFI for staining with anti-IL-10Rα antibody minus MFI for staining with an isotype-
matched control antibody for each monocyte subset. Mean and SD are displayed for normally 
distributed data sets, while median and IQR are displayed for non-normally distributed data sets. An 
unpaired T-tests was used to compare two groups of normally distributed data, while a Mann-Whitney 
test was used to compare two groups of data that were non-normally distributed.  
 
Appendix 6d: Stratification of IL-10Rα expression data from IBD cohort into active CD vs active UC. 
Whole blood from 10 active CD and 5 active UC patients were labelled with anti-HLA-DR, anti-CD14, 
and anti-CD16 antibodies to distinguish the monocyte subsets, and IL-10Rα before acquiring on the 
flow cytometer. IL-10Rα expression was quantified as A) percentage of cells positive for IL-10Rα and 
B) MFI calculated as MFI for staining with anti-IL-10Rα antibody minus MFI for staining with an isotype-
matched control antibody for each monocyte subset. Mean and SD are displayed for normally 
distributed data sets, while median and IQR are displayed for non-normally distributed data sets. An 
unpaired T-tests was used to compare two groups of normally distributed data, while a Mann-Whitney 
test was used to compare two groups of data that were non-normally distributed.  
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Appendix 6e: Stratification of IL-10Rα expression data from IBD cohort into treatment groups. 
Whole blood from 5 patients on steroids, 18 on IM, 7 on anti-TNFα, and 7 on none of the above 
treatments were labelled with anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish the 
monocyte subsets, and IL-10Rα before acquiring on the flow cytometer. IL-10Rα expression was 
quantified as A) percentage of cells positive for IL-10Rα and B) MFI calculated as MFI for staining with 
anti-IL-10Rα antibody minus MFI for staining with an isotype-matched control antibody for each 
monocyte subset. Mean and SD are displayed for normally distributed data sets, while median and 
IQR are displayed for non-normally distributed data sets. An unpaired one-way ANOVA for normally 
distributed data sets, while a Kruskal-Wallis test was used to compare two groups of unpaired data 
that were non-normally distributed.  
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Appendix 7a: Patient data. Several IBD patients were receiving combination therapies at the time of 
blood collection.  
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Appendix 7b: Stratification of monocyte subset distribution data from IBD cohort into CD vs UC. 
Whole blood from 28 CD and 11 UC patients were labelled with anti-HLA-DR, anti-CD14, and anti-CD16 
antibodies to distinguish the monocyte subsets before acquiring on the flow cytometer. Monocyte 
subset distribution was calculated as A) percentage of PBMCs, B) percentage of total monocyte, and 
C) absolute cell number. Mean and SD are displayed for normally distributed data sets, while median 
and IQR are displayed for non-normally distributed data sets. An unpaired T-tests was used to compare 
two groups of normally distributed data, while a Mann-Whitney test was used to compare two groups 
of data that were non-normally distributed.  
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Appendix 7c: Stratification of monocyte subset distribution data from IBD cohort into active vs 
inactive. Whole blood from 21 active and 20 inactive patients were labelled with anti-HLA-DR, anti-
CD14, and anti-CD16 antibodies to distinguish the monocyte subsets before acquiring on the flow 
cytometer. Monocyte subset distribution was calculated as A) percentage of PBMCs, B) percentage of 
total monocyte, and C) absolute cell number. Mean and SD are displayed for normally distributed data 
sets, while median and IQR are displayed for non-normally distributed data sets. An unpaired T-tests 
was used to compare two groups of normally distributed data, while a Mann-Whitney test was used 
to compare two groups of data that were non-normally distributed.  
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Appendix 7d: Stratification of monocyte subset distribution data from IBD cohort into active CD vs 
active UC. Whole blood from 12 active CD and 8 active UC patients were labelled with anti-HLA-DR, 
anti-CD14, and anti-CD16 antibodies to distinguish the monocyte subsets before acquiring on the flow 
cytometer. Monocyte subset distribution was calculated as A) percentage of PBMCs, B) percentage of 
total monocyte, and C) absolute cell number. Mean and SD are displayed for normally distributed data 
sets, while median and IQR are displayed for non-normally distributed data sets. An unpaired T-tests 
was used to compare two groups of normally distributed data, while a Mann-Whitney test was used 
to compare two groups of data that were non-normally distributed.  
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Appendix 7e: Stratification of monocyte subset distribution data from IBD cohort into treatment 
groups. Whole blood from 5 patients on steroids, 23 on IM, 8 on anti-TNFα, and 11 on none of the 
above treatments were labelled with anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish 
the monocyte subsets before acquiring on the flow cytometer. Monocyte subset distribution was 
calculated as A) percentage of PBMCs, B) percentage of total monocyte, and C) absolute cell number. 
Mean and SD are displayed for normally distributed data sets, while median and IQR are displayed for 
non-normally distributed data sets. An unpaired one-way ANOVA for normally distributed data sets, 
while a Kruskal-Wallis test was used to compare two groups of unpaired data that were non-normally 
distributed.  
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Appendix 8a: Patient data. Several IBD patients were receiving combination therapies at the time of 
blood collection.  
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Appendix 8b: Monocyte subset distribution in health and IBD. Whole blood from 18 healthy controls 
and 19 IBD patients with active disease were labelled with anti-HLA-DR, anti-CD14, and anti-CD16 
antibodies to distinguish the monocyte subsets before acquiring on the flow cytometer. Monocyte 
subset distribution was calculated as A) percentage of PBMCs, B) percentage of total monocyte, and 
C) absolute cell number. Mean and SD are displayed for normally distributed data sets, while median 
and IQR are displayed for non-normally distributed data sets. An unpaired T-tests was used to compare 
two groups of normally distributed data, while a Mann-Whitney test was used to compare two groups 
of data that were non-normally distributed. p ≤ 0.05* p ≤ 0.01** p ≤ 0.001*** p ≤ 0.0001****. 
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Appendix 9a: Stratification of monocyte subset distribution data from IBD cohort into active CD vs 
active UC. Whole blood from 9 CD and 8 UC patients were labelled with anti-HLA-DR, anti-CD14, and 
anti-CD16 antibodies to distinguish the monocyte subsets (excluding CD103+ cells), and β7 before 
acquiring on the flow cytometer. β7 expression was quantified as A) percentage of cells positive for 
β7 and B) MFI calculated as MFI for staining with anti-β7 antibody minus MFI for staining with an 
isotype-matched control antibody for each monocyte subset. Mean and SD are displayed for normally 
distributed data sets, while median and IQR are displayed for non-normally distributed data sets. An 
unpaired T-tests was used to compare two groups of normally distributed data, while a Mann-Whitney 
test was used to compare two groups of data that were non-normally distributed.  
 
Appendix 9b: Stratification of monocyte subset distribution data from IBD cohort into responders 
vs non-responders. Whole blood from 7 responders and 10 non-responders were labelled with anti-
HLA-DR, anti-CD14, and anti-CD16 antibodies to distinguish the monocyte subsets (excluding CD103+ 
cells), and β7 before acquiring on the flow cytometer. β7 expression was quantified as A) percentage 
of cells positive for β7 and B) MFI calculated as MFI for staining with anti-β7 antibody minus MFI for 
staining with an isotype-matched control antibody for each monocyte subset. Mean and SD are 
displayed for normally distributed data sets, while median and IQR are displayed for non-normally 
distributed data sets. An unpaired T-tests was used to compare two groups of normally distributed 
data, while a Mann-Whitney test was used to compare two groups of data that were non-normally 
distributed.  
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Appendix 10a: The effect of vedolizumab therapy on circulating β7+ monocyte subset distribution. 
Whole blood from 19 IBD patients (n=19) starting vedolizumab treatment were labelled with anti-HLA-
DR, anti-CD14, and anti-CD16 antibodies to distinguish the monocyte subsets (excluding CD103+ cells), 
and anti-β7 antibody before acquiring on the flow cytometer. Monocyte subset distribution and cell 
number were determined at baseline and after two and six weeks of treatment. The proportion of β7 
expressing monocytes cells was calculated as a A) percentage of β7 positive monocytes B) β7 positive 
monocytes per μL. Mean and SD are displayed for normally distributed data sets, while median and 
IQR are displayed for non-normally distributed data sets. Data were analysed statistically by RM one-
way ANOVA for normally distributed data sets, while a Friedman test was used for non-normally 
distributed data sets.    
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Appendix 10a: Stratification of monocyte subset distribution data from IBD cohort into responders 
vs non-responders. Whole blood from 19 IBD patients (7 responders and 10 non-responders) starting 
vedolizumab treatment were labelled with anti-HLA-DR, anti-CD14, and anti-CD16 antibodies to 
distinguish the monocyte subsets before acquiring on the flow cytometer. Monocyte subset 
distribution and cell number were determined at baseline and after two and six weeks of treatment. 
Monocyte subset distribution was calculated as A) percentage of PBMCs, B) percentage of total 
monocyte, and C) absolute cell number. Mean and SD are displayed for normally distributed data sets, 
while median and IQR are displayed for non-normally distributed data sets. An unpaired one-way 
ANOVA for normally distributed data sets, while a Kruskal-Wallis test was used to compare two groups 
of unpaired data that were non-normally distributed.  
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Appendix 11a: Stratification of circulating β7+ CD4 and CD8 T cell distribution data from IBD cohort 
into responders vs non-responders. Whole blood from 12 IBD patients (6 CD and 6 UC or 5 responders 
and 7 non-responders) were labelled with anti-CD3, anti-CD45RA, anti-CD8, and anti-CD4 antibodies 
to distinguish effector memory (CD45RA-) CD8+ and CD4+ T cells (excluding CD103+ cells), and anti-
β7 antibody before acquiring on the flow cytometer. The proportion of β7 expressing CD8+ and CD4+ 
T cells was calculated as a percentage of total T cells. A) proportion of β7 expressing CD8+ and CD4+ 
T cells at baseline in CD and UC patients. B) proportion of β7 expressing CD8+ and CD4+ T cells at 
baseline in responders and non-responders. Mean and SD are displayed for normally distributed data 
sets, while median and IQR are displayed for non-normally distributed data sets. An unpaired T-tests 
was used to compare two groups of normally distributed data, while a Mann-Whitney test was used 
to compare two groups of data that were non-normally distributed.  
 
Appendix 11b: Stratification of circulating β7+ CD4 and CD8 T cell distribution data from IBD cohort 
on vedolizumab therapy into responders vs non-responders. Whole blood from 5 responders and 7 
non-responders were labelled with anti-CD3, anti-CD45RA, anti-CD8, and anti-CD4 antibodies to 
distinguish effector memory (CD45RA-) CD8+ and CD4+ T cells (excluding CD103+ cells), and anti-β7 
antibody before acquiring on the flow cytometer. The proportion of β7 expressing CD8+ and CD4+ T 
cells was calculated as a percentage of total T cells. A) proportion of β7 expressing CD8+ T cells at 
baseline and after two and six weeks of treatment. B) proportion of β7 expressing CD4+ T cells at 
baseline and after two and six weeks of treatment. Mean and SD are displayed for normally distributed 
data sets, while median and IQR are displayed for non-normally distributed data sets. A RM one-way 
ANOVA for normally distributed data sets, while a Friedman test was used to compare two groups of 
paired data that were non-normally distributed.  
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Appendix 12: Measuring cell viability. LPMCs extracted from colonic biopsies from a non-IBD patient 
(n=1) were labelled with anti-CD45 antibody before adding the viability dye at a final dilution of 
1:10,000 and incubated for 30min in the dark. The sample was then acquired on the flow cytometer. 
 
 
Appendix 13: Representative flow cytometry plots of isotype controls. LPMCs extracted from colonic 
biopsies from a non-IBD patient were labelled with corresponding isotype controls for anti-CD45, anti-
HLA-DR, and anti-CD14 antibodies. The sample was then acquired on the flow cytometer. 
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Appendix 14: Raw values for IL-10 response in Mo/moMφs from non-IBD colon. LPMCs extracted 
from endoscopic biopsies from non-IBD patients (n=8) were stimulated with 1ng/ml LPS and 2ng/ml 
IL-10 for three hours in the presence of monensin and ADAM17 inhibitor (TMI-005). The LPMCs were 
labelled anti-CD45, anti-HLA-DR, and anti-CD14 antibodies to distinguish the intestinal Mo/moMφs, 
fixed, permeabilised, and stained intracellularly for TNFα before acquiring on the flow cytometer. 
Percentage inhibition of TNFα production at 2ng/ml IL-10 was calculated. Median and IQR is displayed. 
A paired Wilcoxon tests was used to compare two groups of non-normally distributed data. 
 
 
Appendix 15: Raw values for IL-10 response in Mo/moMφs from non-IBD and inflamed IBD colon. 
LPMCs extracted from endoscopic biopsies from non-IBD patients (n=8), UC patients with active 
disease (n=8), CD patients with active disease (n=7), and four patients in remission (three UC and one 
CD) were stimulated with 1ng/ml LPS and 2ng/ml IL-10 for three hours in the presence of monensin 
and ADAM17 inhibitor (TMI-005). The LPMCs were labelled anti-CD45, anti-HLA-DR, and anti-CD14 
antibodies to distinguish the intestinal Mo/moMφs, fixed, permeabilised and stained intracellularly 
for TNFα before acquiring on the flow cytometer. Percentage inhibition of TNFα production at 2ng/ml 
IL-10 was calculated for A) P1 and B) P2. Median and IQR is displayed. Data were analysed statistically 
by Kruskal-Wallis test. 
%
 i
n
h
ib
it
io
n
 a
t 
2
n
g
/m
l 
IL
-1
0
P 1 P 2
0
2 0
4 0
6 0
n s
246 
 
 
Appendix 16: Patient data. Several IBD patients were receiving combination therapies at the time of 
biopsy collection.  
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Limitations  
 
Chapter 3: 
• Some of the negative findings were not verified (n=1). 
• Did not measure soluble CD16 or CD14. 
• Did not measure TNFα production as secretion levels by ELISA. 
Chapter 4 & 5: 
• IL-10Rα expression was measured as the subunit specific to the IL-10R. However, IL-10Rβ is 
the signal transducer, and therefore its expression level could have an impact on IL-10 
signalling. 
• STAT3 phosphorylation was measured at 15 minutes, however, the kinetics were not 
investigated using timepoint analysis in the monocytes. The peak of STAT3 phosphorylation 
could have occurred earlier and differed between the monocyte subsets.  
• Baseline SOCS3 mRNA expression was used as a potential surrogate measure for protein levels 
in the monocyte subsets. It would be informative to also compare the level of IL-10 induced 
SOCS3 mRNA expression between the monocyte subsets.  
• A reduced response to IL-10 in classical monocytes was observed in IBD patients. However, 
the study consists of small numbers and the magnitude of the difference in response to IL-10 
between healthy individuals and IBD patients was also relatively small, therefore, a larger 
cohort is required to verify this finding.  
o The genome of patients included in the cohort were not sequenced to test whether 
the donors express genetic variants along the IL-10R pathway that could impact IL-10 
response. However, a reduced response to IL-10 was a common feature of the IBD 
patients studied here, such genetic variation is unlikely to be a significant contributor 
to the differences observed. 
Chapter 6: 
• A difference in the distribution of P1 and P2 was observed between the colon and the ilium 
therefore, biopsies were restricted to the colon. However, there could be a gradient from the 
ascending colon to the rectum. The majority of biopsies from UC patients were taken in the 
sigmoid colon, whilst from the CD patients the majority of biopsies were taken from the 
ascending colon, which could account for the difference in distribution of P1 and P2 between 
CD and UC patients. However, non-IBD biopsies were taken from across the colon, and 
therefore, a gradient cannot account for the difference in distribution of P1 and P2 between 
non-IBD and CD patients. 
• LPMCs were not harvested using trypsin, therefore, cells were likely to have been lost due to 
adherence to the plate. There could be variation in the adherence of P1 and P2, as well as 
between non-IBD and IBD samples.  
• Live/dead stain was not included in the panel. 
 
 
 
